Table of Contents

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 10-Q

 


 

(Mark one)

 

x       QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2011

 

Or

 

o          TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                 to                       

 

Commission file number:

001-32701

 


 

 

EMERGENCY MEDICAL SERVICES CORPORATION

(Exact name of Registrants as Specified in their Charters)

 

Delaware

 

20-3738384

(State or other jurisdiction of

 

(IRS Employer

incorporation or organization)

 

Identification Number)

 

 

 

6200 S. Syracuse Way, Suite 200

 

 

Greenwood Village, CO

 

80111

(Address of principal executive offices)

 

(Zip Code)

 

Registrants’ telephone number, including area code: 303-495-1200

 

Former name, former address and former fiscal year, if changed since last report:

Not applicable

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  o   No  x

 

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x  No  o

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer o

 

Accelerated filer o

 

 

 

Non-accelerated filer x

 

Smaller reporting company o

(Do not check if a smaller reporting company)

 

 

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange act).  Yes   o   No   x

 

The registrant is a privately held corporation, and its common stock is not publicly traded.  Shares of common stock outstanding at August 10, 2011 — 1,000.  All of our outstanding stock was held at such date by CDRT Acquisition Corporation, our sole stockholder.

 

The registrant is not required to file this Quarterly Report on Form 10-Q with the Securities and Exchange Commission and is doing so on a voluntary basis.

 

 


Table of Contents

 

INDEX

 

Part 1. Financial Information

 

3

 

 

 

 

Item 1.

Financial Statements (unaudited):

 

3

 

 

 

 

 

Consolidated Statements of Operations and Comprehensive Income (Loss) for the period from May 25, 2011 through June 30, 2011 for the Successor and for the period from April 1, 2011 through May 24, 2011, the period from January 1, 2011 through May 24, 2011, and the three and six months ended June 30, 2010 for the Predecessor

 

3

 

 

 

 

 

Consolidated Balance Sheets as of June 30, 2011 for the Successor and December 31, 2010 for the Predecessor

 

5

 

 

 

 

 

Consolidated Statements of Cash Flows for the period from May 25, 2011 through June 30, 2011 for the Successor and for the period from April 1, 2011 through May 24, 2011, the period from January 1, 2011 through May 24, 2011, and the three and six months ended June 30, 2010 for the Predecessor

 

6

 

 

 

 

 

Notes to Consolidated Financial Statements

 

9

 

 

 

 

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

27

 

 

 

 

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

 

40

 

 

 

 

Item 4.

Controls and Procedures

 

40

 

 

 

 

Part II. Other Information

 

42

 

 

 

 

Item 1.

Legal Proceedings

 

42

 

 

 

 

Item 1A.

Risk Factors

 

42

 

 

 

 

Item 2.

Issuer’s Purchase of Equity Securities

 

45

 

 

 

 

Item 5.

Other Information

 

45

 

 

 

 

Item 6.

Exhibits

 

46

 

 

 

 

Signatures

 

 

48

 

2



Table of Contents

 

EMERGENCY MEDICAL SERVICES CORPORATION

PART I. FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

 

EMERGENCY MEDICAL SERVICES CORPORATION

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)

(unaudited; in thousands)

 

 

 

Successor

 

 

Predecessor

 

 

 

Period from May 25
through June 30,

 

 

Period from April 1
through May 24,

 

Quarter ended
June 30,

 

 

 

2011

 

 

2011

 

2010

 

Net revenue

 

$

 319,543

 

 

$

 460,955

 

$

 708,804

 

Compensation and benefits

 

221,804

 

 

337,556

 

496,443

 

Operating expenses

 

41,856

 

 

59,777

 

90,586

 

Insurance expense

 

10,089

 

 

20,690

 

25,942

 

Selling, general and administrative expenses

 

6,861

 

 

11,406

 

18,298

 

Depreciation and amortization expense

 

11,061

 

 

10,942

 

15,692

 

Income from operations

 

27,872

 

 

20,584

 

61,843

 

Interest income from restricted assets

 

162

 

 

728

 

859

 

Interest expense

 

(17,950

)

 

(3,069

)

(5,060

)

Realized gain (loss) on investments

 

7

 

 

(5

)

57

 

Interest and other (expense) income

 

(140

)

 

(27,127

)

206

 

Loss on early debt extinguishment

 

 

 

(10,069

)

(19,091

)

Income (loss) before income taxes and equity in earnings of unconsolidated subsidiary

 

9,951

 

 

(18,958

)

38,814

 

Income tax (expense) benefit

 

(4,158

)

 

3,410

 

(14,955

)

Income (loss) before equity in earnings of unconsolidated subsidiary

 

5,793

 

 

(15,548

)

23,859

 

Equity in earnings of unconsolidated subsidiary

 

33

 

 

52

 

105

 

Net income (loss)

 

5,826

 

 

(15,496

)

23,964

 

Other comprehensive (loss) income, net of tax:

 

 

 

 

 

 

 

 

Unrealized holding (losses) gains during the period

 

(140

)

 

872

 

1,101

 

Unrealized losses on derivative financial instruments

 

(253

)

 

(959

)

(563

)

Comprehensive income (loss)

 

$

 5,433

 

 

$

 (15,583

)

$

 24,502

 

 

The accompanying notes are an integral part of these financial statements.

 

3



Table of Contents

 

 

 

Successor

 

 

Predecessor

 

 

 

Period from May 25
through June 30,

 

 

Period from January 1
through May 24,

 

Six months
ended June 30,

 

 

 

2011

 

 

2011

 

2010

 

Net revenue

 

$

319,543

 

 

$

1,221,790

 

$

1,388,158

 

Compensation and benefits

 

221,804

 

 

874,633

 

976,760

 

Operating expenses

 

41,856

 

 

156,740

 

177,115

 

Insurance expense

 

10,089

 

 

47,229

 

48,012

 

Selling, general and administrative expenses

 

6,861

 

 

29,241

 

35,156

 

Depreciation and amortization expense

 

11,061

 

 

28,467

 

31,872

 

Income from operations

 

27,872

 

 

85,480

 

119,243

 

Interest income from restricted assets

 

162

 

 

1,124

 

1,714

 

Interest expense

 

(17,950

)

 

(7,886

)

(13,326

)

Realized gain (loss) on investments

 

7

 

 

(9

)

149

 

Interest and other (expense) income

 

(140

)

 

(28,873

)

471

 

Loss on early debt extinguishment

 

 

 

(10,069

)

(19,091

)

Income before income taxes and equity in earnings of unconsolidated subsidiary

 

9,951

 

 

39,767

 

89,160

 

Income tax expense

 

(4,158

)

 

(19,242

)

(34,365

)

Income before equity in earnings of unconsolidated subsidiary

 

5,793

 

 

20,525

 

54,795

 

Equity in earnings of unconsolidated subsidiary

 

33

 

 

143

 

199

 

Net income

 

5,826

 

 

20,668

 

54,994

 

Other comprehensive (loss) income, net of tax:

 

 

 

 

 

 

 

 

Unrealized holding (losses) gains during the period

 

(140

)

 

1,501

 

1,543

 

Unrealized losses on derivative financial instruments

 

(253

)

 

25

 

(85

)

Comprehensive income

 

$

5,433

 

 

$

22,194

 

$

56,452

 

 

The accompanying notes are an integral part of these financial statements.

 

4



Table of Contents

 

EMERGENCY MEDICAL SERVICES CORPORATION

CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share data)

 

 

 

Successor

 

 

Predecessor

 

 

 

June 30,
2011

 

 

December 31,
2010

 

 

 

(Unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

 186,811

 

 

$

 287,361

 

Insurance collateral

 

36,649

 

 

33,476

 

Trade and other accounts receivable, net

 

510,279

 

 

489,658

 

Parts and supplies inventory

 

23,349

 

 

23,031

 

Prepaids and other current assets

 

26,305

 

 

18,617

 

Total current assets

 

783,393

 

 

852,143

 

Non-current assets:

 

 

 

 

 

 

Property, plant and equipment, net

 

135,479

 

 

133,731

 

Intangible assets, net

 

758,031

 

 

180,374

 

Insurance collateral

 

116,952

 

 

136,063

 

Goodwill

 

2,163,961

 

 

427,405

 

Other long-term assets

 

114,980

 

 

18,836

 

Total assets

 

$

 4,072,796

 

 

$

 1,748,552

 

Liabilities and Equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

 39,767

 

 

$

 39,581

 

Accrued liabilities

 

336,028

 

 

259,638

 

Current deferred tax liabilities

 

7,345

 

 

5,114

 

Current portion of long-term debt

 

15,065

 

 

16,333

 

Total current liabilities

 

398,205

 

 

320,666

 

Long-term debt

 

2,364,270

 

 

404,943

 

Long-term deferred tax liabilities

 

238,286

 

 

5,971

 

Insurance reserves and other long-term liabilities

 

180,734

 

 

169,767

 

Total liabilities

 

3,181,495

 

 

901,347

 

Equity:

 

 

 

 

 

 

Preferred stock ($0.01 par value; 20,000,000 shares authorized in 2010, 0 issued and outstanding)

 

 

 

 

Common stock ($0.01 par value; 1,000 shares authorized, issued and outstanding in 2011)

 

 

 

 

Class A common stock ($0.01 par value; 100,000,000 shares authorized and 30,404,572 issued and outstanding in 2010)

 

 

 

304

 

Class B common stock ($0.01 par value; 40,000,000 shares authorized in 2010, 65,052 issued and outstanding in 2010)

 

 

 

1

 

Class B special voting stock ($0.01 par value; 1 share authorized, issued and outstanding in 2010)

 

 

 

 

LP exchangeable units (13,724,676 shares issued and outstanding in 2010)

 

 

 

90,776

 

Treasury stock at cost (30,778 shares in 2010)

 

 

 

(1,684

)

Additional paid-in capital

 

885,868

 

 

305,258

 

Retained earnings

 

5,826

 

 

450,766

 

Accumulated other comprehensive (loss) income

 

(393

)

 

1,784

 

Total equity

 

891,301

 

 

847,205

 

Total liabilities and equity

 

$

 4,072,796

 

 

$

 1,748,552

 

 

The accompanying notes are an integral part of these financial statements.

 

5



Table of Contents

 

EMERGENCY MEDICAL SERVICES CORPORATION

CONSOLIDATED STATEMENTS OF CASH FLOWS

(unaudited; in thousands)

 

 

 

Successor

 

 

Predecessor

 

 

 

Period from May 25
through June 30,

 

 

Period from April 1
through May 24,

 

Quarter ended
June 30,

 

 

 

2011

 

 

2011

 

2010

 

Cash Flows from Operating Activities

 

 

 

 

 

 

 

 

Net income (loss)

 

$

 5,826

 

 

$

 (15,496

)

$

 23,964

 

Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

12,962

 

 

11,485

 

16,321

 

Loss on disposal of property, plant and equipment

 

12

 

 

 

45

 

Equity-based compensation expense

 

430

 

 

13,150

 

1,441

 

Excess tax benefits from stock-based compensation

 

 

 

(11,258

)

(2,917

)

Loss on early debt extinguishment

 

 

 

10,069

 

19,091

 

Equity in earnings of unconsolidated subsidiary

 

(33

)

 

(52

)

(105

)

Deferred income taxes

 

48

 

 

 

973

 

Changes in operating assets/liabilities, net of acquisitions:

 

 

 

 

 

 

 

 

Trade and other accounts receivable

 

7,102

 

 

613

 

(21,750

)

Parts and supplies inventory

 

18

 

 

(35

)

75

 

Prepaids and other current assets

 

2,511

 

 

(3,828

)

(8,828

)

Accounts payable and accrued liabilities

 

1,708

 

 

(3,750

)

7,093

 

Insurance accruals

 

7,137

 

 

(4,922

)

4,754

 

Net cash provided by (used in) operating activities

 

37,721

 

 

(4,024

)

40,157

 

Cash Flows from Investing Activities

 

 

 

 

 

 

 

 

Merger, net of cash received

 

(2,844,221

)

 

 

 

Purchases of property, plant and equipment

 

(2,892

)

 

(3,190

)

(8,652

)

Proceeds from sale of property, plant and equipment

 

55

 

 

45

 

66

 

Acquisition of businesses, net of cash received

 

(4,668

)

 

(62,150

)

(47,675

)

Net change in insurance collateral

 

4,542

 

 

10,630

 

(7,627

)

Other investing activities

 

(262

)

 

342

 

10,648

 

Net cash used in investing activities

 

(2,847,446

)

 

(54,323

)

(53,240

)

Cash Flows from Financing Activities

 

 

 

 

 

 

 

 

EMSC issuance of class A common stock

 

 

 

8

 

1,791

 

Borrowings under senior secured credit facility

 

1,440,000

 

 

 

425,000

 

Proceeds from issuance of senior subordinated notes

 

950,000

 

 

 

 

Proceeds from CD&R equity investment

 

887,051

 

 

 

 

Repayments of capital lease obligations and other debt

 

(418,875

)

 

(2,150

)

(451,443

)

Equity issuance costs

 

(26,196

)

 

 

 

Debt issue costs

 

(114,021

)

 

 

(11,749

)

Payment for debt extinguishment premiums

 

 

 

 

(14,513

)

Excess tax benefits from stock-based compensation

 

 

 

11,258

 

2,917

 

Class A common stock repurchased as treasury stock

 

 

 

(1,137

)

 

Net change in bank overdrafts

 

(7,971

)

 

2,144

 

(6,942

)

Net cash provided by (used in) financing activities

 

2,709,988

 

 

10,123

 

(54,939

)

Change in cash and cash equivalents

 

(99,737

)

 

(48,224

)

(68,022

)

Cash and cash equivalents, beginning of period

 

286,548

 

 

334,772

 

381,055

 

Cash and cash equivalents, end of period

 

$

 186,811

 

 

$

 286,548

 

$

 313,033

 

 

The accompanying notes are an integral part of these financial statements.

 

6



Table of Contents

 

 

 

Successor

 

 

Predecessor

 

 

 

Period from May 25
through June 30,

 

 

Period from January 1
through May 24,

 

Six months ended
June 30,

 

 

 

2011

 

 

2011

 

2010

 

Cash Flows from Operating Activities

 

 

 

 

 

 

 

 

Net income

 

$

 5,826

 

 

$

 20,668

 

$

 54,994

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization

 

12,962

 

 

29,800

 

33,008

 

Loss on disposal of property, plant and equipment

 

12

 

 

39

 

89

 

Equity-based compensation expense

 

430

 

 

15,112

 

2,545

 

Excess tax benefits from stock-based compensation

 

 

 

(12,427

)

(13,498

)

Loss on early debt extinguishment

 

 

 

10,069

 

19,091

 

Equity in earnings of unconsolidated subsidiary

 

(33

)

 

(143

)

(199

)

Dividends received

 

 

 

427

 

403

 

Deferred income taxes

 

48

 

 

345

 

840

 

Changes in operating assets/liabilities, net of acquisitions:

 

 

 

 

 

 

 

 

Trade and other accounts receivable

 

7,102

 

 

(10,149

)

(19,559

)

Parts and supplies inventory

 

18

 

 

(116

)

(87

)

Prepaids and other current assets

 

2,511

 

 

(8,569

)

(12,216

)

Accounts payable and accrued liabilities

 

1,708

 

 

25,337

 

13,099

 

Insurance accruals

 

7,137

 

 

(2,418

)

6,232

 

Net cash provided by operating activities

 

37,721

 

 

67,975

 

84,742

 

Cash Flows from Investing Activities

 

 

 

 

 

 

 

 

Merger, net of cash received

 

(2,844,221

)

 

 

 

Purchases of property, plant and equipment

 

(2,892

)

 

(18,496

)

(15,168

)

Proceeds from sale of property, plant and equipment

 

55

 

 

55

 

108

 

Acquisition of businesses, net of cash received

 

(4,668

)

 

(94,870

)

(50,975

)

Net change in insurance collateral

 

4,542

 

 

23,036

 

(5,261

)

Other investing activities

 

(262

)

 

816

 

10,938

 

Net cash used in investing activities

 

(2,847,446

)

 

(89,459

)

(60,358

)

Cash Flows from Financing Activities

 

 

 

 

 

 

 

 

EMSC issuance of class A common stock

 

 

 

559

 

6,193

 

Borrowings under senior secured credit facility

 

1,440,000

 

 

 

425,000

 

Proceeds from issuance of senior subordinated notes

 

950,000

 

 

 

 

Proceeds from CD&R equity investment

 

887,051

 

 

 

 

Repayments of capital lease obligations and other debt

 

(418,875

)

 

(4,116

)

(452,627

)

Equity issuance costs

 

(26,196

)

 

 

 

Debt issue costs

 

(114,021

)

 

 

(11,749

)

Payment for debt extinguishment premiums

 

 

 

 

(14,513

)

Excess tax benefits from stock-based compensation

 

 

 

12,427

 

13,498

 

Class A common stock repurchased as treasury stock

 

 

 

(2,440

)

 

Net change in bank overdrafts

 

(7,971

)

 

14,241

 

(10,041

)

Net cash provided by (used in) financing activities

 

2,709,988

 

 

20,671

 

(44,239

)

Change in cash and cash equivalents

 

(99,737

)

 

(813

)

(19,855

)

Cash and cash equivalents, beginning of period

 

286,548

 

 

287,361

 

332,888

 

Cash and cash equivalents, end of period

 

$

 186,811

 

 

$

 286,548

 

$

 313,033

 

 

The accompanying notes are an integral part of these financial statements.

 

7



Table of Contents

 

EMERGENCY MEDICAL SERVICES CORPORATION

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY

(unaudited; in thousands, except share data)

 

 

 

Shares/Units

 

 

 

 

 

Class A

 

Class B

 

Class B

 

LP

 

 

 

 

 

Common

 

Common

 

Common

 

Special

 

Exchangeable

 

Treasury

 

 

 

Stock

 

Stock

 

Stock

 

Voting Stock

 

Units

 

Stock

 

Predecessor

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances December 31, 2010

 

 

30,404,572

 

65,052

 

1

 

13,724,676

 

30,778

 

Exercise of options

 

 

24,879

 

 

 

 

 

Restricted stock awarded

 

 

118,453

 

 

 

 

 

Shares repurchased

 

 

(38,263

)

 

 

 

38,263

 

Exchange of Class B common

 

 

65,007

 

(65,007

)

 

 

 

Balances May 24, 2011

 

 

30,574,648

 

45

 

1

 

13,724,676

 

69,041

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Successor

 

 

 

 

 

 

 

 

 

 

 

 

 

Investment by Parent

 

1,000

 

 

 

 

 

 

Balances June 30, 2011

 

1,000

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

Class A

 

Class B

 

LP

 

 

 

Additional

 

 

 

Other

 

 

 

 

 

Common

 

Common

 

Common

 

Exchangeable

 

Treasury

 

Paid-in

 

Retained

 

Comprehensive

 

Total

 

 

 

Stock

 

Stock

 

Stock

 

Units

 

Stock

 

Capital

 

Earnings

 

Income (Loss)

 

Equity

 

Predecessor

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balances December 31, 2010

 

$

 —

 

$

 304

 

$

 1

 

$

 90,776

 

$

(1,684

)

$

 305,258

 

$

 450,766

 

$

 1,784

 

$

 847,205

 

Exercise of options

 

 

 

 

 

 

559

 

 

 

559

 

Restricted stock awarded

 

 

1

 

 

 

 

 

 

 

1

 

Shares repurchased

 

 

 

 

 

(2,440

)

 

 

 

(2,440

)

Equity-based compensation

 

 

 

 

 

 

27,539

 

 

 

27,539

 

Exchange of Class B common stock

 

 

1

 

(1

)

 

 

 

 

 

 

Net income

 

 

 

 

 

 

 

20,668

 

 

20,668

 

Unrealized holding gains

 

 

 

 

 

 

 

 

1,501

 

1,501

 

Fair value of fuel hedge

 

 

 

 

 

 

 

 

25

 

25

 

Balances May 24, 2011

 

$

 —

 

$

 306

 

$

 —

 

$

 90,776

 

$

(4,124

)

$

 333,356

 

$

 471,434

 

$

 3,310

 

$

 895,058

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Successor

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Investment by Parent, net of issuance costs of $29,878

 

$

 —

 

$

 —

 

$

 —

 

$

 —

 

$

 —

 

$

 857,173

 

$

 —

 

$

 —

 

$

 857,173

 

Investment by management

 

 

 

 

 

 

28,265

 

 

 

28,265

 

Equity-based compensation

 

 

 

 

 

 

430

 

 

 

430

 

Net income

 

 

 

 

 

 

 

5,826

 

 

5,826

 

Unrealized holding losses

 

 

 

 

 

 

 

 

(140

)

(140

)

Fair value of fuel hedge

 

 

 

 

 

 

 

 

(253

)

(253

)

Balances June 30, 2011

 

$

 —

 

$

 —

 

$

 —

 

$

 —

 

$

 —

 

$

 885,868

 

$

 5,826

 

$

(393

)

$

 891,301

 

 

The accompanying notes are an integral part of these financial statements.

 

8



Table of Contents

 

EMERGENCY MEDICAL SERVICES CORPORATION

NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

(in thousands, except share and per share data)

 

1.      General

 

Basis of Presentation of Financial Statements

 

The accompanying interim consolidated financial statements for Emergency Medical Services Corporation (“EMSC” or the “Company”) have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim reporting, and accordingly, do not include all of the disclosures required for annual financial statements.  For further information, see the Company’s consolidated financial statements, including the accounting policies and notes thereto, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010.

 

On May 25, 2011, EMSC was acquired through a merger transaction (“Merger”) by investment funds (the “CD&R Affiliates”) sponsored by, or affiliated with, Clayton, Dubilier & Rice LLC (“CD&R”).  As a result of the Merger, EMSC became a wholly-owned subsidiary of CDRT Acquisition Corporation and the Company’s stock ceased to be traded on the New York Stock Exchange.  In addition, Emergency Medical Services LP, a wholly-owned subsidiary of the Company, ceased to be a reporting entity with the Securities and Exchange Commission.  Details of the Merger are more fully discussed in Note 2.  The transaction was accounted for as a reverse acquisition with CDRT Acquisition Corporation.  Although EMSC continued as the surviving corporation and same legal entity after the Merger, the accompanying consolidated results of operations and cash flows are presented for two periods: the period prior to the merger (“Predecessor”) and succeeding the Merger (“Successor”).  The Company applied purchase accounting to the opening balance sheet and results of operations on May 25, 2011.  The Merger resulted in a new basis of accounting beginning on May 25, 2011 and the financial reporting periods are presented as follows:

 

·                   The three month period ended June 30, 2011 includes the Predecessor period of the Company from April 1, 2011 through May 24, 2011 and the Successor period, reflecting the Merger of the Company and the affiliate of CD&R, from May 25, 2011 through June 30, 2011.

 

·                   The six month period ended June 30, 2011 includes the Predecessor period of the Company from January 1, 2011 through May 24, 2011 and the Successor period, reflecting the Merger of the Company and the affiliate of CD&R, from May 25, 2011 through June 30, 2011.

 

·                   The 2010 periods presented are on a Predecessor basis. The consolidated financial statements for all Predecessor periods have been prepared using the historical basis of accounting for the Company. As a result of the Merger and the associated purchase accounting, the consolidated financial statements of the Successor are not comparable to periods preceding the Merger.

 

In the opinion of management, the consolidated financial statements include all normal recurring adjustments necessary for a fair presentation of the periods presented.  Operating results for interim periods are not necessarily indicative of the results that may be expected for the full year ended December 31, 2011.

 

The Company’s business is conducted primarily through two operating subsidiaries, EmCare Holdings Inc. (“EmCare”), its facility-based physician services segment, and American Medical Response, Inc. (“AMR”), its medical transportation services segment.

 

2.               Summary of Significant Accounting Policies

 

Consolidation

 

The consolidated financial statements include all wholly-owned subsidiaries of EMSC, including AMR and EmCare and their respective subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.

 

Use of Estimates

 

The preparation of financial statements requires management to make estimates and assumptions relating to the reporting of results of operations, financial condition and related disclosure of contingent assets and liabilities at the date of the financial statements. Actual results may differ from those estimates under different assumptions or conditions.

 

9



Table of Contents

 

Insurance

 

Insurance collateral is comprised principally of government and investment grade securities and cash deposits with third parties and supports the Company’s insurance program and reserves. Certain of these investments, if sold or otherwise liquidated, would have to be replaced by other suitable financial assurances and are, therefore, considered restricted.  Insurance collateral also includes a receivable from insurers of $10.8 million for liabilities in excess of our self-insured retention.

 

Insurance reserves are established for automobile, workers compensation, general liability and professional liability claims utilizing policies with both fully-insured and self-insured components. This includes the use of an off-shore captive insurance program through a wholly-owned subsidiary for certain liability programs for both EmCare and AMR. In those instances where the Company has obtained third-party insurance coverage, the Company normally retains liability for the first $1 to $2 million of the loss. Insurance reserves cover known claims and incidents within the level of Company retention that may result in the assertion of additional claims, as well as claims from unknown incidents that may be asserted arising from activities through the balance sheet date.

 

The Company establishes reserves for claims based upon an assessment of actual claims and claims incurred but not reported.  The reserves are established based on quarterly consultation with third-party independent actuaries using actuarial principles and assumptions that consider a number of factors, including historical claim payment patterns (including legal costs) and changes in case reserves and the assumed rate of inflation in healthcare costs and property damage repairs.

 

The Company’s most recent actuarial valuation was completed in June 2011. As a result of this and previous actuarial valuations, the Company recorded increases in its provisions for insurance liabilities for prior year losses of $5.7 million and $8.2 million during the Predecessor periods from April 1, 2011 through May 24, 2011 and January 1, 2011 through May 24, 2011, respectively.  During the Predecessor three months ended June 30, 2010, the Company recorded an increase of $2.9 million in its provision for insurance liabilities for prior year losses and a total increase of $0.1 million during the Predecessor six months ended June 30, 2010.

 

The long-term portion of insurance reserves was $165.8 million and $158.3 million as of June 30, 2011 and December 31, 2010, respectively.

 

Trade and Other Accounts Receivable, net

 

The Company estimates its allowances based on payor reimbursement schedules, historical collections and write-off experience and other economic data. The allowances for contractual discounts and uncompensated care are reviewed monthly. Account balances are charged off against the uncompensated care allowance, which relates principally to receivables recorded for self-pay patients, when it is probable the receivable will not be recovered. Write-offs to the contractual allowance occur when payment is received. The Company’s accounts receivable and allowances are as follows:

 

 

 

Successor
June 30,
2011

 

 

Predecessor
December 31,
2010

 

Gross trade accounts receivable

 

$

2,318,154

 

 

$

2,119,854

 

Allowance for contractual discounts

 

1,195,537

 

 

1,092,188

 

Allowance for uncompensated care

 

710,001

 

 

629,419

 

Net trade accounts receivable

 

412,616

 

 

398,247

 

Other receivables, net

 

97,663

 

 

91,411

 

Net accounts receivable

 

$

510,279

 

 

$

489,658

 

 

Other receivables primarily represent EmCare hospital subsidies and fees and AMR fees for stand-by and special events and subsidies from community organizations.

 

AMR contractual allowances are determined primarily on payor reimbursement schedules that are included and regularly updated in the billing systems, and by historical collection experience.  The billing systems calculate the difference betweenpayor specific gross billings and contractually agreed to, or governmentally driven, reimbursement rates.  The allowance for uncompensated care at AMR is related principally to receivables recorded for self-pay patients.  AMR’s allowances on self-pay accounts receivable are estimated on claim level, historical write-off experience.

 

10



Table of Contents

 

Accounts receivable allowances at EmCare are estimated based on cash collection and write-off experience at a facility level contract and facility specific payor mix.  These allowances are reviewed and adjusted monthly through revenue provisions.  In addition, a look-back analysis is done, typically after 15 months, to compare actual cash collected on a date of service basis to the revenue recorded for that period.  Any adjustment necessary for an overage or deficit in these allowances based on actual collections is recorded through a revenue adjustment in the current period.

 

Business Combinations

 

Effective January 1, 2009, the Company adopted ASC 805, Business Combinations , which revised the accounting guidance required to be applied to acquisitions in comparison to prior fiscal years . In accordance with this guidance, the assets and liabilities of an acquired business are recorded at their fair values at the date of acquisition. The excess of the purchase price over the estimated fair values is recorded as goodwill. All acquisition costs are expensed as incurred. While the Company uses its best estimates and assumptions as a part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, the estimates are inherently uncertain and subject to refinement. As a result, during the measurement period the Company may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period any subsequent adjustments are recorded as expense.

 

Revenue Recognition

 

Revenue is recognized at the time of service and is recorded net of provisions for contractual discounts and estimated uncompensated care. Provisions for contractual discounts are related principally to differences between gross charges and specific payor, including governmental, reimbursement schedules. Provisions for estimated uncompensated care are related principally to the number of self-pay patients treated in the period. Provisions for contractual discounts and estimated uncompensated care as a percentage of gross revenue and as a percentage of gross revenue less provision for contractual discounts are as follows.  Predecessor and Successor periods are not disclosed because they are not materially different than the three and six month periods presented.

 

 

 

Three months ended
June 30,

 

Six months ended
June 30,

 

 

 

2011

 

2010

 

2011

 

2010

 

Gross revenue

 

100.0

%

100.0

%

100.0

%

100.0

%

Provision for contractual discounts

 

53.7

%

53.1

%

53.6

%

52.6

%

Revenue net of contractual discounts

 

46.3

%

46.9

%

46.4

%

47.4

%

Provision for uncompensated care as a percentage of gross revenue

 

18.8

%

18.3

%

18.8

%

18.5

%

Provision for uncompensated care as a percentage of gross revenue less contractual discounts

 

40.6

%

39.0

%

40.6

%

39.1

%

 

Healthcare reimbursement is complex and may involve lengthy delays. Third-party payors are continuing their efforts to control expenditures for healthcare, including proposals to revise reimbursement policies. The Company has from time to time experienced delays in reimbursement from third-party payors. In addition, third-party payors may disallow, in whole or in part, claims for payment based on determinations that certain amounts are not reimbursable under plan coverage, determinations of medical necessity, or the need for additional information. Laws and regulations governing the Medicare and Medicaid programs are very complex and subject to interpretation. Revenue is recognized on an estimated basis in the period in which related services are rendered.  As a result, there is a reasonable possibility that recorded estimates will change materially in the short-term. Such amounts, including adjustments between provisions for contractual discounts and uncompensated care, are adjusted in future periods, as adjustments become known.  These adjustments were less than 1% of net revenue for the Successor and Predecessor periods.

 

The Company also provides services to patients who have no insurance or other third-party payor coverage. In certain circumstances, federal law requires providers to render services to any patient who requires care regardless of their ability to pay. Services to these patients are not considered to be charity care.

 

Merger

 

On February 13, 2011, the Company entered into an Agreement and Plan of Merger (“Merger Agreement”) with CDRT Acquisition Corporation, a Delaware corporation (“Parent”), and CDRT Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent (“Sub”).  On May 25, 2011, pursuant to the Merger Agreement, Sub merged with and into the Company, with the Company as the surviving entity and a wholly-owned subsidiary of Parent (the “Merger”).

 

At the time the Merger was effective, each issued and outstanding share of class A common stock and class B common stock (including shares of Class B common stock issued immediately prior to the effective time of the Merger in exchange for the LP exchangeable units of EMS LP, but excluding treasury shares, shares held by Parent or Sub and shares held by stockholders who perfected their appraisal rights), were converted into the right to receive $64.00 per share in cash, without interest and subject to any applicable withholding taxes.  In addition, vesting of stock options, restricted stock, and restricted share units was accelerated upon closing of the Merger. As a result, holders of stock options received cash equal to the intrinsic value of the awards based on a market price of $64.00 per share while holders of restricted stock and restricted share units received $64.00 per share in cash, without interest.

 

11



Table of Contents

 

The Merger was financed by a combination of borrowings under the Company’s new senior secured term loan facility, the issuance of new senior unsecured notes, and the equity investment by the CD&R Affiliates and members of EMSC management. The purchase price was approximately $3.2 billion including approximately $150 million in capitalized issuance costs, of which $110 million are debt issuance costs. The Merger was funded primarily through a $915 million equity contributions from the CD&R Affiliates and members of EMSC management and $2.4 billion in debt financing discussed more fully in Note 5.

 

Preliminary Purchase Price Allocation

 

The total purchase price was allocated to the Company’s net tangible and identifiable intangible assets, including customer relationships, software and trade names, based on their estimated fair values as set forth below. Property and equipment were carried forward at historical net balances as a current best estimate of fair value and will be adjusted in a subsequent period upon completion of a full valuation. The excess of the purchase price over the net tangible and identifiable intangible assets was recorded as goodwill. The preliminary allocation of the purchase price to identifiable intangible assets was based upon preliminary valuation data from a third party valuation firm and the estimates and assumptions are subject to change.

 

Property, plant and equipment

 

$

136,400

 

Identifiable intangible assets

 

764,400

 

Goodwill

 

2,164,000

 

Deferred taxes

 

(245,600

)

Other net assets acquired

 

352,500

 

Total purchase price

 

$

3,171,700

 

 

The preliminary estimated useful life associated with identifiable intangible assets is a weighted average of approximately 9.5 years and the amortization methodology will be determined upon finalization of the valuation. Deferred tax liabilities of $232.5 million were recorded related to the allocation of purchase price to increase the existing value of intangible assets. Goodwill of $2,164.0 million resulted from the Merger, the majority of which is not deductible for tax purposes. The preliminary allocation of goodwill by segment is as follows (in millions):

 

AMR

 

$

650

 

EmCare

 

1,514

 

 

 

$

2,164

 

 

Goodwill will be reviewed at least annually for impairment.

 

Merger and Other Related Costs

 

During the period from January 1, 2011 through May 24, 2011, the Company recorded $29.8 million of pretax Merger related costs consisting primarily of investment banking, accounting and legal fees. The Company also recognized a pretax charge of $12.4 million related to accelerated vesting of all outstanding unvested stock options, restricted stock awards and restricted stock units including associated payroll taxes and $10.1 million related to loss on early debt extinguishment.

 

U naudited Pro Forma Combined Consolidated Statements of Operations

 

The following Unaudited Pro Forma Combined Consolidated Statements of Operation reflect the consolidated results of operations of the Company as if the Merger had occurred on January 1, 2011 and 2010. The historical financial information has been adjusted to give effect to events that are (1) directly attributed to the Merger, (2) factually supportable, and (3) with respect to the income statement, expected to have a continuing impact on the combined results. Such items include interest expense related to debt issued in conjunction with the Merger as well as additional amortization expense associated with the preliminary valuation of intangible assets. This unaudited pro forma information should not be relied upon as necessarily being indicative of the historical results that would have been obtained if the Merger had actually occurred on that date, nor of the results that may be obtained in the future.

 

12



Table of Contents

 

Unaudited Pro Forma Combined Consolidated Statements of Operation

 

 

 

Quarter ended

 

Six months ended

 

 

 

June 30,

 

June 30,

 

 

 

2011

 

2010

 

2011

 

2010

 

Net revenue

 

$

780,498

 

$

708,804

 

$

1,541,333

 

$

1,388,158

 

Compensation and benefits

 

546,929

 

496,443

 

1,084,006

 

976,760

 

Operating expenses

 

101,633

 

90,586

 

198,596

 

177,115

 

Insurance expense

 

30,779

 

25,942

 

57,318

 

48,012

 

Selling, general and administrative expenses

 

19,267

 

19,298

 

38,102

 

37,156

 

Depreciation and amortization expense

 

29,635

 

30,066

 

59,770

 

60,368

 

Income from operations

 

52,255

 

46,469

 

103,541

 

88,747

 

Interest income from restricted assets

 

890

 

859

 

1,286

 

1,714

 

Interest expense

 

(43,294

)

(43,230

)

(86,509

)

(86,431

)

Realized gains (losses) on investments

 

2

 

57

 

(2

)

149

 

Interest and other income

 

610

 

206

 

819

 

471

 

Income before income taxes and equity in earnings of unconsolidated subsidiary

 

10,463

 

4,361

 

19,135

 

4,650

 

Income tax expense

 

(4,133

)

(1,679

)

(7,558

)

(1,837

)

Income before equity in earnings of unconsolidated subsidiary

 

6,330

 

2,682

 

11,577

 

2,813

 

Equity in earnings of unconsolidated subsidiary

 

85

 

105

 

176

 

199

 

Net income

 

$

6,415

 

$

2,787

 

$

11,753

 

$

3,012

 

 

Fair Value Measurement

 

The Company classifies its financial instruments that are reported at fair value based on a hierarchal framework which ranks the level of market price observability used in measuring financial instruments at fair value. Market price observability is impacted by a number of factors, including the type of instrument and the characteristics specific to the instrument. Instruments with readily available active quoted prices or for which fair value can be measured from actively quoted prices generally will have a higher degree of market price observability and a lesser degree of judgment used in measuring fair value.

 

Financial instruments measured and reported at fair value are classified and disclosed in one of the following categories:

 

Level 1—Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. The Company does not adjust the quoted price for these assets or liabilities.

 

Level 2—Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies.  Balances in this category include mortgage backed securities, corporate bonds, and derivatives.

 

Level 3—Pricing inputs are unobservable as of the reporting date and reflect the Company’s own assumptions about the fair value of the asset or liability.

 

The following table summarizes the valuation of EMSC’s financial instruments by the above fair value hierarchy levels as of June 30, 2011:

 

Description

 

Total

 

Level 1

 

Level 2

 

Level 3

 

Assets:

 

 

 

 

 

 

 

 

 

Securities

 

$

116,599

 

$

103,620

 

$

12,979

 

$

 

Derivatives

 

$

1,962

 

$

 

$

1,962

 

$

 

Liabilities:

 

 

 

 

 

 

 

 

 

Contingent consideration

 

$

9,522

 

$

 

$

 

$

9,522

 

 

The contingent consideration balance classified as a level 3 liability decreased by $10.8 million since December 31, 2010 due to payments made by the Company during the six months ended June 30, 2011.

 

13



Table of Contents

 

Recent Accounting Pronouncements

 

In July 2011, the Financial Accounting Standards Board (“FASB”) provided guidance to give further transparency about a health care entity’s net patient service revenue and the related allowance for doubtful accounts.  This update will be effective for the Company for the year ended December 31, 2013 and interim periods thereafter.  Adoption of this guidance will not have a material effect on the Company’s consolidated financial statements and related disclosures.

 

3.               Acquisitions

 

On April 1, 2011, the Company acquired all the capital stock of BestPractices, Inc., an emergency department staffing and management company based in Virginia.

 

4.               Accrued Liabilities

 

Accrued liabilities were as follows at June 30, 2011 and December 31, 2010:

 

 

 

Successor

 

 

Predecessor

 

 

 

June 30,

 

 

December 31,

 

 

 

2011

 

 

2010

 

Accrued wages and benefits

 

$

124,061

 

 

$

103,238

 

Accrued paid time-off

 

28,050

 

 

24,420

 

Current portion of self-insurance reserves

 

58,096

 

 

50,064

 

Accrued restructuring

 

149

 

 

160

 

Current portion of compliance and legal

 

2,614

 

 

5,929

 

Accrued billing and collection fees

 

4,884

 

 

3,500

 

Accrued incentive compensation

 

17,080

 

 

21,446

 

Accrued interest

 

8,758

 

 

979

 

Transaction related liabilities

 

50,278

 

 

 

Other

 

42,058

 

 

49,902

 

Total accrued liabilities

 

$

336,028

 

 

$

259,638

 

 

5.               Long-Term Debt

 

On May 25, 2011, the Company issued $950 million of senior unsecured notes and entered into $1.8 billion of senior secured credit facilities (the “Credit Facilities”).

 

The senior unsecured notes have a fixed interest rate of 8.125%, payable semi-annually with the principle due at maturity in 2019. The senior unsecured notes are general unsecured obligations of EMSC and are guaranteed by each of EMSC’s domestic subsidiaries, except for any of EMSC’s subsidiaries subject to regulation as an insurance company, including EMSC’s captive insurance subsidiary.

 

EMSC may redeem the senior unsecured notes, in whole or in part, at any time prior to June 1, 2014, at a price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to the redemption date, plus the applicable make-whole premium.  EMSC may redeem the senior unsecured notes, in whole or in part, at any time (i) on and after June 1, 2014 and prior to June 1, 2015, at a price equal to 106.094% of the principal amount of the senior unsecured notes, (ii) on or after June 1, 2015 and prior to June 1, 2016, at a price equal to 104.063% of the principal amount of the senior unsecured notes, (iii) on or after June 1, 2016 and prior to June 1, 2017, at a price equal to 102.031% of the principal amount of the senior unsecured notes, and (iv) on or after June 1, 2017, at a price equal to 100.000% of the principal amount of the senior unsecured notes, in each case, plus accrued and unpaid interest, if any, to the redemption date.  In addition, at any time prior to June 1, 2014, EMSC may redeem up to 35% of the aggregate principal amount of the senior unsecured notes with the proceeds of certain equity offerings at a redemption price of 108.125%, plus accrued and unpaid interest, if any, to the applicable redemption date.

 

The indenture governing the senior unsecured notes contains covenants that, among other things, limit EMSC’s ability and the ability of its restricted subsidiaries to:  incur more indebtedness or issue certain preferred shares; pay dividends, redeem stock or make other distributions; make investments; create restrictions on the ability of EMSC’s restricted subsidiaries to pay dividends to EMSC or make other intercompany transfers; create liens; transfer or sell assets; merge or consolidate; enter into certain transactions with affiliates; and designate subsidiaries as unrestricted subsidiaries.  Upon the occurrence of certain events constituting a change of control, EMSC is required to make an offer to repurchase all of the senior unsecured notes (unless otherwise redeemed) at a purchase price equal to 101% of their principal amount, plus accrued and unpaid interest, if

 

14



Table of Contents

 

any to the repurchase date.  If EMSC sells assets under certain circumstances, it must use the proceeds to make an offer to purchase the senior unsecured notes at a price equal to 100% of their principal amount, plus accrued and unpaid interest, if any, to the date of purchase.

 

The Credit Facilities consist of a $1.44 billion senior secured term loan facility (the “Term Loan Facility”) and a $350 million asset-based revolving credit facility (the “ABL Facility”).  Loans under the Term Loan Facility bear interest at EMSC’s election at a rate equal to (i) the highest of (x) the rate for deposits in U.S. dollars in the London interbank market (adjusted for maximum reserves) for the applicable interest period (“Term Loan LIBOR rate”) and (y) 1.50%, plus, in each case, 3.75%, or (ii) the base rate, which will be the highest of (w) the corporate base rate established by the administrative agent from time to time, (x) 0.50% in excess of the overnight federal funds rate, (y) the one-month Term Loan LIBOR rate (adjusted for maximum reserves) plus 1.00% per annum and (x) 2.50%, plus, in each case, 2.75%.

 

Loans under the ABL Facility bear interest at EMSC’s election at a rate equal to (i) the rate for deposits in U.S. dollars in the London interbank market (adjusted for maximum reserves) for the applicable interest period (“ABL LIBOR rate”), plus an applicable margin that ranges from 2.25% to 2.75% based on the average available loan commitments, or (ii) the base rate, which is the highest of (x) the corporate base rate established by the administrative agent from time to time, (y) the overnight federal funds rate plus 0.5% and (z) the one-month ABL LIBOR rate plus 1.0% per annum, plus, in each case, an applicable margin that ranges from 1.25% to 1.75% based on the average available loan commitments.  The ABL Facility bears a commitment fee that ranges from 0.500% to 0.375%, payable quarterly in arrears, based on the utilization of the ABL Facility.  The ABL Facility also bears customary letter of credit fees.

 

As of June 30, 2011, letters of credit outstanding which impact the available credit under the ABL Facility were $47.4 million and the maximum available under the ABL Facility was $302.6 million. There were no borrowings under the ABL Facility as of June 30, 2011.

 

The Term Loan Facility contains customary representations and warranties and customary affirmative and negative covenants.  The negative covenants are limited to the following: limitations on the incurrence of debt, liens, fundamental changes, restrictions on subsidiary distributions, transactions with affiliates, further negative pledge, asset sales, restricted payments, investments and acquisitions, repayment of certain junior debt (including the senior notes) or amendments of junior debt documents related thereto and line of business.  The negative covenants are subject to the customary exceptions.

 

The ABL Facility contains customary representations and warranties and customary affirmative and negative covenants. The negative covenants are limited to the following: limitations on indebtedness, dividends and distributions, investments, acquisitions, prepayments or redemptions of junior indebtedness, amendments of junior indebtedness, transactions with affiliates, asset sales, mergers, consolidations and sales of all or substantially all assets, liens, negative pledge clauses, changes in fiscal periods, changes in line of business and hedging transactions.  The negative covenants are subject to the customary exceptions and also permit the payment of dividends and distributions, investments, permitted acquisitions and payments or redemptions of junior indebtedness upon satisfaction of a “payment condition.”  The payment condition is deemed satisfied upon 30-day average excess availability exceeding agreed upon thresholds and, in certain cases, the absence of specified events of default and pro forma compliance with a fixed charge coverage ratio of 1.0 to 1.0.

 

In conjunction with completing the financing under the new credit facilities, the Company repaid the balance outstanding on the previous senior secured term loan.  During the Predecessor period ended May 24, 2011, the Company recorded a loss on early debt extinguishment of $10.1 million related to unamortized debt issuance costs.

 

Long-term debt and capital leases consisted of the following at June 30, 2011 and December 31, 2010:

 

 

 

Successor

 

 

Predecessor

 

 

 

June 30,
 2011

 

 

December 31,
 2010

 

Senior subordinated unsecured notes due 2019

 

$

950,000

 

 

$

 

Senior secured term loan due 2018 (5.25% at June 30, 2011)

 

1,427,568

 

 

 

Senior secured term loan due 2015

 

 

 

419,688

 

Notes due at various dates from 2011 to 2022 with interest rates from 6% to 10%

 

1,097

 

 

832

 

Capital lease obligations due at various dates from 2011 to 2018

 

670

 

 

756

 

 

 

2,379,335

 

 

421,276

 

Less current portion

 

(15,065

)

 

(16,333

)

Total long-term debt

 

$

2,364,270

 

 

$

404,943

 

 

15



Table of Contents

 

6.               Derivative Instruments and Hedging Activities

 

The Company manages its exposure to changes in fuel prices and, from time to time, uses highly effective derivative instruments to manage well-defined risk exposures.  The Company monitors its positions and the credit ratings of its counterparties and does not anticipate non-performance by the counterparties.  The Company does not use derivative instruments for speculative purposes.

 

At June 30, 2011, the Company was party to a series of fuel hedge transactions with a major financial institution under one master agreement. Each of the transactions effectively fixes the cost of diesel fuel at prices ranging from $3.12 to $3.29 per gallon. The Company purchases the diesel fuel at the market rate and periodically settles with its counterparty for the difference between the national average price for the period published by the Department of Energy and the agreed upon fixed price. The transactions fix the price for a total of 3.0 million gallons, which represents approximately 28% of the Company’s total estimated annual usage, and are spread over periods from July 2011 through June 2012.  As of June 30, 2011, the Company recorded, as a component of other comprehensive income before applicable tax impacts, an asset associated with the fair value of the fuel hedge in the amount of $2.0 million, compared to $1.7 million as of December 31, 2010.  Settlement of hedge agreements totaled $0.3 million for the Successor period from May 25, 2011 through June 30, 2011, $0.5 million for the Predecessor period from April 1, 2011 through May 24, 2011, $1.0 million for the Predecessor period from January 1, 2011 through May 24, 2011 and less than $0.1 million during each of the three and six months ended June 30, 2010.

 

7.               Commitments and Contingencies

 

Lease Commitments

 

The Company leases various facilities and equipment under operating lease agreements.

 

The Company also leases certain leasehold improvements under capital leases.  Assets under capital leases are capitalized using inherent interest rates at the inception of each lease. Capital leases are collateralized by the underlying assets.

 

Services

 

The Company is subject to the Medicare and Medicaid fraud and abuse laws which prohibit, among other things, any false claims, or any bribe, kickback or rebate in return for the referral of Medicare and Medicaid patients. Violation of these prohibitions may result in civil and criminal penalties and exclusion from participation in the Medicare and Medicaid programs. Management has implemented policies and procedures that management believes will assure that the Company is in substantial compliance with these laws and regulations but there can be no assurance the Company will not be found to have violated certain of these laws and regulations. From time to time, the Company receives requests for information from government agencies pursuant to their regulatory or investigational authority. Such requests can include subpoenas or demand letters for documents to assist the government agencies in audits or investigations. The Company is cooperating with the government agencies conducting these investigations and is providing requested information to the government agencies. Other than the proceedings described below, management believes that the outcome of any of these investigations would not have a material adverse effect on the Company.

 

Other Legal Matters

 

In December 2006, AMR received a subpoena from the Department of Justice (“DOJ”).  The subpoena requested copies of documents for the period from January 2000 through the present.  The subpoena required AMR to produce a broad range of documents relating to the operations of certain AMR affiliates in New York.  The Company produced documents responsive to the subpoena. The government identified claims for reimbursement that the government believes lack support for the level billed, and invited the Company to respond to the identified areas of concern. The Company reviewed the information provided by the government, provided its response, and is currently in discussions with the DOJ and the Office of the Inspector General of Health and Human Services regarding resolution of this matter.  During the second quarter of 2010, the Company recorded a $3.1 million reserve for its estimate of likely exposure in this matter.  During the second quarter of 2011, the Company entered into a Corporate Integrity Agreement and settlement agreement and paid approximately $3.0 million.

 

Four different lawsuits purporting to be class actions have been filed against AMR and certain subsidiaries in California alleging violations of California wage and hour laws.  On April 16, 2008, Lori Bartoni commenced a suit in the Superior Court for the State of California, County of Alameda; on July 8, 2008, Vaughn Banta filed suit in the Superior Court of the State of California, County of Los Angeles; on January 22, 2009, Laura Karapetian filed suit in the Superior Court of the State of California, County of Los Angeles, and on March 11, 2010, Melanie Aguilar filed suit in Superior Court of the State

 

16



Table of Contents

 

of California, County of Los Angeles.  The Banta and Karapetian cases have been coordinated with the Bartoni case in the Superior Court for the State of California, County of Alameda.  At the present time, courts have not certified classes in any of these cases.  Plaintiffs allege principally that the AMR entities failed to pay overtime charges pursuant to California law, and failed to provide required meal breaks or pay premium compensation for missed meal breaks.  Plaintiffs are seeking to certify the classes and are seeking lost wages, punitive damages, attorneys’ fees and other sanctions permitted under California law for violations of wage hour laws.  The Company is unable at this time to estimate the amount of potential damages, if any.

 

Eleven purported shareholder class actions relating to the transactions contemplated by the Merger Agreement described in Note 2 herein have been filed in state court in Delaware and federal and state courts in Colorado against various combinations of the Company, the members of the Company’s board of directors, and other parties. Seven actions were filed in the Delaware Court of Chancery beginning on February 22, 2011, which were consolidated into one action entitled In re Emergency Medical Services Corporation Shareholder Litigation, Consolidated C.A. No. 6248-VCS. On April 4, 2011, the Delaware plaintiffs filed their consolidated class action complaint. Two actions, entitled Scott A. Halliday v. Emergency Medical Services Corporation, et al., Case No. 2011CV316 (filed on February 15, 2011), and Alma C. Howell v. William Sanger, et. al., Case No. 2011CV488 (filed on March 1, 2011), were filed in the District Court, Arapahoe County, Colorado. Two other actions, entitled Michael Wooten v. Emergency Medical Services Corporation, et al., Case No. 11-CV-00412 (filed on February 17, 2011), and Neal Greenberg v. Emergency Medical Services Corporation, et. al., Case No. 11-CV-00496 (filed on February 28, 2011), were filed in the U.S. District Court for the District of Colorado and have been consolidated. These actions generally allege that the directors of the Company, Onex Corporation and/or Onex Corporation’s subsidiaries breached their fiduciary duties by, among other things: approving the transactions contemplated by the Merger Agreement, which allegedly were financially unfair to the Company and its public stockholders; agreeing to provisions in the Merger Agreement that would allegedly prevent the board from considering other offers; permitting the unitholders agreement (which secured the majority votes in favor of the Merger) and failing to require a provision in the Merger Agreement requiring that a majority of the public stockholders approve the transactions contemplated by the Merger Agreement; and/or making allegedly materially inadequate disclosures. These actions further allege that certain other defendants aided and abetted these breaches. In addition, the two actions filed in the U.S. District Court for the District of Colorado contain individual claims brought under Section 14(a) and Section 20(a) of the Securities Exchange Act of 1934, as amended, pertaining to the purported dissemination of allegedly misleading proxy materials. These actions seek unspecified damages and equitable relief. The Company believes that all of the allegations in these actions are without merit and intends to vigorously defend these matters.

 

In addition to the foregoing shareholder class actions, Merion Capital, L.P., a former stockholder of the Company, has filed an action in the Delaware Court of Chancery seeking to exercise its right to appraisal of its holdings in the Company prior to the Merger. Merion Capital was the holder of 599,000 shares of class A common stock in the Company prior to the Merger.  The Company has not paid any merger consideration for these shares and has recorded a reserve in the amount of $38.3 million for such unpaid merger consideration pending conclusion of the appraisal action.

 

In July 2011, AMR received a request from the Civil Division of the U.S. Attorney’s Office for the Central District of California (“USAO”) asking AMR to preserve certain documents concerning AMR’s provision of ambulance services within the City of Riverside, California.  The USAO indicated that it, together with the Department of Health and Human Services, Office of the Inspector General, are investigating whether AMR violated the federal False Claims Act and/or the federal Anti-Kickback Statute in connection with AMR’s provision of ambulance transport services within the City of Riverside.  The California Attorney General’s Office is conducting a parallel state investigation for possible violations of the California False Claims Act.  The Company has complied with the USAO’s request to preserve documents.

 

The Company is involved in other litigation arising in the ordinary course of business.  Management believes the outcome of these legal proceedings will not have a material adverse effect on its financial condition, results of operations or liquidity.

 

8.               Equity Based Compensation

 

Successor Equity Plans

 

Management of EMSC was allowed to rollover stock options of the Predecessor into fully vested options of the Successor.  In addition, EMSC established a stock compensation plan after the Merger whereby certain members of management were awarded stock options in the Successor Company.  The stock options are valued using the Black-Scholes valuation model on the date of grant.  These options have a $64.00 strike price and vest ratably through December 2015.  A compensation charge of $430 was recorded for the Successor period from May 25, 2011 through June 30, 2011.

 

17



Table of Contents

 

Predecessor Equity Plans

 

For a detailed description of the Company’s pre-merger stock compensation plans, refer to Note 11 to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2010.

 

Total stock-based compensation expense recognized in the Consolidated Statements of Operations resulting from stock options, non-vested restricted stock awards and non-vested restricted stock units was $13.2 million for the Predecessor period from April 1, 2011 through May 24, 2011, $15.1 million for the Predecessor period from January 1, 2011 through May 24, 2011 and $1.4 million and $2.5 million for the three and six months ended June 30, 2010, respectively. Included in the Predecessor periods is $11.7 million of stock-based compensation expense and $0.7 million of payroll tax expense incurred during the period from April 1, 2011 through May 24, 2011 due to the accelerated vesting of stock options, restricted stock awards and restricted stock units as the result of change in control provisions upon closing of the Merger.

 

As discussed in Note 2, vesting of stock options, restricted stock awards and restricted stock units was accelerated upon closing of the Merger. As a result, holders of stock options received cash equal to the intrinsic value of the awards based on a market price of $64.00 per share while holders of restricted stock awards and restricted stock units received $64.00 per share in cash, without interest and the associated options and restricted stock were cancelled.

 

9.               Related Party Transactions

 

Upon completion of the Merger, the Company and CDRT Holding Corporation (“Holding”), the Company’s indirect parent company, entered into a consulting agreement with CD&R, dated May 25, 2011 (the “Consulting Agreement”), pursuant to which CD&R will provide Holding and its subsidiaries, including the Company, with financial, investment banking, management, advisory and other services.  Pursuant to the consulting agreement, Holding, or one or more of its subsidiaries, will pay CD&R an annual fee of $5 million, plus expenses.  CD&R may also charge a transaction fee for certain types of transactions completed by Holding or one or more of its subsidiaries, plus expenses.  During the period from May 25, 2011 through June 30, 2011, the Company expensed $514 in respect of this fee.

 

Pursuant to the Consulting Agreement, CD&R received a transaction fee of $40.0 million and $2.6 million for out-of-pocket and consulting expenses to third-parties CD&R paid prior to the closing of the Merger.  This amount was capitalized as part of the Merger and has been allocated between deferred financing costs, which is included in other long-term assets, and equity on the accompanying balance sheet as of June 30, 2011.

 

The Company was party to a management agreement with a wholly-owned subsidiary of Onex Corporation, the Company’s prior principal equityholder, until May 25, 2011. In exchange for an annual management fee of $1.0 million, the Onex subsidiary provided the Company with corporate finance and strategic planning consulting services. For the periods April 1, 2011 through May 24, 2011 and January 1, 2011 through May 24, 2011, the Company expensed $149 and $399, respectively, in respect of this fee.

 

10.        Segment Information

 

The Company is organized around two separately managed business units: medical transportation services and facility-based physician services, which have been identified as operating segments. The medical transportation services reportable segment focuses on providing a full range of medical transportation services from basic patient transit to the most advanced emergency care and pre-hospital assistance. The facility-based physician services reportable segment provides physician services to hospitals primarily for emergency departments and urgent care centers, as well as for hospitalist/inpatient, radiology, teleradiology and anesthesiology services. The Chief Executive Officer has been identified as the chief operating decision maker (“CODM”) as he assesses the performance of the business units and decides how to allocate resources to the business units.

 

Net income before equity in earnings of unconsolidated subsidiary, income tax expense, loss on early debt extinguishment, interest and other (expense) income, realized (loss) gain on investments, interest expense, stock-based compensation, related party management fees, and depreciation and amortization expense (“Adjusted EBITDA”) is the measure of profit and loss that the CODM uses to assess performance, measure liquidity and make decisions. The Company modified the definition of Adjusted EBITDA following the Merger.  The accounting policies for reported segments are the same as for the Company as a whole.

 

18



Table of Contents

 

The following table presents the Company’s operating segment results for the Successor period from May 25, 2011 through June 30, 2011, the Predecessor period from April 1, 2011 through May 24, 2011, the Predecessor period from January 1, 2011 through May 24, 2011 and the Predecessor periods for the three and six months ended June 30, 2010:

 

 

 

Successor

 

 

Predecessor

 

 

 

Period from May 25
through June 30,

 

 

Period from April 1
through May 24,

 

Quarter ended
June 30,

 

Period from January
1 through May 24,

 

Six months ended
June 30,

 

 

 

2011

 

 

2011

 

2010

 

2011

 

2010

 

Facility-Based Physician Services

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue

 

$

171,714

 

 

$

245,432

 

$

364,645

 

$

642,059

 

$

707,037

 

Segment Adjusted EBITDA

 

24,434

 

 

29,462

 

47,395

 

77,686

 

90,037

 

Medical Transportation Services

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue

 

147,829

 

 

215,523

 

344,159

 

579,731

 

681,121

 

Segment Adjusted EBITDA

 

15,605

 

 

16,091

 

32,690

 

52,896

 

65,837

 

Total

 

 

 

 

 

 

 

 

 

 

 

 

Total net revenue

 

319,543

 

 

460,955

 

708,804

 

1,221,790

 

1,388,158

 

Total Adjusted EBITDA

 

40,039

 

 

45,553

 

80,085

 

130,582

 

155,874

 

Reconciliation of Adjusted EBITDA to Net Income (Loss)

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

 

$

40,039

 

 

$

45,553

 

$

80,085

 

$

130,582

 

$

155,874

 

Depreciation and amortization expense

 

(11,061

)

 

(10,942

)

(15,692

)

(28,467

)

(31,872

)

Equity-based compensation expense

 

(430

)

 

(13,150

)

(1,441

)

(15,112

)

(2,545

)

Related party management fees

 

(514

)

 

(149

)

(250

)

(399

)

(500

)

Interest expense

 

(17,950

)

 

(3,069

)

(5,060

)

(7,886

)

(13,326

)

Realized gain (loss) on investments

 

7

 

 

(5

)

57

 

(9

)

149

 

Interest and other (expense) income

 

(140

)

 

(27,127

)

206

 

(28,873

)

471

 

Loss on early debt extinguishment

 

 

 

(10,069

)

(19,091

)

(10,069

)

(19,091

)

Income tax (expense) benefit

 

(4,158

)

 

3,410

 

(14,955

)

(19,242

)

(34,365

)

Equity in earnings of unconsolidated subsidiary

 

33

 

 

52

 

105

 

143

 

199

 

Net income (loss)

 

$

5,826

 

 

$

(15,496

)

$

23,964

 

$

20,668

 

$

54,994

 

 

A reconciliation of Adjusted EBITDA to cash flows provided by (used in) operating activities is as follows:

 

 

 

Successor

 

 

Predecessor

 

 

 

Period from May 25
through June 30,

 

 

Period from April 1
through May 24,

 

Quarter ended
June 30,

 

Period from January 1
through May 24,

 

Six months ended
June 30,

 

 

 

2011

 

 

2011

 

2010

 

2011

 

2010

 

Adjusted EBITDA

 

$

40,039

 

 

$

45,553

 

$

80,085

 

$

130,582

 

$

155,874

 

Related party management fees

 

(514

)

 

(149

)

(250

)

(399

)

(500

)

Interest expense (less deferred loan fee amortization)

 

(16,046

)

 

(2,538

)

(4,431

)

(6,556

)

(12,190

)

Change in accounts receivable

 

7,102

 

 

613

 

(21,750

)

(10,149

)

(19,559

)

Change in other operating assets/liabilities

 

11,374

 

 

(12,535

)

3,094

 

14,234

 

7,028

 

Excess tax benefits from stock-based compensation

 

 

 

(11,258

)

(2,917

)

(12,427

)

(13,498

)

Interest and other income (expense)

 

(140

)

 

(27,127

)

206

 

(28,873

)

471

 

Income tax (expense) benefit, net of change in deferred taxes

 

(4,110

)

 

3,410

 

(13,982

)

(18,897

)

(33,525

)

Other

 

16

 

 

7

 

102

 

460

 

641

 

Cash flows provided by (used in) operating activities Net income

 

$

37,721

 

 

$

(4,024

)

$

40,157

 

$

67,975

 

$

84,742

 

 

11.                  Guarantors of Debt

 

EMSC is the issuer of the senior unsecured notes and the borrower under the Credit Facilities. The senior unsecured notes and the Credit Facilities are guaranteed by each of EMSC’s domestic subsidiaries, except for any subsidiaries subject to regulation as an insurance company, including EMSC’s captive insurance subsidiary. All of the

 

19



Table of Contents

 

operating income and cash flow of EMSC is generated by AMR, EmCare and their subsidiaries. As a result, funds necessary to meet the debt service obligations under the senior unsecured notes and the Credit Facilities are provided by the distributions or advances from the subsidiary companies, AMR and EmCare. Investments in subsidiary operating companies are accounted for on the equity method. Accordingly, entries necessary to consolidate EMSC and all of its subsidiaries are reflected in the Eliminations/Adjustments column. Separate complete financial statements of EMSC and subsidiary guarantors would not provide additional material information that would be useful in assessing the financial composition of EMSC or the subsidiary guarantors. The condensed consolidating financial statements for EMSC, the guarantors and the non-guarantors are as follows:

 

Consolidating Statements of Operations

 

 

 

Successor

 

 

 

For the period May 25 through June 30, 2011

 

 

 

 

 

Subsidiary

 

Subsidiary

 

Eliminations/

 

 

 

 

 

EMSC

 

Guarantors

 

Non-Guarantors

 

Adjustments

 

Total

 

Net revenue

 

$

 

$

319,319

 

$

1,562

 

$

(1,338

)

$

319,543

 

Compensation and benefits

 

 

221,699

 

105

 

 

221,804

 

Operating expenses

 

 

41,856

 

 

 

41,856

 

Insurance expense

 

 

10,011

 

1,416

 

(1,338

)

10,089

 

Selling, general and administrative expenses

 

 

6,820

 

41

 

 

6,861

 

Depreciation and amortization expense

 

 

11,061

 

 

 

11,061

 

Income from operations

 

 

27,872

 

 

 

27,872

 

Interest income from restricted assets

 

 

98

 

64

 

 

162

 

Interest expense

 

 

(17,950

)

 

 

(17,950

)

Realized gain on investments

 

 

 

7

 

 

7

 

Interest and other income (expense)

 

 

(110

)

(30

)

 

(140

)

Income before income taxes

 

 

9,910

 

41

 

 

9,951

 

Income tax expense

 

 

(4,156

)

(2

)

 

(4,158

)

Income before equity in earnings of unconsolidated subsidiaries

 

 

5,754

 

39

 

 

5,793

 

Equity in earnings of unconsolidated subsidiaries

 

5,826

 

 

33

 

(5,826

)

33

 

Net income

 

$

5,826

 

$

5,754

 

$

72

 

$

(5,826

)

$

5,826

 

 

 

 

Predecessor

 

 

 

For the period from April 1 through May 24, 2011

 

 

 

 

 

Subsidiary

 

Subsidiary

 

Eliminations/

 

 

 

 

 

EMSC

 

Guarantors

 

Non-Guarantors

 

Adjustments

 

Total

 

Net revenue

 

$

 

$

460,574

 

$

2,334

 

$

(1,953

)

$

460,955

 

Compensation and benefits

 

 

337,394

 

162

 

 

337,556

 

Operating expenses

 

 

59,780

 

(3

)

 

59,777

 

Insurance expense

 

 

22,114

 

529

 

(1,953

)

20,690

 

Selling, general and administrative expenses

 

 

11,404

 

2

 

 

11,406

 

Depreciation and amortization expense

 

 

10,942

 

 

 

10,942

 

Income from operations

 

 

18,940

 

1,644

 

 

20,584

 

Interest income from restricted assets

 

 

133

 

595

 

 

728

 

Interest expense

 

 

(3,069

)

 

 

(3,069

)

Realized loss on investments

 

 

 

(5

)

 

(5

)

Interest and other income (expense)

 

 

(27,086

)

(41

)

 

(27,127

)

Loss on early debt extinguishment

 

 

(10,069

)

 

 

(10,069

)

Income (loss) before income taxes

 

 

(21,151

)

2,193

 

 

(18,958

)

Income tax benefit (expense)

 

 

3,414

 

(4

)

 

3,410

 

Income (loss) before equity in earnings of unconsolidated subsidiaries

 

 

(17,737

)

2,189

 

 

(15,548

)

Equity in earnings of unconsolidated subsidiaries

 

(15,496

)

 

52

 

15,496

 

52

 

Net income (loss)

 

$

(15,496

)

$

(17,737

)

$

2,241

 

$

15,496

 

$

(15,496

)

 

20



Table of Contents

 

 

 

Predecessor

 

 

 

For the quarter ended June 30, 2010

 

 

 

 

 

Subsidiary

 

Subsidiary

 

Eliminations/

 

 

 

 

 

EMSC

 

Guarantors

 

Non-Guarantors

 

Adjustments

 

Total

 

Net revenue

 

$

 

$

708,224

 

$

19,443

 

$

(18,863

)

$

708,804

 

Compensation and benefits

 

 

496,186

 

257

 

 

496,443

 

Operating expenses

 

 

90,362

 

224

 

 

90,586

 

Insurance expense

 

 

25,359

 

19,446

 

(18,863

)

25,942

 

Selling, general and administrative expenses

 

 

18,143

 

155

 

 

18,298

 

Depreciation and amortization expense

 

 

15,692

 

 

 

15,692

 

Income (loss) from operations

 

 

62,482

 

(639

)

 

61,843

 

Interest income from restricted assets

 

 

344

 

515

 

 

859

 

Interest expense

 

 

(5,060

)

 

 

(5,060

)

Realized gain on investments

 

 

 

57

 

 

57

 

Interest and other income

 

 

218

 

(12

)

 

206

 

Loss on early debt extinguishment

 

 

(19,091

)

 

 

(19,091

)

Income (loss) before income taxes

 

 

38,893

 

(79

)

 

38,814

 

Income tax expense

 

 

(14,945

)

(10

)

 

(14,955

)

Income (loss) before equity in earnings of unconsolidated subsidiaries

 

 

23,948

 

(89

)

 

23,859

 

Equity in earnings of unconsolidated subsidiaries

 

23,964

 

 

105

 

(23,964

)

105

 

Net income

 

$

23,964

 

$

23,948

 

$

16

 

$

(23,964

)

$

23,964

 

 

 

 

Predecessor

 

 

 

For the period from January 1 through May 24, 2011

 

 

 

 

 

Subsidiary

 

Subsidiary

 

Eliminations/

 

 

 

 

 

EMSC

 

Guarantors

 

Non-Guarantors

 

Adjustments

 

Total

 

Net revenue

 

$

 

$

1,221,024

 

$

20,709

 

$

(19,943

)

$

1,221,790

 

Compensation and benefits

 

 

874,135

 

498

 

 

874,633

 

Operating expenses

 

 

156,734

 

6

 

 

156,740

 

Insurance expense

 

 

48,471

 

18,701

 

(19,943

)

47,229

 

Selling, general and administrative expenses

 

 

28,801

 

440

 

 

29,241

 

Depreciation and amortization expense

 

 

28,467

 

 

 

28,467

 

Income from operations

 

 

84,416

 

1,064

 

 

85,480

 

Interest income from restricted assets

 

 

364

 

760

 

 

1,124

 

Interest expense

 

 

(7,886

)

 

 

(7,886

)

Realized loss on investments

 

 

 

(9

)

 

(9

)

Interest and other income (expense)

 

 

(28,782

)

(91

)

 

(28,873

)

Loss on early debt extinguishment

 

 

(10,069

)

 

 

(10,069

)

Income before income taxes

 

 

38,043

 

1,724

 

 

39,767

 

Income tax expense

 

 

(19,233

)

(9

)

 

(19,242

)

Income before equity in earnings of unconsolidated subsidiaries

 

 

18,810

 

1,715

 

 

20,525

 

Equity in earnings of unconsolidated subsidiaries

 

20,668

 

 

143

 

(20,668

)

143

 

Net income

 

$

20,668

 

$

18,810

 

$

1,858

 

$

(20,668

)

$

20,668

 

 

21



Table of Contents

 

 

 

Predecessor

 

 

 

For the six months ended June 30, 2010

 

 

 

 

 

Subsidiary

 

Subsidiary

 

Eliminations/

 

 

 

 

 

EMSC

 

Guarantors

 

Non-Guarantors

 

Adjustments

 

Total

 

Net revenue

 

$

 

$

1,387,096

 

$

27,163

 

$

(26,101

)

$

1,388,158

 

Compensation and benefits

 

 

976,245

 

515

 

 

976,760

 

Operating expenses

 

 

176,879

 

236

 

 

177,115

 

Insurance expense

 

 

46,816

 

27,297

 

(26,101

)

48,012

 

Selling, general and administrative expenses

 

 

34,961

 

195

 

 

35,156

 

Depreciation and amortization expense

 

 

31,871

 

1

 

 

31,872

 

Income (loss) from operations

 

 

120,324

 

(1,081

)

 

119,243

 

Interest income from restricted assets

 

 

688

 

1,026

 

 

1,714

 

Interest expense

 

 

(13,326

)

 

 

(13,326

)

Realized gain on investments

 

 

 

149

 

 

149

 

Interest and other income

 

 

471

 

 

 

471

 

Loss on early extinguishment of debt

 

 

(19,082

)

(9

)

 

(19,091

)

Income before income taxes

 

 

89,075

 

85

 

 

89,160

 

Income tax expense

 

 

(34,350

)

(15

)

 

(34,365

)

Income before equity in earnings of unconsolidated subsidiaries

 

 

54,725

 

70

 

 

54,795

 

Equity in earnings of unconsolidated subsidiaries

 

54,994

 

 

199

 

(54,994

)

199

 

Net income

 

$

54,994

 

$

54,725

 

$

269

 

$

(54,994

)

$

54,994

 

 

22



Table of Contents

 

Consolidating Balance Sheet

As of June 30, 2011

 

 

 

Successor

 

 

 

 

 

Subsidiary

 

Subsidiary

 

Eliminations/

 

 

 

 

 

EMSC

 

Guarantors

 

Non-Guarantor

 

Adjustments

 

Total

 

Assets

 

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

 

$

157,692

 

$

29,119

 

$

 

$

186,811

 

Insurance collateral

 

 

23,980

 

22,070

 

(9,401

)

36,649

 

Trade and other accounts receivable, net

 

 

508,549

 

1,730

 

 

510,279

 

Parts and supplies inventory

 

 

23,340

 

9

 

 

23,349

 

Prepaids and other current assets

 

 

27,328

 

595

 

(1,618

)

26,305

 

Current deferred tax assets

 

 

(3,595

)

3,595

 

 

 

Current assets

 

 

737,294

 

57,118

 

(11,019

)

783,393

 

Non-current assets:

 

 

 

 

 

 

 

 

 

 

 

Property, plant, and equipment, net

 

 

135,479

 

 

 

135,479

 

Intercompany receivable

 

2,920,239

 

 

 

(2,920,239

)

 

Intangible assets, net

 

 

758,031

 

 

 

758,031

 

Non-current deferred tax assets

 

 

4,125

 

(6,120

)

1,995

 

 

Insurance collateral

 

 

8,331

 

108,621

 

 

116,952

 

Goodwill

 

 

2,163,145

 

816

 

 

2,163,961

 

Other long-term assets

 

108,072

 

5,313

 

1,595

 

 

114,980

 

Investment and advances in subsidiaries

 

299,493

 

6,145

 

 

(305,638

)

 

Assets

 

$

3,327,804

 

$

3,817,863

 

$

162,030

 

$

(3,234,901

)

$

4,072,796

 

Liabilities and Equity

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

 

 

 

Accounts payable

 

$

 

$

39,474

 

$

293

 

$

 

$

39,767

 

Accrued liabilities

 

58,935

 

258,885

 

18,208

 

 

336,028

 

Current deferred tax liability

 

 

7,345

 

 

 

7,345

 

Current portion of long-term debt

 

14,400

 

665

 

 

 

15,065

 

Current liabilities

 

73,335

 

306,369

 

18,501

 

 

398,205

 

Long-term debt

 

2,363,168

 

1,102

 

 

 

2,364,270

 

Long-term deferred tax liability

 

 

238,286

 

 

 

238,286

 

Insurance reserves and other long-term liabilities

 

 

104,392

 

85,366

 

(9,024

)

180,734

 

Intercompany payable

 

 

2,868,221

 

52,018

 

(2,920,239

)

 

Liabilities

 

2,436,503

 

3,518,370

 

155,885

 

(2,929,263

)

3,181,495

 

Equity:

 

 

 

 

 

 

 

 

 

 

 

Common stock

 

 

 

30

 

(30

)

 

Additional paid-in capital

 

885,868

 

296,332

 

4,316

 

(300,648

)

885,868

 

Retained earnings

 

5,826

 

3,554

 

2,272

 

(5,826

)

5,826

 

Comprehensive income

 

(393

)

(393

)

(473

)

866

 

(393

)

Equity

 

891,301

 

299,493

 

6,145

 

(305,638

)

891,301

 

Liabilities and Equity

 

$

3,327,804

 

$

3,817,863

 

$

162,030

 

$

(3,234,901

)

$

4,072,796

 

 

23



Table of Contents

 

Consolidating Balance Sheet

As of December 31, 2010

 

 

 

Predecessor

 

 

 

 

 

Subsidiary

 

Subsidiary

 

Eliminations/

 

 

 

 

 

EMSC

 

Guarantors

 

Non-Guarantor

 

Adjustments

 

Total

 

Assets

 

 

 

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

 

$

260,834

 

$

26,527

 

$

 

$

287,361

 

Insurance collateral

 

 

6,409

 

30,046

 

(2,979

)

33,476

 

Trade and other accounts receivable, net

 

 

488,354

 

1,304

 

 

489,658

 

Parts and supplies inventory

 

 

23,005

 

26

 

 

23,031

 

Prepaids and other current assets

 

 

22,623

 

193

 

(4,199

)

18,617

 

Current deferred tax assets

 

 

(3,834

)

3,834

 

 

 

Current assets

 

 

797,391

 

61,930

 

(7,178

)

852,143

 

Non-current assets:

 

 

 

 

 

 

 

 

 

 

 

Property, plant, and equipment, net

 

 

133,731

 

 

 

133,731

 

Intercompany receivable

 

409,362

 

 

 

(409,362

)

 

Intangible assets, net

 

 

180,374

 

 

 

180,374

 

Non-current deferred tax assets

 

 

4,126

 

(6,120

)

1,994

 

 

Insurance collateral

 

 

31,664

 

109,669

 

(5,270

)

136,063

 

Goodwill

 

 

426,947

 

458

 

 

427,405

 

Other long-term assets

 

11,333

 

5,657

 

1,846

 

 

18,836

 

Investment and advances in subsidiaries

 

847,191

 

37,427

 

 

(884,619

)

 

Assets

 

$

1,267,886

 

$

1,617,317

 

$

167,783

 

$

(1,304,435

)

$

1,748,552

 

Liabilities and Equity

 

 

 

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

 

 

 

Accounts payable

 

$

 

$

39,279

 

$

302

 

$

 

$

39,581

 

Accrued liabilities

 

979

 

231,148

 

27,511

 

 

259,638

 

Current deferred tax liabilities

 

 

5,114

 

 

 

5,114

 

Current portion of long-term debt

 

15,938

 

395

 

 

 

16,333

 

Current liabilities

 

16,917

 

275,936

 

27,813

 

 

320,666

 

Long-term debt

 

403,750

 

1,193

 

 

 

404,943

 

Long-term deferred tax liabilities

 

 

5,971

 

 

 

5,971

 

Insurance reserves and other long-term liabilities

 

 

89,582

 

90,625

 

(10,440

)

169,767

 

Intercompany payable

 

 

397,444

 

11,918

 

(409,362

)

 

Liabilities

 

420,667

 

770,126

 

130,356

 

(419,802

)

901,347

 

Equity:

 

 

 

 

 

 

 

 

 

 

 

Class A common stock

 

304

 

 

30

 

(30

)

304

 

Class B common stock

 

1

 

 

 

 

1

 

Partnership equity

 

90,776

 

393,139

 

 

(393,140

)

90,776

 

Treasury stock at cost

 

(1,684

)

 

 

 

(1,684

)

Additional paid-in capital

 

305,258

 

 

4,316

 

(4,316

)

305,258

 

Retained earnings

 

450,780

 

452,268

 

30,968

 

(483,250

)

450,766

 

Comprehensive income

 

1,784

 

1,784

 

2,113

 

(3,897

)

1,784

 

Equity

 

847,219

 

847,191

 

37,427

 

(884,633

)

847,205

 

Liabilities and Equity

 

$

1,267,886

 

$

1,617,317

 

$

167,783

 

$

(1,304,435

)

$

1,748,552

 

 

24



Table of Contents

 

Condensed Consolidating Statements of Cash Flows

 

 

 

Successor

 

 

 

For the period May 25 through June 30, 2011

 

 

 

 

 

Subsidiary

 

Subsidiary

 

 

 

 

 

EMSC

 

Guarantors

 

Non-guarantors

 

Total

 

Cash Flows from Operating Activities

 

 

 

 

 

 

 

 

 

Net cash provided by (used in) operating activities

 

$

 

$

38,487

 

$

(766

)

$

37,721

 

Cash Flows from Investing Activities

 

 

 

 

 

 

 

 

 

Merger, net of cash received

 

(2,844,221

)

 

 

(2,844,221

)

Purchase of property, plant and equipment

 

 

(2,892

)

 

(2,892

)

Proceeds from sale of property, plant and equipment

 

 

55

 

 

55

 

Acquisition of businesses, net of cash received

 

 

(4,668

)

 

(4,668

)

Net change in insurance collateral

 

 

2,835

 

1,707

 

4,542

 

Net change in deposits and other assets

 

 

(262

)

 

(262

)

Net cash (used in) provided by investing activities

 

(2,844,221

)

(4,932

)

1,707

 

(2,847,446

)

Cash Flows from Financing Activities

 

 

 

 

 

 

 

 

 

Borrowings under senior secured credit facility

 

1,440,000

 

 

 

1,440,000

 

Proceeds from issuance of senior subordinated notes

 

950,000

 

 

 

950,000

 

Proceeds from CD&R equity investment

 

887,051

 

 

 

887,051

 

Repayments of capital lease obligations and other debt

 

(418,875

)

 

 

(418,875

)

Equity issuance costs

 

(26,196

)

 

 

(26,196

)

Debt issue costs

 

(114,021

)

 

 

 

(114,021

)

Net change in bank overdrafts

 

 

(7,971

)

 

(7,971

)

Net intercompany borrowings (payments)

 

126,262

 

(124,812

)

(1,450

)

 

Net cash provided by (used in) financing activities

 

2,844,221

 

(132,783

)

(1,450

)

2,709,988

 

Change in cash and cash equivalents

 

 

(99,228

)

(509

)

(99,737

)

Cash and cash equivalents, beginning of period

 

 

256,919

 

29,628

 

286,547

 

Cash and cash equivalents, end of period

 

$

 

$

157,691

 

$

29,119

 

$

186,810

 

 

 

 

Predecessor

 

 

 

For the period from January 1 through May 24, 2011

 

 

 

 

 

Subsidiary

 

Subsidiary

 

 

 

 

 

EMSC

 

Guarantors

 

Non-guarantors

 

Total

 

Cash Flows from Operating Activities

 

 

 

 

 

 

 

 

 

Net cash provided by (used in) operating activities

 

$

 

$

73,707

 

$

(5,732

)

$

67,975

 

Cash Flows from Investing Activities

 

 

 

 

 

 

 

 

 

Purchase of property, plant and equipment

 

 

(18,496

)

 

(18,496

)

Proceeds from sale of property, plant and equipment

 

 

55

 

 

55

 

Acquisition of businesses, net of cash received

 

 

(94,870

)

 

(94,870

)

Net change in insurance collateral

 

 

14,510

 

8,526

 

23,036

 

Net change in deposits and other assets

 

 

816

 

 

816

 

Net cash (used in) provided by investing activities

 

 

(97,985

)

8,526

 

(89,459

)

Cash Flows from Financing Activities

 

 

 

 

 

 

 

 

 

EMSC issuance of class A common stock

 

559

 

 

 

559

 

Class A common stock repurchased as treasury stock

 

(2,440

)

 

 

(2,440

)

Repayments of capital lease obligations and other debt

 

 

(4,116

)

 

(4,116

)

Excess tax benefits from stock-based compensation

 

 

12,427

 

 

12,427

 

Net change in bank overdrafts

 

 

14,241

 

 

14,241

 

Net intercompany borrowings (payments)

 

1,881

 

(1,828

)

(53

)

 

Net cash provided by (used in) financing activities

 

 

20,724

 

(53

)

20,671

 

Change in cash and cash equivalents

 

 

(3,554

)

2,741

 

(813

)

Cash and cash equivalents, beginning of period

 

 

260,834

 

26,527

 

287,361

 

Cash and cash equivalents, end of period

 

$

 

$

257,280

 

$

29,268

 

$

286,548

 

 

25



Table of Contents

 

 

 

Predecessor

 

 

 

For the six months ended June 30, 2010

 

 

 

 

 

Subsidiary

 

Subsidiary

 

 

 

 

 

EMSC

 

Guarantors

 

Non-guarantors

 

Total

 

Cash Flows from Operating Activities

 

 

 

 

 

 

 

 

 

Net cash provided by operating activities

 

$

 

$

58,108

 

$

26,634

 

$

84,742

 

Cash Flows from Investing Activities

 

 

 

 

 

 

 

 

 

Purchase of property, plant and equipment

 

 

(15,168

)

 

(15,168

)

Proceeds from sale of property, plant and equipment

 

 

108

 

 

108

 

Acquisition of businesses, net of cash received

 

 

(50,975

)

 

(50,975

)

Net change in insurance collateral

 

 

22,573

 

(27,834

)

(5,261

)

Net change in deposits and other assets

 

 

10,938

 

 

10,938

 

Net cash used in investing activities

 

 

(32,524

)

(27,834

)

(60,358

)

Cash Flows from Financing Activities

 

 

 

 

 

 

 

 

 

EMSC issuance of class A common stock

 

6,193

 

 

 

6,193

 

Repayments of capital lease obligations and other debt

 

 

(452,627

)

 

(452,627

)

Borrowings under credit facility

 

 

425,000

 

 

425,000

 

Debt issue costs

 

 

(11,749

)

 

(11,749

)

Payment of premiums for debt extinguishment

 

 

(14,513

)

 

(14,513

)

Excess tax benefits from stock-based compensation

 

 

13,498

 

 

13,498

 

Net change in bank overdrafts

 

 

(10,041

)

 

(10,041

)

Net intercompany borrowings (payments)

 

(6,193

)

3,592

 

2,601

 

 

Net cash (used in) provided by financing activities

 

 

(46,840

)

2,601

 

(44,239

)

Change in cash and cash equivalents

 

 

(21,256

)

1,401

 

(19,855

)

Cash and cash equivalents, beginning of period

 

 

314,033

 

18,855

 

332,888

 

Cash and cash equivalents, end of period

 

$

 

$

292,777

 

$

20,256

 

$

313,033

 

 

11.          Subsequent Events

 

The Company’s management has evaluated events subsequent to June 30, 2011 through the issuance date of this report to identify any necessary changes to the consolidated financial statements or related disclosures.  Below is a description of events for which disclosure was deemed necessary.

 

On August 1, 2011, the Company acquired all the capital stock of Medics Ambulance Service and substantially all of its subsidiaries and corporate affiliates (collectively, “Medics Ambulance”) through its indirect, wholly-owned subsidiaries. Medics Ambulance provides ground medical transportation services in south Florida.

 

26



Table of Contents

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-Looking Statements and Factors That May Affect Results

 

Certain statements and information herein may be deemed to be “forward-looking statements” within the meaning of the Federal Private Securities Litigation Reform Act of 1995. Forward-looking statements may include, but are not limited to, statements relating to our objectives, plans and strategies, and all statements (other than statements of historical facts) that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future. Any forward-looking statements herein are made as of the date this Quarterly Report on Form 10-Q is filed with the Securities and Exchange Commission, and EMSC undertakes no duty to update or revise any such statements. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in EMSC’s filings with the SEC from time to time, including in the section entitled “Risk Factors” in EMSC’s most recent Annual Report on Form 10-K and in Item 1A, Risk Factors of this Quarterly Report. Among the factors that could cause future results to differ materially from those provided in this Quarterly Report on Form 10-Q are: the impact on our revenue of changes in transport volume, mix of insured and uninsured patients, and third party reimbursement rates and methods; the adequacy of our insurance coverage and insurance reserves; potential penalties or changes to our operations if we fail to comply with extensive and complex government regulation of our industry; the impact of changes in the healthcare industry; our ability to recruit and retain qualified physicians and other healthcare professionals, and enforce our non-compete agreements with our physicians; our ability to generate cash flow to service our debt obligations; the cost of capital expenditures to maintain and upgrade our vehicle fleet and medical equipment; the loss of one or more members of our senior management team; the outcome of government investigations of certain of our business practices; our ability to successfully restructure our operations to comply with future changes in government regulation; the loss of existing contracts and the accuracy of our assessment of costs under new contracts; the high level of competition in our industry; our ability to maintain or implement complex information systems; our ability to implement our business strategy; our ability to successfully integrate strategic acquisitions; our ability to comply with the terms of our settlement agreements with the government; the risk that the benefits from the Merger, as defined below, and related transactions may not be fully realized or may take longer to realize than expected; and risks related to other factors discussed in the Quarterly Report.

 

Words such as “anticipates,” “believes,” “continues,” “estimates,” “expects,” “goal,” “objectives,” “intends,” “may,” “opportunity,” “plans,” “potential,” “near-term,” “long-term,” “projections,” “assumptions,” “projects,” “guidance,” “forecasts,” “outlook,” “target,” “trends,” “should,” “could,” “would,” “will” and similar expressions are intended to identify such forward-looking statements.  We qualify any forward-looking statements entirely by these cautionary factors.

 

All references to “we”, “our”, “us”, or “EMSC”,  refer to Emergency Medical Services Corporation and its subsidiaries. Our business is conducted primarily through two operating subsidiaries, EmCare Holdings Inc., or EmCare, and American Medical Response, Inc., or AMR.

 

This Quarterly Report should be read in conjunction with EMSC’s consolidated financial statements and notes thereto included in our Annual Report on Form 10-K filed with the SEC on February 18, 2011.

 

Company Overview

 

We are a leading provider of medical transportation services and facility-based physician services in the United States. We operate our business and market our services under the EmCare and AMR brands.  EmCare, over its more than 35 years of operating history, is a leading provider of physician services in the United States based on number of contracts with hospitals and affiliated physician groups.  Through EmCare, we provide facility-based physician services for emergency departments and hospitalist/inpatient, anesthesiology, radiology, and teleradiology programs.  AMR, over its more than 50 years of operating history, is a leading provider of ground and fixed-wing ambulance services in the United States based on net revenue and number of transports.

 

Merger

 

On February 13, 2011, EMSC entered into an Agreement and Plan of Merger, or Merger Agreement, with CDRT Acquisition Corporation, a Delaware corporation, or Parent, and CDRT Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent, or Sub.  Parent and Sub are and were, respectively, affiliates of investment funds sponsored by, or affiliated with, Clayton, Dubilier & Rice, LLC, or the CD&R Affiliates.  On May 25, 2011, pursuant to the Merger Agreement and subject to the conditions set forth therein, Sub merged with and into EMSC with EMSC as the surviving entity and a wholly-owned subsidiary of Parent, or the Merger.

 

27



Table of Contents

 

At the time the Merger was effective, each issued and outstanding share of class A common stock and class B common stock, including shares of Class B common stock issued immediately prior to the effective time of the Merger in exchange for the LP exchangeable units of EMS LP, but excluding treasury shares, shares held by Parent or Sub and shares held by stockholders who perfected their appraisal rights, were converted into the right to receive $64.00 per share in cash, without interest and subject to any applicable withholding taxes.  In addition, vesting of stock options, restricted stock, and restricted share units was accelerated upon closing of the Merger. As a result, holders of stock options received cash equal to the intrinsic value of the awards based on a market price of $64.00 per share while holders of restricted stock and restricted share units received $64.00 per share in cash, without interest.

 

The Merger was financed by a combination of borrowings under EMSC’s new senior secured term loan facility, the issuance of new senior unsecured notes, and the equity investment by the CD&R Affiliates and members of EMSC management. The purchase price was approximately $3.2 billion including approximately $150 million in capitalized issuance costs, of which $110 million are debt issuance costs. The Merger was funded primarily through a $915 million equity contribution from the CD&R Affiliates and members of EMSC management and $2.4 billion in debt financing discussed more fully in Note 5 to the accompanying consolidated financial statements.

 

EMSC applied purchase accounting to the opening balance sheet and results of operations on May 25, 2011 as the Merger occurred at the close of business on May 24, 2011. The purchase accounting adjustments had a material impact on the Successor period presented, from May 25, 2011 through June 30, 2011, due most significantly to the amortization of intangible assets and interest expense and will have a material impact on future earnings. The value assigned at June 30, 2011 to intangible assets is based on preliminary valuation data and may change once an external valuation is completed during the third quarter of 2011.

 

Presentation

 

The accompanying Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q are presented for two periods for 2011: Predecessor and Successor results, which primarily relate to the periods preceding the Merger and the period succeeding the Merger, respectively. The discussion in this MD&A is presented on a combined basis of the Predecessor and Successor periods for 2011. The 2011 Predecessor and Successor results are presented but are not discussed separately. Management believes that the discussion on a combined basis is more meaningful as it allows the results of operations to be analyzed to a comparable period in 2010.  Exceptions to this include depreciation and amortization expense, interest expense, and interest and other (expense) income, which had significant impacts as a result of the Merger, but are addressed separately in the discussion below.  See Note 1 to the accompanying consolidated financial statements.

 

Key Factors and Measures We Use to Evaluate Our Business

 

The key factors and measures we use to evaluate our business focus on the number of patients we treat and transport and the costs we incur to provide the necessary care and transportation for each of our patients.

 

We evaluate our revenue net of provisions for contractual payor discounts and provisions for uncompensated care. Medicaid, Medicare and certain other payors receive discounts from our standard charges, which we refer to as contractual discounts. In addition, individuals we treat and transport may be personally responsible for a deductible or co-pay under their third party payor coverage, and most of our contracts require us to treat and transport patients who have no insurance or other third party payor coverage. Due to the uncertainty regarding collectability of charges associated with services we provide to these patients, which we refer to as uncompensated care, our net revenue recognition is based on expected cash collections. Our net revenue represents gross billings after provisions for contractual discounts and estimated uncompensated care. Provisions for contractual discounts and uncompensated care have increased historically primarily as a result of increases in gross billing rates without corresponding increases in payor reimbursement.

 

The table below summarizes our approximate payor mix as a percentage of both net revenue and total transports and patient encounters for the three and six months ended June 30, 2011 and 2010.  In determining the net revenue payor mix, we use cash collections in the period as an approximation of net revenue recorded.

 

28



Table of Contents

 

 

 

Percentage of Cash Collections (Net Revenue)

 

Percentage of Total Volume

 

 

 

Quarter ended
June 30,

 

Six months ended
June 30,

 

Quarter ended
June 30,

 

Six months ended
June 30,

 

 

 

2011

 

2010

 

2011

 

2010

 

2011

 

2010

 

2011

 

2010

 

Medicare

 

21.7

%

21.7

%

22.0

%

21.9

%

26.1

%

24.7

%

26.3

%

24.9

%

Medicaid

 

6.3

%

5.3

%

6.1

%

5.1

%

12.8

%

12.7

%

13.1

%

12.5

%

Commercial insurance and managed care

 

49.0

%

49.9

%

48.7

%

49.8

%

43.1

%

43.3

%

42.6

%

43.0

%

Self-pay

 

5.1

%

4.2

%

4.9

%

4.2

%

18.0

%

19.3

%

18.0

%

19.6

%

Subsidies & fees

 

17.9

%

18.9

%

18.3

%

19.0

%

 

 

 

 

Total

 

100.0

%

100.0

%

100.0

%

100.0

%

100.0

%

100.0

%

100.0

%

100.0

%

 

Our 2011 volume mix has been positively impacted compared to our 2010 volume mix primarily by the continued expansion of our anesthesia business, which has a lower percentage of self-pay volume than our emergency department, radiology and inpatient services businesses.

 

In addition to continually monitoring our payor mix, we also analyze certain measures in each of our business segments.

 

EmCare

 

Of EmCare’s net revenue for the six months ended June 30, 2011, approximately 74% was derived from our hospital contracts for emergency department staffing, 15% from contracts related to anesthesiology services, 5% from our hospitalist/inpatient services, 3% from our services provided to radiology/teleradiology services, and 3% from other hospital management services. Approximately 78% of EmCare’s net revenue was generated from billings to third party payors and patients for patient encounters and approximately 22% was generated from billings to hospitals and affiliated physician groups for professional services. EmCare’s key net revenue measures are patient encounters, segregated into emergency department visits, radiology reads, and anesthesiology and hospitalist encounters and that we weight in certain analyses, net revenue per patient encounter, and number of contracts.

 

The change from period to period in the number of patient encounters under our “same store” contracts is influenced by general community conditions as well as hospital-specific elements, many of which are beyond our direct control.

 

The costs incurred in our EmCare business segment consist primarily of compensation and benefits for physicians and other professional providers, professional liability costs, and contract and other support costs. EmCare’s key cost measures include provider compensation per patient encounter and professional liability costs.

 

We have developed extensive professional liability risk mitigation processes, including risk assessments on medical professionals and hospitals, extensive incident reporting and tracking processes, clinical fail-safe programs, training and education and other risk mitigation programs which we believe have resulted in a reduction in the frequency, severity and development of claims.

 

Our EmCare business segment is less capital intensive than AMR, and EmCare’s depreciation expense relates primarily to charges for usage of computer hardware and software, and other technologies. Amortization expense relates primarily to intangibles recorded for customer relationships.

 

AMR

 

Approximately 87% of AMR’s net revenue for the six months ended June 30, 2011 was transport revenue derived from the treatment and transportation of patients, including fixed wing medical transportation services, based on billings to third party payors, healthcare facilities and patients. The balance of AMR’s net revenue is derived from direct billings to communities and government agencies for the provision of training, dispatch center and other services.  AMR’s measures for net revenue include transports, segregated into ambulance and wheelchair transports and that we weight in certain analyses, and net revenue per transport.

 

The change from period to period in the number of transports and net revenue per transport is influenced by the mix of emergency versus non-emergency transports, changes in transports in existing markets from both new and existing facilities we serve for non-emergency transports, the effects of general community conditions for emergency transports and the impact of newly acquired businesses and markets AMR has exited.

 

29



Table of Contents

 

The costs we incur in our AMR business segment consist primarily of compensation and benefits for ambulance crews and support personnel, direct and indirect operating costs to provide transportation services, and costs related to accident and insurance claims. AMR’s key cost measures include unit hours and cost per unit hour (to measure compensation-related costs and the efficiency of our ambulance deployment), operating costs per transport, and accident and insurance claims.

 

We have focused our risk mitigation efforts on employee training for proper patient handling techniques, development of clinical and medical equipment protocols, driving safety, implementation of technology to reduce auto incidents and other risk mitigation processes which we believe have resulted in a reduction in the frequency, severity and development of claims.

 

Our AMR business segment requires various investments in long-term assets and depreciation expense relates primarily to charges for usage of these assets, including vehicles, computer hardware and software, equipment, and other technologies.  Amortization expense relates primarily to intangibles recorded for customer relationships.

 

Factors Affecting Operating Results

 

Changes in Net New Contracts

 

Our operating results are affected directly by the number of net new contracts and related volumes we have in a period, reflecting the effects of both new contracts and contract expirations. We regularly bid for new contracts, frequently in a formal competitive bidding process that often requires written responses to a Request for Proposal, or RFP, and, in any fiscal period, certain of our contracts will expire. We may elect not to seek extension or renewal of a contract, or may reduce certain services, if we determine that we cannot continue to provide such services on favorable terms. With respect to expiring contracts we would like to renew, we may be required to seek renewal through an RFP, and we may not be successful in retaining any such contracts, or retaining them on terms that are as favorable as present terms.

 

Inflation

 

Certain of our expenses, such as wages and benefits, insurance, fuel and equipment repair and maintenance costs, are subject to normal inflationary pressures. Fuel expense represented 11.7% and 10.0% of AMR’s operating expenses for the three months ended June 30, 2011 and 2010, respectively, and 11.2% and 9.8% for the six months ended June 30, 2011 and 2010, respectively.  Although we have generally been able to offset inflationary cost increases through increased operating efficiencies and successful negotiation of fees and subsidies, we can provide no assurance that we will be able to offset any future inflationary cost increases through similar efficiencies and fee changes.

 

Critical Accounting Policies

 

For a discussion of accounting policies that we consider critical to our business operations and the understanding of our results of operations that affect the more significant judgments and estimates used in the preparation of our unaudited condensed consolidated financial statements, please refer to Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations — Critical Accounting Policies” contained in our annual report on Form 10-K for the year ended December 31, 2010 and incorporated by reference herein. As of June 30, 2011, there were no significant changes in our critical accounting policies or estimation procedures.

 

Business Combinations

 

Effective January 1, 2009, we adopted ASC 805, Business Combinations , which revised the accounting guidance that we were required to apply for our acquisitions in comparison to prior fiscal years . In accordance with this guidance, the assets and liabilities of an acquired business are recorded at their fair values at the date of acquisition. The excess of the purchase price over the estimated fair values is recorded as goodwill. All acquisition costs are expensed as incurred. While we use our best estimates and assumptions as a part of the purchase price allocation process to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period we may record adjustments to the assets acquired and liabilities assumed, with the corresponding offset to goodwill. Upon the conclusion of the measurement period any subsequent adjustments are recorded as expense.

 

Revenue Recognition

 

Revenue is recognized at the time of service and is recorded net of provisions for contractual discounts and estimated uncompensated care.  We estimate our provision for contractual discounts and uncompensated care based on payor reimbursement schedules, historical collections and write-off experience and other economic data.  As a result of the estimates used in recording the provisions and the nature of healthcare collections, which may involve lengthy delays, there is a reasonable possibility that recorded estimates will change materially in the short-term.

 

The changes in the provisions for contractual discounts and uncompensated care are primarily a result of changes in our gross fee-for-service rate schedules and gross accounts receivable balances. These gross fee schedules, including any changes to existing fee schedules, generally are negotiated with various contracting entities, including municipalities and facilities. Fee schedule increases are billed for all revenue sources and to all payors under that specific contract; however, reimbursement in the case of certain state and federal payors, including Medicare and Medicaid, will not change as a result of the change in gross fee schedules. In certain cases, this results in a higher level of contractual and uncompensated care provisions and allowances, requiring a higher percentage of contractual discount and uncompensated care provisions compared to gross charges.

 

30



Table of Contents

 

In addition, management analyzes the ultimate collectability of revenue and accounts receivable after certain stages of the collection cycle using a look-back analysis to determine the amount of receivables subsequently collected.  Adjustments related to this analysis are recorded as a reduction or increase to net revenue each month, and were less than 1% of net revenue during each of three and six month periods ending June 30, 2011 and 2010.

 

Results of Operations

 

Quarter and Six Months Ended June 30, 2011 Compared to the Quarter and Six Months Ended June 30, 2010

 

The following tables present a comparison of financial data from our unaudited consolidated statements of operations for the three and six months ended June 30, 2011 and 2010 for EMSC and our two operating segments.  As noted previously in Item 2, the results of operations will be discussed on a combined basis for 2011.  Management believes that the discussion on a combined basis is more meaningful as it allows the results of operations to be analyzed to a comparable period in 2010.  Exceptions to this include depreciation and amortization expense, interest expense, and interest and other (expense) income, which had significant impacts as a result of the Merger, but are addressed separately in the discussion below. The Predecessor and Successor breakout is presented for information purposes only.

 

Non-GAAP Measures

 

Adjusted EBITDA.  Adjusted EBITDA is defined as net income before equity in earnings of unconsolidated subsidiary, income tax expense, loss on early debt extinguishment, interest and other (expense) income, realized (loss) gain on investments, interest expense, stock-based compensation, related party management fees, and depreciation and amortization expense.  Adjusted EBITDA is commonly used by management and investors as a performance measure and liquidity indicator. Adjusted EBITDA is not considered a measure of financial performance under U.S. generally accepted accounting principles, or GAAP, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing our financial performance. Adjusted EBITDA should not be considered in isolation or as an alternative to such GAAP measures as net income, cash flows provided by or used in operating, investing or financing activities or other financial statement data presented in our financial statements as an indicator of financial performance or liquidity. Since Adjusted EBITDA is not a measure determined in accordance with GAAP and is susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. The tables set forth a reconciliation of Adjusted EBITDA to net income and cash flows provided by operating activities.

 

Unaudited Consolidated Results of Operations and as a Percentage of Net Revenue

(dollars in thousands)

EMSC

 

 

 

Combined

 

Predecessor

 

Combined

 

Predecessor

 

 

 

Quarter ended June 30,

 

Six months ended June 30,

 

 

 

2011

 

% of net
revenue

 

2010

 

% of net
revenue

 

2011

 

% of net
revenue

 

2010

 

% of net
revenue

 

Net revenue

 

$

780,498

 

100.0

%

$

708,804

 

100.0

%

$

1,541,333

 

100.0

%

$

1,388,158

 

100.0

%

Compensation and benefits

 

559,360

 

71.7

 

496,443

 

70.0

 

1,096,437

 

71.1

 

976,760

 

70.4

 

Operating expenses

 

101,633

 

13.0

 

90,586

 

12.8

 

198,596

 

12.9

 

177,115

 

12.8

 

Insurance expense

 

30,779

 

3.9

 

25,942

 

3.7

 

57,318

 

3.7

 

48,012

 

3.5

 

Selling, general and administrative expenses

 

18,267

 

2.3

 

18,298

 

2.6

 

36,102

 

2.3

 

35,156

 

2.5

 

Equity-based compensation expense

 

(13,580

)

(1.7

)

(1,441

)

(0.2

)

(15,542

)

(1.0

)

(2,545

)

(0.2

)

Related party management fees

 

(663

)

(0.1

)

(250

)

(0.0

)

(913

)

(0.1

)

(500

)

(0.0

)

Interest income from restricted assets

 

(890

)

(0.1

)

(859

)

(0.1

)

(1,286

)

(0.1

)

(1,714

)

(0.1

)

Adjusted EBITDA

 

$

85,592

 

11.0

%

$

80,085

 

11.3

%

$

170,621

 

11.1

%

$

155,874

 

11.2

%

Equity-based compensation expense

 

(13,580

)

(1.7

)

(1,441

)

(0.2

)

(15,542

)

(1.0

)

(2,545

)

(0.2

)

Related party management fees

 

(663

)

(0.1

)

(250

)

(0.0

)

(913

)

(0.1

)

(500

)

(0.0

)

Depreciation and amortization expense

 

(22,003

)

(2.8

)

(15,692

)

(2.2

)

(39,528

)

(2.6

)

(31,872

)

(2.3

)

Interest expense

 

(21,019

)

(2.7

)

(5,060

)

(0.7

)

(25,836

)

(1.7

)

(13,326

)

(1.0

)

Realized gain (loss) on investments

 

2

 

0.0

 

57

 

0.0

 

(2

)

(0.0

)

149

 

0.0

 

Interest and other (expense) income

 

(27,267

)

(3.5

)

206

 

0.0

 

(29,013

)

(1.9

)

471

 

0.0

 

Loss on early debt extinguishment

 

(10,069

)

(1.3

)

(19,091

)

(2.7

)

(10,069

)

(0.7

)

(19,091

)

(1.4

)

Income tax expense

 

(748

)

(0.1

)

(14,955

)

(2.1

)

(23,400

)

(1.5

)

(34,365

)

(2.5

)

Equity in earnings of unconsolidated subsidiary

 

85

 

0.0

 

105

 

0.0

 

176

 

0.0

 

199

 

0.0

 

Net (loss) income

 

$

(9,670

)

(1.2

)%

$

23,964

 

3.4

%

$

26,494

 

1.7

%

$

54,994

 

4.0

%

 

31



Table of Contents

 

 

 

Successor

 

 

Predecessor

 

 

 

Period from May 25
through June 30,

 

 

Period from April 1
through May 24,

 

Period from January 1
through May 24,

 

 

 

2011

 

% of net
revenue

 

 

2011

 

% of net
revenue

 

2011

 

% of net
revenue

 

Net revenue

 

$

319,543

 

100.0

%

 

$

460,955

 

100.0

%

$

1,221,790

 

100.0

%

Compensation and benefits

 

221,804

 

69.4

 

 

337,556

 

73.2

 

874,633

 

71.6

 

Operating expenses

 

41,856

 

13.1

 

 

59,777

 

13.0

 

156,740

 

12.8

 

Insurance expense

 

10,089

 

3.2

 

 

20,690

 

4.5

 

47,229

 

3.9

 

Selling, general and administrative expenses

 

6,861

 

2.1

 

 

11,406

 

2.5

 

29,241

 

2.4

 

Equity-based compensation expense

 

(430

)

(0.1

)

 

(13,150

)

(2.9

)

(15,112

)

(1.2

)

Related party management fees

 

(514

)

(0.2

)

 

(149

)

(0.0

)

(399

)

(0.0

)

Interest income from restricted assets

 

(162

)

(0.1

)

 

(728

)

(0.2

)

(1,124

)

(0.1

)

Adjusted EBITDA

 

$

40,039

 

12.5

%

 

$

45,553

 

9.9

%

$

130,582

 

10.7

%

Equity-based compensation expense

 

(430

)

(0.1

)

 

(13,150

)

(2.9

)

(15,112

)

(1.2

)

Related party management fees

 

(514

)

(0.2

)

 

(149

)

(0.0

)

(399

)

(0.0

)

Depreciation and amortization expense

 

(11,061

)

(3.5

)

 

(10,942

)

(2.4

)

(28,467

)

(2.3

)

Interest expense

 

(17,950

)

(5.6

)

 

(3,069

)

(0.7

)

(7,886

)

(0.6

)

Realized gain (loss) on investments

 

7

 

0.0

 

 

(5

)

(0.0

)

(9

)

(0.0

)

Interest and other income (expense)

 

(140

)

(0.0

)

 

(27,127

)

(5.9

)

(28,873

)

(2.4

)

Loss on early debt extinguishment

 

 

 

 

(10,069

)

(2.2

)

(10,069

)

(0.8

)

Income tax expense

 

(4,158

)

(1.3

)

 

3,410

 

0.7

 

(19,242

)

(1.6

)

Equity in earnings of unconsolidated subsidiary

 

33

 

0.0

 

 

52

 

0.0

 

143

 

0.0

 

Net income (loss)

 

$

5,826

 

1.8

%

 

$

(15,496

)

(3.4

)%

$

20,668

 

1.7

%

 

Unaudited Reconciliation of Adjusted EBITDA to Cash Flows Provided by Operating Activities

(dollars in thousands)

 

 

 

Combined

 

Predecessor

 

Combined

 

Predecessor

 

 

 

For the quarter ended June 30,

 

For the six months ended June 30,

 

 

 

2011

 

2010

 

2011

 

2010

 

Adjusted EBITDA

 

$

85,592

 

$

80,085

 

$

170,621

 

$

155,874

 

Related party management fees

 

(663

)

(250

)

(913

)

(500

)

Interest expense (less deferred loan fee amortization)

 

(18,585

)

(4,431

)

(22,602

)

(12,190

)

Change in accounts receivable

 

7,715

 

(21,750

)

(3,047

)

(19,559

)

Change in other operating assets/liabilities

 

(1,161

)

3,094

 

25,608

 

7,028

 

Excess tax benefits from stock-based compensation

 

(11,258

)

(2,917

)

(12,427

)

(13,498

)

Interest and other income (expense)

 

(27,267

)

206

 

(29,013

)

471

 

Income tax expense, net of change in deferred taxes

 

(700

)

(13,982

)

(23,007

)

(33,525

)

Other

 

24

 

102

 

476

 

641

 

Cash flows provided by operating activities

 

$

33,697

 

$

40,157

 

$

105,696

 

$

84,742

 

 

 

 

Successor

 

 

Predecessor

 

 

 

Period from May 25
through June 30,

 

 

Period from April 1
through May 24,

 

Period from January 1
through May 24,

 

 

 

2011

 

 

2011

 

2011

 

Adjusted EBITDA

 

$

40,039

 

 

$

45,553

 

$

130,582

 

Related party management fees

 

(514

)

 

(149

)

(399

)

Interest expense (less deferred loan fee amortization)

 

(16,046

)

 

(2,538

)

(6,556

)

Change in accounts receivable

 

7,102

 

 

613

 

(10,149

)

Change in other operating assets/liabilities

 

11,374

 

 

(12,535

)

14,234

 

Excess tax benefits from stock-based compensation

 

 

 

(11,258

)

(12,427

)

Interest and other income (expense)

 

(140

)

 

(27,127

)

(28,873

)

Income tax (expense) benefit, net of change in deferred taxes

 

(4,110

)

 

3,410

 

(18,897

)

Other

 

16

 

 

7

 

460

 

Cash flows provided by (used in) operating activities

 

$

37,721

 

 

$

(4,024

)

$

67,975

 

 

32


 


Table of Contents

 

Unaudited Segment Results of Operations and as a Percentage of Net Revenue

(dollars in thousands)

 

EmCare

 

 

 

Combined

 

Predecessor

 

Combined

 

Predecessor

 

 

 

Quarter ended June 30,

 

Six months ended June 30,

 

 

 

2011

 

% of net
revenue

 

2010

 

% of net
revenue

 

2011

 

% of net
revenue

 

2010

 

% of net
revenue

 

Net revenue

 

$

417,146

 

100.0

%

$

364,645

 

100.0

%

$

813,773

 

100.0

%

$

707,037

 

100.0

%

Compensation and benefits

 

331,792

 

79.5

 

285,141

 

78.2

 

646,831

 

79.5

 

557,107

 

78.8

 

Operating expenses

 

14,405

 

3.5

 

12,147

 

3.3

 

27,078

 

3.3

 

23,037

 

3.3

 

Insurance expense

 

15,335

 

3.7

 

13,167

 

3.6

 

29,992

 

3.7

 

24,052

 

3.4

 

Selling, general and administrative expenses

 

8,612

 

2.1

 

8,071

 

2.2

 

15,807

 

1.9

 

15,200

 

2.1

 

Interest income from restricted assets

 

(485

)

(0.1

)

(515

)

(0.1

)

(650

)

(0.1

)

(1,026

)

(0.1

)

Equity-based compensation expense

 

(6,111

)

(1.5

)

(648

)

(0.2

)

(6,994

)

(0.9

)

(1,145

)

(0.2

)

Related party management fees

 

(298

)

(0.1

)

(113

)

(0.0

)

(411

)

(0.1

)

(225

)

(0.0

)

Adjusted EBITDA

 

$

53,896

 

12.9

%

$

47,395

 

13.0

%

$

102,120

 

12.5

%

$

90,037

 

12.7

%

Reconciliation of Adjusted EBITDA to income from operations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

 

53,896

 

12.9

 

47,395

 

13.0

 

102,120

 

12.5

 

90,037

 

12.7

 

Depreciation and amortization expenses

 

(8,144

)

(2.0

)

(4,622

)

(1.3

)

(14,098

)

(1.7

)

(9,568

)

(1.4

)

Interest income from restricted assets

 

(485

)

(0.1

)

(515

)

(0.1

)

(650

)

(0.1

)

(1,026

)

(0.1

)

Equity-based compensation expense

 

(6,111

)

(1.5

)

(648

)

(0.2

)

(6,994

)

(0.9

)

(1,145

)

(0.2

)

Related party management fees

 

(298

)

(0.1

)

(113

)

(0.0

)

(411

)

(0.1

)

(225

)

(0.0

)

Income from operations

 

$

38,858

 

9.3

%

$

41,497

 

11.4

%

$

79,967

 

9.8

%

$

78,073

 

11.0

%

 

 

 

Successor

 

 

Predecessor

 

 

 

Period from May 25
through June 30,

 

 

Period from April 1
through May 24,

 

Period from January
1 through May 24,

 

 

 

2011

 

% of net
revenue

 

 

2011

 

% of net
revenue

 

2011

 

% of net
revenue

 

Net revenue

 

$

171,714

 

100.0

%

 

$

245,432

 

100.0

%

$

642,059

 

100.0

%

Compensation and benefits

 

133,192

 

77.6

 

 

198,600

 

80.9

 

513,639

 

80.0

 

Operating expenses

 

6,040

 

3.5

 

 

8,365

 

3.4

 

21,038

 

3.3

 

Insurance expense

 

5,631

 

3.3

 

 

9,704

 

4.0

 

24,361

 

3.8

 

Selling, general and administrative expenses

 

2,907

 

1.7

 

 

5,705

 

2.3

 

12,900

 

2.0

 

Interest income from restricted assets

 

(66

)

(0.0

)

 

(419

)

(0.2

)

(584

)

(0.1

)

Equity-based compensation expense

 

(193

)

(0.1

)

 

(5,918

)

(2.4

)

(6,801

)

(1.1

)

Related party management fees

 

(231

)

(0.1

)

 

(67

)

(0.0

)

(180

)

(0.0

)

Adjusted EBITDA

 

$

24,434

 

14.2

%

 

$

29,462

 

12.0

%

$

77,686

 

12.1

%

Reconciliation of Adjusted EBITDA to income from operations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

 

24,434

 

14.2

 

 

29,462

 

12.0

 

77,686

 

12.1

 

Depreciation and amortization expense

 

(4,687

)

(2.7

)

 

(3,457

)

(1.4

)

(9,411

)

(1.5

)

Interest income from restricted assets

 

(66

)

(0.0

)

 

(419

)

(0.2

)

(584

)

(0.1

)

Equity-based compensation expense

 

(193

)

(0.1

)

 

(5,918

)

(2.4

)

(6,801

)

(1.1

)

Related party management fees

 

(231

)

(0.1

)

 

(67

)

(0.0

)

(180

)

(0.0

)

Income from operations

 

$

19,257

 

11.2

%

 

$

19,601

 

8.0

%

$

60,710

 

9.5

%

 

33



Table of Contents

 

AMR

 

 

 

Combined

 

Predecessor

 

Combined

 

Predecessor

 

 

 

Quarter ended June 30,

 

Six months ended June 30,

 

 

 

2011

 

% of net
revenue

 

2010

 

% of net
revenue

 

2011

 

% of net
revenue

 

2010

 

% of net
revenue

 

Net revenue

 

$

363,352

 

100.0

%

$

344,159

 

100.0

%

$

727,560

 

100.0

%

$

681,121

 

100.0

%

Compensation and benefits

 

227,568

 

62.6

 

211,302

 

61.4

 

449,606

 

61.8

 

419,653

 

61.6

 

Operating expenses

 

87,228

 

24.0

 

78,439

 

22.8

 

171,518

 

23.6

 

154,078

 

22.6

 

Insurance expense

 

15,444

 

4.3

 

12,775

 

3.7

 

27,326

 

3.8

 

23,960

 

3.5

 

Selling, general and administrative expenses

 

9,655

 

2.7

 

10,227

 

3.0

 

20,295

 

2.8

 

19,956

 

2.9

 

Interest income from restricted assets

 

(405

)

(0.1

)

(344

)

(0.1

)

(636

)

(0.1

)

(688

)

(0.1

)

Equity-based compensation expense

 

(7,469

)

(2.1

)

(793

)

(0.2

)

(8,548

)

(1.2

)

(1,400

)

(0.2

)

Related party management fees

 

(365

)

(0.1

)

(137

)

(0.0

)

(502

)

(0.1

)

(275

)

(0.0

)

Adjusted EBITDA

 

$

31,696

 

8.7

%

$

32,690

 

9.5

%

$

68,501

 

9.4

%

$

65,837

 

9.7

%

Reconciliation of Adjusted EBITDA to income from operations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

 

31,696

 

8.7

%

32,690

 

9.5

 

68,501

 

9.4

 

65,837

 

9.7

 

Depreciation and amortization expense

 

(13,859

)

(3.8

)

(11,070

)

(3.2

)

(25,430

)

(3.5

)

(22,304

)

(3.3

)

Interest income from restricted assets

 

(405

)

(0.1

)

(344

)

(0.1

)

(636

)

(0.1

)

(688

)

(0.1

)

Equity-based compensation expense

 

(7,469

)

(2.1

)

(793

)

(0.2

)

(8,548

)

(1.2

)

(1,400

)

(0.2

)

Related party management fees

 

(365

)

(0.1

)

(137

)

(0.0

)

(502

)

(0.1

)

(275

)

(0.0

)

Income from operations

 

$

9,598

 

2.6

%

$

20,346

 

5.9

%

$

33,385

 

4.6

%

$

41,170

 

6.0

%

 

 

 

Successor

 

 

Predecessor

 

 

 

Period from May 25
through June 30,

 

 

Period from April 1
through May 24,

 

Period from January
1 through May 24,

 

 

 

2011

 

% of net
revenue

 

 

2011

 

% of net
revenue

 

2011

 

% of net
revenue

 

Net revenue

 

$

147,829

 

100.0

%

 

$

215,523

 

100.0

%

$

579,731

 

100.0

%

Compensation and benefits

 

88,612

 

59.9

 

 

138,956

 

64.5

 

360,994

 

62.3

 

Operating expenses

 

35,816

 

24.2

 

 

51,412

 

23.9

 

135,702

 

23.4

 

Insurance expense

 

4,458

 

3.0

 

 

10,986

 

5.1

 

22,868

 

3.9

 

Selling, general and administrative expenses

 

3,954

 

2.7

 

 

5,701

 

2.6

 

16,341

 

2.8

 

Interest income from restricted assets

 

(96

)

(0.1

)

 

(309

)

(0.1

)

(540

)

(0.1

)

Equity-based compensation expense

 

(237

)

(0.2

)

 

(7,232

)

(3.4

)

(8,311

)

(1.4

)

Related party management fees

 

(283

)

(0.2

)

 

(82

)

(0.0

)

(219

)

(0.0

)

Adjusted EBITDA

 

$

15,605

 

10.6

%

 

$

16,091

 

7.5

%

$

52,896

 

9.1

%

Reconciliation of Adjusted EBITDA to income from operations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Adjusted EBITDA

 

15,605

 

10.6

 

 

16,091

 

7.5

 

52,896

 

9.1

 

Depreciation and amortization expense

 

(6,374

)

(4.3

)

 

(7,485

)

(3.5

)

(19,056

)

(3.3

)

Interest income from restricted assets

 

(96

)

(0.1

)

 

(309

)

(0.1

)

(540

)

(0.1

)

Equity-based compensation expense

 

(237

)

(0.2

)

 

(7,232

)

(3.4

)

(8,311

)

(1.4

)

Related party management fees

 

(283

)

(0.2

)

 

(82

)

(0.0

)

(219

)

(0.0

)

Income from operations

 

$

8,615

 

5.8

%

 

$

983

 

0.5

%

$

24,770

 

4.3

%

 

Quarter ended June 30, 2011 compared to the quarter ended June 30, 2010

 

Consolidated

 

         Our results for the three months ended June 30, 2011 reflect an increase in net revenue of $71.7 million and a decrease in net income of $33.6 million compared to the three months ended June 30, 2010.  The decrease in net income is attributable primarily to an increase in interest expense and other fees associated with the Merger, partially offset by a decrease in income tax expense.  During the three months ended June 30, 2011, we recorded $27.9 million for fees associated with the Merger, which are included in interest and other (expense) income.  An additional $12.4 million in stock compensation expense was recorded for stock options and restricted stock which automatically vested with the Merger and the associated payroll taxes; see Note 1 to the accompanying unaudited consolidated financial statements.

 

34



Table of Contents

 

Net revenue.  For the three months ended June 30, 2011, we generated net revenue of $780.5 million compared to net revenue of $708.8 million for the three months ended June 30, 2010, representing an increase of 10.1%.  The increase is attributable primarily to increases in rates and volumes on existing contracts combined with increased volume from net new contracts and acquisitions.

 

Adjusted EBITDA. Adjusted EBITDA was $85.6 million, or 11.0% of net revenue, for the three months ended June 30, 2011 compared to $80.1 million, or 11.3% of net revenue, for the three months ended June 30, 2010.

 

Interest and other (expense) income. During the three months ended June 30, 2011, $27.3 million was expensed compared to $0.2 million of income recognized during the three months ended June 30, 2010.  The increase in expense was due to $27.9 million expensed during the second quarter of 2011 for investment banking, legal, accounting and other advisory services related to the Merger.

 

Loss on early debt extinguishment. During the three months ended June 30, 2011, we recorded a loss on early debt extinguishment of $10.1 million which included unamortized debt issuance associated with our credit facility in place prior to the Merger.  During the three months ended June 30, 2010, we recorded a loss on early debt extinguishment of $19.1 million as we entered into a new credit facility and redeemed our senior subordinated notes.

 

Interest expense. Interest expense for the three months ended June 30, 2011 was $21.0 million compared to $5.1 million for the three months ended June 30, 2010.  The change was due to the increase in our outstanding debt and effective interest rate associated with the issuance of our new senior subordinated unsecured notes and borrowings under our new credit facilities in May 2011.  In conjunction with entering into our new credit facilities, we increased our total outstanding debt by $2.0 billion.

 

Income tax expense (benefit).  Income tax expense decreased by $14.2 million for the three months ended June 30, 2011 compared to the same period in 2010.  Our effective tax rate was 41.8% for the Successor period from May 25, 2011 through June 30, 2011 and 48.4% for the Predecessor period from January 1, 2011 through May 24, 2011.  Our effective tax rate for the quarter ended June 30, 2010 was 38.5%.  The increase in our effective tax rate was a result of certain Merger related costs that are not deductible for tax purposes.

 

EmCare

 

Net revenue.  Net revenue for the three months ended June 30, 2011 was $417.1 million, an increase of $52.5 million, or 14.4%, from $364.6 million for the three months ended June 30, 2010. The increase was due primarily to an increase in patient encounters from net new hospital contracts and net revenue increases in existing contracts.  Net new contracts since March 31, 2010 accounted for a net revenue increase of $41.4 million for the three months ended June 30, 2011, of which $31.7 million came from net new contracts added in 2010 with the remaining increase in net revenue from those added in 2011.  Net revenue under our “same store” contracts (contracts in existence for the entirety of both periods) increased $11.1 million, or 3.6%, for the three months ended June 30, 2011.  The change was due primarily to a 4.3% increase in same store weighted patient encounters, partially offset by a 0.7% decrease in revenue per weighted patient encounter.

 

Compensation and benefits. Compensation and benefits costs for the three months ended June 30, 2011 were $331.8 million, or 79.5% of net revenue, compared to $285.1 million, or 78.2% of net revenue, for the same period in 2010. Stock-based compensation expense was $6.1 million during the three months ended June 30, 2011 compared to $0.6 million during the same quarter last year.  The increase was due primarily to accelerated stock-based compensation expense associated with the Merger.  Provider compensation costs increased $30.2 million from net new contract additions. Same store provider compensation costs were $8.2 million higher than the prior period due primarily to a 4.3% increase in same store weighted patient encounters, partially offset by a 0.2% decrease in provider compensation per weighted patient encounter. Non-provider compensation and total benefits costs, excluding stock-based compensation expense, increased by $2.7 million during the three months ended June 30, 2011 compared to the same period in 2010. The increase is due to our recent acquisitions and organic growth. Payroll taxes related to the Merger of $0.3 million were also expensed during the quarter ended June 30, 2011.

 

Operating expenses.  Operating expenses for the three months ended June 30, 2011 were $14.4 million, or 3.5% of net revenue, compared to $12.1 million, or 3.3% of net revenue, for the same period in 2010.  Operating expenses increased $2.3 million due primarily to our recent acquisitions and organic growth.

 

Insurance expense.  Professional liability insurance expense for the three months ended June 30, 2011 was $15.3 million, or 3.7% of net revenue, compared to $13.2 million, or 3.6% of net revenue, for the three months ended June 30, 2010.  We recorded an increase of prior year insurance provisions of $1.6 million during the three months ended June 30, 2011 compared to an increase of $1.8 million during the three months ended June 30, 2010.

 

35



Table of Contents

 

Selling, general and administrative.  Selling, general and administrative expense for the three months ended June 30, 2011 was $8.6 million, or 2.1% of net revenue, compared to $8.1 million, or 2.2% of net revenue, for the three months ended June 30, 2010.

 

Depreciation and amortization.  Depreciation and amortization expense for the three months ended June 30, 2011 was $8.1 million, or 2.0% of net revenue, compared to $4.6 million, or 1.3% of net revenue, for the three months ended June 30, 2010.  The $3.5 million increase is due primarily to additional amortization expense associated with intangible assets recorded as a result of the Merger transaction during the second quarter of 2011 as well as amortization expense associated with contract intangible assets recorded on acquisitions completed since March 31, 2010.

 

AMR

 

Net revenue.  Net revenue for the three months ended June 30, 2011 was $363.4 million, an increase of $19.2 million, or 5.6%, from $344.2 million for the same period in 2010. The increase in net revenue was due primarily to an increase of 2.3%, or $7.8 million, in weighted transport volume and an increase in net revenue per weighted transport of 3.3%, or $11.4 million.  The increase in net revenue per weighted transport of 3.3% was due to a 1.7% increase in net revenue per transport resulting primarily from a higher mix of emergency versus non-emergency transports and rate increases in several markets, with the remaining increase coming from growth in our managed transportation business. AMR’s managed transportation business represented 6.2% of AMR’s net revenue for the quarter ended June 30, 2011 compared to 4.7% for the quarter ended June 30, 2010.  Weighted transports increased 16,400 from the same quarter last year.  The change was due to an increase in weighted transport volume in existing markets of 0.1%, or 600 weighted transports, an increase of 11,800 weighted transports from acquisitions, and an increase of 5,200 weighted transports from our entry into new markets, which increases were partially offset by a decrease of 1,200 weighted transports from the exit of certain markets.

 

Compensation and benefits. Compensation and benefit costs for the three months ended June 30, 2011 were $227.6 million, or 62.6% of net revenue, compared to $211.3 million, or 61.4% of net revenue, for the same period last year. Stock-based compensation expense was $7.5 million during the three months ended June 30, 2011 compared to $0.8 million during the same quarter last year.  The increase was due primarily to accelerated stock-based compensation expense associated with the Merger. Ambulance crew wages per ambulance unit hour increased by approximately 2.7%, or $3.2 million, attributable primarily to annual wage rate increases. Ambulance unit hours increased period over period by 2.4%, or $2.9 million, due primarily to our recent acquisitions and entry into new markets. Non-crew compensation, excluding stock-based compensation expense, increased period over period by $0.1 million. Total benefits related costs increased $3.4 million due primarily to increases in payroll taxes, of which $0.3 million were related to the Merger, and higher costs for our health insurance plans.

 

Operating expenses.  Operating expenses for the three months ended June 30, 2011 were $87.2 million, or 24.0% of net revenue, compared to $78.4 million, or 22.8% of net revenue, for the three months ended June 30, 2010.  The change is due primarily to increased costs associated with our managed transportation business of $6.7 million and an increase in fuel costs of $2.4 million.

 

Insurance expense.  Insurance expense for the three months ended June 30, 2011 was $15.4 million, or 4.3% of net revenue, compared to $12.8 million, or 3.7% of net revenue, for the same period in 2010.  We recorded an increase of prior year insurance provisions of $4.1 million during the three months ended June 30, 2011 compared to an increase of $1.0 million during the three months ended June 30, 2010.

 

Selling, general and administrative.  Selling, general and administrative expense for the three months ended June 30, 2011 was $9.7 million, or 2.7% of net revenue, compared to $10.2 million, or 3.0% of net revenue, for the three months ended June 30, 2010.

 

Depreciation and amortization.  Depreciation and amortization expense for the three months ended June 30, 2011 was $13.9 million, or 3.8% of net revenue, compared to $11.1 million, or 3.2% of net revenue, for the same period in 2010.  The increase was due primarily to additional amortization expense associated with intangible assets recorded as a result of the Merger transaction during the second quarter of 2011.

 

Six months ended June 30, 2011 compared to the six months ended June 30, 2010

 

Consolidated

 

Our results for the six months ended June 30, 2011 reflect an increase in net revenue of $153.2 million and a decrease in net income of $28.5 million compared to the six months ended June 30, 2010.  The decrease in net income is attributable primarily to an increase in interest expense and other fees associated with the Merger, partially offset by a decrease in income tax expense. 

 

36



Table of Contents

 

During the six months ended June 30, 2011, we recorded $29.8 million for fees associated with the Merger, which are included in interest and other (expense) income.  An additional $12.4 million in stock compensation expense was recorded for stock options and restricted stock which automatically vested with the Merger and the associated payroll taxes; see Note 1 to the accompanying unaudited consolidated financial statements.

 

Net revenue.  For the six months ended June 30, 2011, we generated net revenue of $1,541.3 million compared to net revenue of $1,388.2 million for the six months ended June 30, 2010, representing an increase of 11.0%.  The increase is attributable primarily to increases in rates and volumes on existing contracts combined with increased volume from net new contracts and acquisitions.

 

Adjusted EBITDA. Adjusted EBITDA was $170.6 million, or 11.1% of net revenue, for the six months ended June 30, 2011 compared to $155.9 million, or 11.2% of net revenue, for the six months ended June 30, 2010.

 

Interest expense. Interest expense for the six months ended June 30, 2011 was $25.8 million compared to $13.3 million for the six months ended June 30, 2010.  The change was due to the increase in our outstanding debt and effective interest rate associated with the issuance of our new senior subordinated unsecured notes and borrowings under our new credit facilities in May 2011.  In conjunction with entering into our new credit facility, we increased our total outstanding debt by $2.0 billion.

 

Interest and other (expense) income. During the six months ended June 30, 2011, $29.0 million was expensed compared to $0.5 million of income recognized during the six months ended June 30, 2010.  The increase in expense was due to $29.8 million expensed during the second quarter of 2011 for investment banking, legal, accounting and other advisory services related to the Merger.

 

Loss on early debt extinguishment. During the six months ended June 30, 2011, we recorded a loss on early debt extinguishment of $10.1 million which included unamortized debt issuance associated with our credit facility in place prior to the Merger.  During the six months ended June 30, 2010, we recorded a loss on early debt extinguishment of $19.1 million as we entered into a new credit facility and redeemed our senior subordinated notes.

 

Income tax expense.  Income tax expense decreased by $11.0 million for the six months ended June 30, 2011 compared to the same period in 2010.  Our effective tax rate was 41.8% for the Successor period from May 25, 2011 through June 30, 2011 and 48.4% for the Predecessor period from January 1, 2011 through May 24, 2011.  Our effective tax rate for the six months ended June 30, 2010 was 38.5%.  The increase in our effective tax rate was a result of certain Merger related costs that are not deductible for tax purposes.

 

EmCare

 

Net revenue.  Net revenue for the six months ended June 30, 2011 was $813.8 million, an increase of $106.7 million, or 15.1%, from $707.0 million for the six months ended June 30, 2010. The increase was due primarily to an increase in patient encounters from net new hospital contracts and net revenue increases in existing contracts. Net new contracts since December 31, 2009 accounted for a net revenue increase of $81.5 million for the six months ended June 30, 2011, of which $69.6 million came from net new contracts added in 2010 with the remaining increase in net revenue from those added in 2011.  Net revenue under our “same store” contracts (contracts in existence for the entirety of both periods) increased $25.2 million, or 4.3%, for the six months ended June 30, 2011.  The change was due primarily to a 5.5% increase in same store weighted patient encounters, partially offset by a 1.2% decrease in revenue per weighted patient encounter.  The increase in same store net revenue was due primarily to additional volume, partially offset by a lower average charge per patient, related to a stronger flu season in the first quarter of 2011 compared to the same period in 2010.

 

Compensation and benefits. Compensation and benefits costs for the six months ended June 30, 2011 were $646.8 million, or 79.5% of net revenue, compared to $557.1 million, or 78.8% of net revenue, for the same period in 2010. Stock-based compensation expense was $7.0 million during the six months ended June 30, 2011 compared to $1.1 million during the same quarter last year.  The increase was due primarily to accelerated stock-based compensation expense associated with the Merger.  Provider compensation costs increased $62.3 million from net new contract additions. Same store provider compensation costs were $15.5 million higher than the prior period due primarily to a 5.5% increase in same store weighted patient encounters, partially offset by a 1.5% decrease in provider compensation per weighted patient encounter. Non-provider compensation and total benefits costs, excluding stock-based compensation expense, increased by $6.0 million during the three months ended June 30, 2011 compared to the same period in 2010. The increase is due to our recent acquisitions and organic growth. Payroll taxes related to Merger of $0.3 million were also expensed during the six months ended June 30, 2011.

 

37



Table of Contents

 

Operating expenses.  Operating expenses for the six months ended June 30, 2011 were $27.1 million, or 3.3% of net revenue, compared to $23.0 million, or 3.3% of net revenue, for the same period in 2010.  Operating expenses increased $4.1 million due primarily to our recent acquisitions and organic growth.

 

Insurance expense.  Professional liability insurance expense for the six months ended June 30, 2011 was $30.0 million, or 3.7% of net revenue, compared to $24.1 million, or 3.4% of net revenue, for the six months ended June 30, 2010.  We recorded an increase of prior year insurance provisions of $3.3 million during the six months ended June 30, 2011 compared to a decrease of less than $0.1 million during the six months ended June 30, 2010.

 

Selling, general and administrative.  Selling, general and administrative expense for the six months ended June 30, 2011 was $15.8 million, or 1.9% of net revenue, compared to $15.2 million, or 2.1% of net revenue, for the six months ended June 30, 2010.

 

Depreciation and amortization.  Depreciation and amortization expense for the six months ended June 30, 2011 was $14.1 million, or 1.7% of net revenue, compared to $9.6 million, or 1.4% of net revenue, for the six months ended June 30, 2010.  The $4.5 million increase is due primarily to additional amortization expense associated with intangible assets recorded as a result of the Merger transaction during the second quarter of 2011 as well as amortization expense associated with contract intangible assets recorded on acquisitions completed since December 31, 2009.

 

AMR

 

Net revenue.  Net revenue for the six months ended June 30, 2011 was $727.6 million, an increase of $46.4 million, or 6.8%, from $681.1 million for the same period in 2010. The increase in net revenue was due primarily to an increase of 3.5%, or $23.7 million, in weighted transport volume and an increase in net revenue per weighted transport of 3.3%, or $22.7 million.  The increase in net revenue per weighted transport of 3.3% was due to a 1.7% increase in net revenue per transport resulting primarily from a higher mix of emergency versus non-emergency transports and rate increases in several markets, with the remaining increase coming from growth in our managed transportation business. AMR’s managed transportation business represented 6.1% of AMR’s net revenue for the six months ended June 30, 2011 compared to 4.6% for the six months ended June 30, 2010.  Weighted transports increased 50,100 from the same period last year.  The change was due to an increase in weighted transport volume in existing markets of 1.5%, or 21,700 weighted transports, an increase of 21,500 weighted transports from acquisitions, and an increase of 9,500 weighted transports from our entry into new markets, which increases were partially offset by a decrease of 2,600 weighted transports from the exit of certain markets.

 

Compensation and benefits. Compensation and benefit costs for the six months ended June 30, 2011 were $449.6 million, or 61.8% of net revenue, compared to $419.7 million, or 61.6% of net revenue, for the same period last year. Stock-based compensation expense was $8.5 million during the six months ended June 30, 2011 compared to $1.4 million during the same quarter last year.  The increase was due primarily to accelerated stock-based compensation expense associated with the Merger. Ambulance crew wages per ambulance unit hour increased by approximately 2.7%, or $6.4 million, attributable primarily to annual wage rate increases. Ambulance unit hours increased period over period by 2.9%, or $6.7 million, due primarily to our recent acquisitions and our entry into new markets. Non-crew compensation, excluding stock-based compensation expense, increased period over period by $1.8 million due primarily to increased costs of $1.5 million in our managed transportation business. Total benefits related costs increased $8.1 million due primarily to increases in payroll taxes, of which $0.3 million were related to the Merger, and higher costs for our health insurance plans.

 

Operating expenses.  Operating expenses for the six months ended June 30, 2011 were $171.5 million, or 23.6% of net revenue, compared to $154.1 million, or 22.6% of net revenue, for the six months ended June 30, 2010.  The change is due primarily to increased costs associated with our managed transportation business of $12.9 million and an increase in fuel costs of $4.1 million.

 

Insurance expense.  Insurance expense for the six months ended June 30, 2011 was $27.3 million, or 3.8% of net revenue, compared to $24.0 million, or 3.5% of net revenue, for the same period in 2010.  We recorded an increase of prior year insurance provisions of $4.8 million during the six months ended June 30, 2011 compared to an increase of $0.1 million during the six months ended June 30, 2010.

 

Selling, general and administrative.  Selling, general and administrative expense for the six months ended June 30, 2011 was $20.3 million, or 2.8% of net revenue, compared to $20.0 million, or 2.9% of net revenue, for the six months ended June 30, 2010.

 

Depreciation and amortization.  Depreciation and amortization expense for the six months ended June 30, 2011 was $25.4 million, or 3.5% of net revenue, compared to $22.3 million, or 3.3% of net revenue, for the same period in 2010.  The $3.1 million increase is due primarily to additional amortization expense associated with intangible assets recorded as a result of the

 

38



Table of Contents

 

Merger transaction during the second quarter of 2011 as well as amortization expense associated with contract intangible assets recorded on acquisitions completed since December 31, 2009.

 

Liquidity and Capital Resources

 

Our primary source of liquidity is cash flows provided by our operating activities. We can also use our asset-based revolving credit facility, to supplement cash flows provided by our operating activities if we decide to do so for strategic or operating reasons. Our liquidity needs are primarily to service long-term debt and to fund working capital requirements, capital expenditures related to the acquisition of vehicles and medical equipment, technology-related assets and insurance-related deposits.

 

Concurrent with the completion of the Merger on May 25, 2011, we issued $950 million of senior unsecured notes and entered into the $1.8 billion senior secured credit facilities, which are further described in Note 5 to the accompanying consolidated financial statements, and consist of a $1.44 billion senior secured term loan facility, or the Term Loan Facility, and a $350 million asset-based revolving credit facility, or the ABL Facility.

 

Our ABL Facility provides for up to $350 million of senior secured first priority borrowings, subject to a borrowing base of $350 million as of June 30, 2011.  The ABL Facility is available to fund working capital and for general corporate purposes.  As of June 30, 2011, we had available borrowing capacity under the ABL Facility of approximately $303 million.  As of June 30, 2011, we had approximately $47 million of letters of credit issued under the ABL Facility.

 

We believe that our cash and cash equivalents, cash provided by our operating activities and amounts available under our credit facility will be adequate to meet the liquidity requirements of our business through at least the next 12 months.

 

While the ABL Facility generally does not contain financial maintenance covenants, a springing fixed charge coverage ratio of not less than 1.0 to 1.0 will be tested if our excess availability (as defined in the ABL Facility credit agreement) falls below specified thresholds at any time.  If we require additional financing to meet cyclical increases in working capital needs, to fund acquisitions or unanticipated capital expenditures, we may need to access the financial markets.

 

The indenture related to the senior notes, the ABL Facility credit agreement and the Term Loan Facility agreement contain significant covenants, including prohibitions on our ability to incur certain additional indebtedness and to make certain investments and to pay dividends.

 

Cash Flow

 

The table below summarizes cash flow information derived from our statements of cash flows for the periods indicated, amounts in thousands.

 

 

 

Combined

 

Predecessor

 

 

 

Six months ended   June 30,

 

 

 

2011

 

2010

 

Net cash provided by (used in):

 

 

 

 

 

Operating activities

 

$

105,696

 

$

84,742

 

Investing activities

 

(2,936,905

)

(60,358

)

Financing activities

 

2,730,659

 

(44,239

)

 

Operating activities . Net cash provided by operating activities was $105.7 million for the six months ended June 30, 2011 compared to $84.7 million for the same period in 2010.  The increase in operating cash flows was affected primarily by increases in cash flows from operating assets and liabilities, offset by a decrease in net income.  Accounts payable and accrued liabilities increased cash flows from operations $27.0 million during the six months ended June 30, 2011 compared to $13.1 million during the six months ended June 30, 2010.  The change is due primarily to the timing of income tax related payments, and lower incentive compensation payments during the six months ended June 30, 2011 compared to the same period in 2010.  Accounts receivable increased $3.0 million and days sales outstanding, or DSO, decreased 2 days during the six months ended June 30, 2011.

 

We regularly analyze DSO which is calculated by dividing our net revenue for the quarter by the number of days in the quarter.  The result is divided into net accounts receivable at the end of the period.  DSO provides us with a gauge to measure receivables, revenue and collection activities.  The following table outlines our DSO by segment and in total excluding the impact of acquisitions completed within the specific quarter:

 

39



Table of Contents

 

 

 

Q2 2011

 

Q1 2011

 

Q4 2010

 

Q3 2010

 

Q2 2010

 

Q1 2010

 

AMR

 

68

 

66

 

69

 

70

 

68

 

66

 

EmCare

 

52

 

54

 

54

 

54

 

55

 

56

 

EMSC

 

59

 

60

 

61

 

61

 

62

 

61

 

 

Investing activities .  Net cash used in investing activities was $2,936.9 million for the six months ended June 30, 2011 compared to $60.4 million for the same period in 2010.  The increase is primarily due to the purchase of EMSC by CD&R for $2.8 billion combined with increases in acquisition activity.  Acquisitions of businesses totaled $99.5 million during the six months ended June 30, 2011 compared to $51.0 million during the same period in 2010.

 

Financing activities.   Net cash provided by financing activities was $2,730.7 million for the six months ended June 30, 2011 compared to net cash used in financing activities of $44.2 million for the same period in 2010.  We entered into new credit facilities in connection with CD&R’s acquisition of EMSC which resulted in new borrowings of $2,390.0 million during the six months ended June 30, 2011 compared to the same period in 2010. During the six months ended June 30, 2011 we also received $887.1 million in proceeds from CD&R’s equity investment in EMSC.  These sources of cash from financing activities were partially offset by $114.0 million in debt issuance costs and $26.2 million in equity issuance costs, and repayment of the Predecessor term loan of $415.0 million related to the Merger.  At June 30, 2011, there were no amounts outstanding under our revolving credit facility.

 

Contractual Obligations

 

During the six months ended June 30, 2011, our contractual obligations have increased approximately $3,139 million. Approximately $3,064 of the increase is related to the principal and interest payments due under the terms of our new debt instruments entered into as part of the Merger and the remaining increase is due to new management agreement entered into as part of the Merger. There have been no other material changes in our contractual obligations from those reported at December 31, 2010 in our Annual Report on Form 10-K.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Our primary exposure to market risk consists of changes in interest rates on certain of our borrowings and changes in fuel prices.  While we have from time to time entered into transactions to mitigate our exposure to both changes in interest rates and fuel prices, we do not use these instruments for speculative or trading purposes.

 

We manage our exposure to changes in fuel prices and, as appropriate, use highly effective derivative instruments to manage well-defined risk exposures. As of June 30, 2011, we were party to a series of fuel hedge transactions with a major financial institution under one master agreement. Each of the transactions effectively fixes the cost of diesel fuel at prices ranging from $3.12 to $3.29 per gallon. We purchase the diesel fuel at the market rate and periodically settle with our counterparty for the difference between the national average price for the period published by the Department of Energy and the agreed upon fixed price. The transactions fix the price for a total of 3.0 million gallons and are spread over periods from July 2011 through June 2012.

 

As of June 30, 2011, we had $2,378.7 million of debt, excluding capital leases, of which $1,427.6 million was variable rate debt under our senior secured credit facility and the balance was fixed rate debt. An increase or decrease in interest rates of 0.5%, above our LIBOR floor of 1.5%, will impact our interest costs by $7.1 million annually.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Evaluation of Disclosure Controls and Procedures

 

We maintain a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”)) that are designed to ensure that information required to be disclosed in the reports that we file under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or furnishes under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of

 

40



Table of Contents

 

achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

 

Based on their evaluation of our disclosure controls and procedures conducted as of the end of the period covered by this Report on Form 10-Q, our principal executive officer and our principal financial officer have concluded that, as of the date of their evaluation, our disclosure controls and procedures (as defined in Rules 13a -15(e) and 15d -15(e) promulgated under the Exchange Act) were effective as of June 30, 2011.

 

Changes in Internal Control Over Financial Reporting

 

There were no changes in our internal control over financial reporting that occurred during our fiscal quarter ended June 30, 2011 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

 

41



Table of Contents

 

EMERGENCY MEDICAL SERVICES CORPORATION

PART II. OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

For additional information regarding legal proceedings, please refer to Note 7, to the accompanying consolidated financial statements included herein, and to our Annual Report on Form 10-K filed with the SEC on February 18, 2011.

 

Eleven purported shareholder class actions relating to the transactions contemplated by the Agreement and Plan of Merger, dated as of February 13, 2011, among EMSC, CDRT Acquisition Corporation and CDRT Merger Sub, Inc. (the “Merger Agreement”), have been filed in state court in Delaware and federal and state courts in Colorado against various combinations of EMSC, the members of our board of directors, and other parties. Seven actions were filed in the Delaware Court of Chancery beginning on February 22, 2011, which were consolidated into one action entitled In re Emergency Medical Services Corporation Shareholder Litigation, Consolidated C.A. No. 6248-VCS. On April 4, 2011, the Delaware plaintiffs filed their consolidated class action complaint. Two actions, entitled Scott A. Halliday v. Emergency Medical Services Corporation, et al., Case No. 2011CV316 (filed on February 15, 2011), and Alma C. Howell v. William Sanger, et. al., Case No. 2011CV488 (filed on March 1, 2011), were filed in the District Court, Arapahoe County, Colorado. Two other actions, entitled Michael Wooten v. Emergency Medical Services Corporation, et al., Case No. 11-CV-00412 (filed on February 17, 2011), and Neal Greenberg v. Emergency Medical Services Corporation, et. al., Case No. 11-CV-00496 (filed on February 28, 2011), were filed in the U.S. District Court for the District of Colorado and have been consolidated. These actions generally allege that the directors of EMSC, Onex Corporation and/or Onex Corporation’s subsidiaries breached their fiduciary duties by, among other things: approving the transactions contemplated by the Merger Agreement, which allegedly were financially unfair to EMSC and its public stockholders; agreeing to provisions in the Merger Agreement that would allegedly prevent the board from considering other offers; permitting the unitholders agreement (which secured the majority votes in favor of the merger contemplated by the Merger Agreement (the “Merger”)) and failing to require a provision in the Merger Agreement requiring that a majority of the public stockholders approve the transactions contemplated by the Merger Agreement; and/or making allegedly materially inadequate disclosures. These actions further allege that certain other defendants aided and abetted these breaches. In addition, the two actions filed in the U.S. District Court for the District of Colorado contain individual claims brought under Section 14(a) and Section 20(a) of the Securities Exchange Act of 1934, as amended, pertaining to the purported dissemination of allegedly misleading proxy materials. These actions seek unspecified damages and equitable relief. We believe that all of the allegations in these actions are without merit and intend to vigorously defend these matters.

 

In addition to the foregoing shareholder class actions, Merion Capital, L.P., a former stockholder of EMSC, has filed an action in the Delaware Court of Chancery seeking to exercise its right to appraisal of its holdings in EMSC prior to the Merger. Merion Capital was the holder of 599,000 shares of class A common stock in EMSC prior to the Merger.  We have not paid any merger consideration for these shares and have recorded a reserve in the amount of $38.3 million for such unpaid merger consideration pending conclusion of the appraisal action.

 

In July 2011, AMR received a request from the Civil Division of the U.S. Attorney’s Office for the Central District of California (“USAO”) asking AMR to preserve certain documents concerning AMR’s provision of ambulance services within the City of Riverside, California.  The USAO indicated that it, together with the Department of Health and Human Services, Office of the Inspector General, are investigating whether AMR violated the federal False Claims Act and/or the federal Anti-Kickback Statute in connection with AMR’s provision of ambulance transport services within the City of Riverside.  The California Attorney General’s Office is conducting a parallel state investigation for possible violations of the California False Claims Act.  We have complied with the USAO’s request to preserve documents.

 

ITEM 1A. RISK FACTORS

 

Other than with respect to the risk factors below, there have been no material changes from the risk factors disclosed in the “Risk Factors” sections of our Annual Report on Form 10-K for the year ended December 31, 2010.

 

Our substantial indebtedness may adversely affect our financial health.

 

We have substantial indebtedness.  As of June 30, 2011, we had total indebtedness, including capital leases, of approximately $2.4 billion, including $950 million of senior unsecured notes, $1,436 million of borrowings under the Term Loan Facility and approximately $2 million of other long-term indebtedness.  In addition, as of June 30, 2011, after giving effect to approximately $47 million of letters of credit issued under the ABL Facility, we were able to borrow approximately $303 million under the ABL Facility.

 

42



Table of Contents

 

The degree to which we are leveraged may have important consequences for us.  For example, it may:

 

·                   make it more difficult for us to make payments on our indebtedness;

·                   increase our vulnerability to general economic and industry conditions, including recessions and periods of significant inflation and financial market volatility;

·                   expose us to the risk of increased interest rates because any borrowings we make under the ABL Facility, and our borrowings under the Term Loan Facility under certain circumstances, will bear interest at variable rates;

·                   require us to use a substantial portion of our cash flow from operations to service our indebtedness, thereby reducing our ability to fund working capital, capital expenditures and other expenses;

·                   limit our flexibility in planning for, or reacting to, changes in our business and the industries in which we operate;

·                   place us at a competitive disadvantage compared to competitors that have less indebtedness; and

·                   limit our ability to borrow additional funds that may be needed to operate and expand our business.

 

The indenture governing our senior unsecured notes, or the Indenture, the credit agreement governing the ABL Facility, or the ABL Credit Agreement, and credit agreement governing the Term Loan Facility, or the Term Loan Credit Agreement, contain restrictive covenants that limit our ability to engage in activities that may be in our long-term best interests.  Those covenants include restrictions on our ability to, among other things, incur more indebtedness, pay dividends, redeem stock or make other distributions, make investments, create liens, transfer or sell assets, merge or consolidate and enter into certain transactions with our affiliates.  Our failure to comply with those covenants could result in an event of default, which, if not cured or waived, could result in the acceleration of all of our indebtedness.

 

Despite our indebtedness levels, we, our subsidiaries and our affiliated professional corporations may be able to incur substantially more indebtedness which may increase the risks created by our substantial indebtedness.

 

We, our subsidiaries and our affiliated professional corporations may be able to incur substantial additional indebtedness in the future.  The terms of the Indenture do not fully prohibit us, our subsidiaries and our affiliated professional corporations from doing so.  If we or our subsidiaries are in compliance with certain incurrence ratios set forth in the ABL Credit Agreement, the Term Loan Credit Agreement and the Indenture, we and our subsidiaries may be able to incur substantial additional indebtedness, which may increase the risks created by our current substantial indebtedness.  Our affiliated professional corporations will not be subject to the covenants governing our indebtedness.

 

We will require a significant amount of cash to service our indebtedness.  The ability to generate cash or refinance our indebtedness as it becomes due depends on many factors, some of which are beyond our control.

 

EMSC is a holding company, and as such has no independent operations or material assets other than its ownership of equity interests in its subsidiaries, and its subsidiaries’ contractual arrangements with physicians and professional corporations, and it depends on its subsidiaries to distribute funds to it so that it may pay its obligations and expenses.  EMSC’s ability to make scheduled payments on, or to refinance its respective obligations under, its indebtedness, and to fund planned capital expenditures and other corporate expenses will depend on the ability of its subsidiaries to make distributions, dividends or advances to it, which in turn will depend on their future operating performance and on economic, financial, competitive, legislative, regulatory and other factors and any legal and regulatory restrictions on the payment of distributions and dividends to which they may be subject.  Many of these factors are beyond our control.  We cannot assure you that our business will generate sufficient cash flow from operations, that currently anticipated cost savings and operating improvements will be realized or that future borrowings will be available in an amount sufficient to enable us to satisfy our respective obligations under our indebtedness or to fund our other needs.  In order to satisfy our obligations under our indebtedness and fund planned capital expenditures, we must continue to execute our business strategy.  If we are unable to do so, we may need to reduce or delay our planned capital expenditures or refinance all or a portion of our indebtedness on or before maturity.  Significant delays in our planned capital expenditures may materially and adversely affect our future revenue prospects.  In addition, we cannot assure you that we will be able to refinance any of our indebtedness on commercially reasonable terms or at all.

 

The Indenture, the ABL Credit Agreement and the Term Loan Credit Agreement restrict our ability and the ability of most of our subsidiaries to engage in some business and financial transactions.

 

Indenture .  The Indenture contains restrictive covenants that, among other things, limits our ability and the ability of our restricted subsidiaries to:

 

·                   incur additional indebtedness or issue certain preferred shares;

·                   pay dividends, redeem stock or make other distributions;

 

43



Table of Contents

 

·                   make investments;

·                   create restrictions on the ability of our restricted subsidiaries to pay dividends to us or make other intercompany transfers;

·                   create liens;

·                   transfer or sell assets;

·                   merge or consolidate;

·                   enter into certain transactions with our affiliates; and

·                   designate subsidiaries as unrestricted subsidiaries.

 

Senior Secured Credit Facilities .  The ABL Credit Agreement and the Term Loan Credit Agreement contains a number of covenants that limit our ability and the ability of our restricted subsidiaries to:

 

·                   incur additional indebtedness;

·                   declare dividends;

·                   repurchase, prepay or redeem junior indebtedness;

·                   redeem and repurchase capital stock;

·                   incur additional liens;

·                   sell assets;

·                   agree to payment restrictions affecting our restricted subsidiaries;

·                   make negative pledges;

·                   consolidate, merge, sell or otherwise dispose of all or substantially all of our assets;

·                   make investments;

·                   enter into transactions with affiliates; and

·                   designate any of our subsidiaries as unrestricted subsidiaries.

 

The ABL Credit Agreement also contains other covenants customary for asset-based facilities of this nature.  Our ability to borrow additional amounts under the senior secured credit facilities depends upon satisfaction of these covenants.  Events beyond our control can affect our ability to meet these covenants.

 

Our failure to comply with obligations under the Indenture, the ABL Credit Agreement and the Term Loan Credit Agreement may result in an event of default under that indenture or those credit agreements.  A default, if not cured or waived, may permit acceleration of our indebtedness.  We cannot be certain that we will have funds available to remedy these defaults.  If our indebtedness is accelerated, we cannot be certain that we will have sufficient funds available to pay the accelerated indebtedness or that we will have the ability to refinance the accelerated indebtedness on terms favorable to us or at all.

 

We may not have access to the cash flow of our subsidiaries that may be needed to make payment on our indebtedness.

 

Our ability to make payments on our indebtedness is dependent on the earnings and the distribution of funds from our subsidiaries.  All of our business is conducted through our subsidiaries.  The ability of our subsidiaries to make distributions, dividends or advances to us will depend on their future operating performance and on economic, financial, competitive, legislative, regulatory and other factors and any legal and regulatory restrictions on the payment of distributions and dividends to which they may be subject.  Under the terms of the indenture related to the senior notes, the ABL Credit Agreement and the Term Loan Credit Agreement, our subsidiaries will be permitted to incur additional indebtedness that may restrict or prohibit distributions, dividends or loans from those subsidiaries to us.  We cannot assure you that the agreements governing the current and future indebtedness of our subsidiaries will permit our subsidiaries to provide us with sufficient dividends, distributions or loans to fund payments on our indebtedness when due.

 

An increase in interest rates would increase the cost of servicing our debt and could reduce our profitability.

 

Our indebtedness under the ABL Facility will bear interest at variable rates, and, to the extent LIBOR exceeds 1.5%, our indebtedness under the Term Loan Credit Agreement bears interest at variable rates.  As a result, increases in interest rates could increase the cost of servicing such debt and materially reduce our profitability and cash flows.  As of March 31, 2011, assuming all ABL Facility revolving loans were fully drawn and LIBOR exceeded 1.5%, each one percentage point change in interest rates would result in approximately a $17.9 million change in annual interest expense on the senior secured credit facilities.  The impact of such an increase would be more significant for us than it would be for some other companies because of our substantial debt.

 

44



Table of Contents

 

We are indirectly owned and controlled by the CD&R Affiliates, and their interests as equity holders may conflict with other interests of EMSC.

 

We are indirectly owned and controlled by the CD&R Affiliates, who have the ability to control our policy and operations.  The CD&R Affiliates control our board of directors, and thus are able to appoint new management and approve any action requiring the vote of our outstanding common stock, including amendments of our certificate of incorporation, mergers and sales of substantially all of our assets.  The directors controlled by the CD&R Affiliates are also able to make decisions affecting our capital structure, including decisions to issue additional capital stock and incur additional debt.  One or more of the CD&R Affiliates may have an interest in pursuing acquisitions, divestitures, financings or other transactions that, in their judgment, could enhance their equity investments, even though such a transaction might involve other risks to our business.  Furthermore, one or more of the CD&R Affiliates may in the future own businesses that directly or indirectly compete with us.  One or more of the CD&R Affiliates may also pursue acquisition opportunities that may be complementary to our business, and as a result, those acquisition opportunities may not be available to us.

 

ITEM 2. ISSUER PURCHASES OF EQUITY SECURITIES

 

Period

 

Total
Number of
Shares
Purchased

 

Average
Price Paid
Per Share

 

Total Number of
Shares Purchased
as Part of
Publicly
Announced Plans
or Programs

 

Maximum Number (or
Approximate Dollar
Value) of Shares that may
yet be Purchased under
the Plans or Programs

 

 

 

 

 

 

 

 

 

 

 

April 1, 2011 through April 30, 2011

 

 

 

 

N/A

 

May 1, 2011 through May 24, 2011

 

17,838

(1)

$

63.68

 

 

N/A

 

May 25, 2011 through June 30, 2011

 

 

 

 

N/A

 

 


(1)           Represents shares of restricted stock held by employees under EMSC’s Amended and Restated Long-Term Incentive Plan and delivered to EMSC upon vesting to satisfy the recipients’ tax withholding obligation.

 

ITEM 5. OTHER INFORMATION

 

Director Elections

 

On August 10, 2011, the Board of Directors of EMSC appointed Carol Burt, Randel G. Owen, Dr. Leonard Riggs and Michael Smith to the Board of Directors of EMSC (the “New Directors”), thus increasing the number of members serving on the Board of Directors to eight.

 

Ms. Burt will serve on the Audit Committee. Mr. Owen, EMSC’s Chief Financial Officer, will serve on the Compliance Committee and the Finance Committee. Dr. Riggs will serve on the Compensation Committee and the Compliance Committee. Mr. Smith will serve on the Audit Committee and the Compliance Committee.

 

The existing directors of EMSC were also appointed to the committees of the Board of Directors on August 10, 2011. Ronald Williams will serve on the Executive Committee, the Compensation Committee and the Compliance Committee. Ken Giuriceo will serve on the Audit Committee and the Finance Committee. William Sanger will serve on the Executive Committee, the Compliance Committee and the Finance Committee. Rick Schnall will serve on the Executive Committee, the Compensation Committee and the Finance Committee.

 

No arrangements exist between EMSC and any of the New Directors pursuant to which they were selected as a director. There are no transactions in which any of the New Directors has an interest requiring disclosure under Item 404(a) of Regulation S-K.

 

EMSC’s non-employee directors will receive compensation for their services on the Board of Directors, the details of which are not determinable at the time of this disclosure. The amount of compensation is expected to be substantially similar to EMSC’s past practice, and, in addition, EMSC’s directors are expected to be eligible for participating in Holding’s equity investment plans. Mr. Owen will continue to be compensated in his capacity as Chief Financial Officer of EMSC, on the terms previously publicly disclosed, and his compensation has not been modified as a result of his election to the Board of Directors. EMSC will also enter into indemnification agreements with the New Directors, on the effective date of their election, the terms of which will be substantively identical to the indemnification agreements that EMSC has entered into with its other directors.

 

Rollover Agreements

 

In connection with the Merger, effective as of May 25, 2011, certain members of our management entered into agreements (the “Rollover Agreements”) with CDRT Holding Corporation (“Holding”), EMSC’s indirect parent company, pursuant to which they agreed to roll over existing options to purchase EMSC common stock into options to purchase common stock of Holding. Pursuant to the Rollover Agreements, our named executive officers, William A. Sanger, Randel G. Owen, Todd G. Zimmerman, Mark Bruning and Steve W. Ratton, each agreed to receive, in lieu of cash, a portion of the value of their EMSC options at the closing of the Merger in the form of 263,333, 110,974, 46,611, 44,375 and 13,145 fully vested rollover options of Holding, respectively (the “Rollover”). In connection with the Rollover, Holding matched and applied a multiplier to each officer’s Rollover investment, granting 562,499, 175,780, 87,891, 41,503 and 14,062 matching options of Holding to Messrs. Sanger, Owen, Zimmerman, Bruning and Ratton, respectively. Finally, each of Messrs. Owen, Zimmerman, Bruning and Ratton, received a grant of 4,688, 4,688, 4,688 and 2,344 position options of Holding, respectively, based solely on the officers’ level of seniority in the Company.

 

45



Table of Contents

 

ITEM 6. EXHIBITS

 

3.1

Second Amended and Restated Certificate of Incorporation of Emergency Medical Services Corporation (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

3.2

Second Amended and Restated By-Laws of Emergency Medical Services Corporation (incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

4.1

Indenture, dated May 25, 2011, by and between CDRT Merger Sub, Inc. and Wilmington Trust FSB (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

4.2

First Supplemental Indenture, dated May 25, 2011, by and between CDRT Merger Sub, Inc. and Wilmington Trust FSB (incorporated by reference to Exhibit 4.2 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

4.3

Second Supplemental Indenture, dated May 25, 2011, by and among Emergency Medical Services Corporation, the Subsidiary Guarantors named therein and Wilmington Trust FSB (incorporated by reference to Exhibit 4.3 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

4.4

Exchange and Registration Rights Agreement, dated May 25, 2011, by and between CDRT Merger Sub, Inc. and Barclays Capital Inc., as representative of the Initial Purchasers named therein (incorporated by reference to Exhibit 4.4 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

4.5

Joinder Agreement to the Exchange and Registration Rights Agreement, dated May 25, 2011, by and among Emergency Medical Services Corporation, the Guarantors named therein and Barclays Capital Inc., as representative of the Initial Purchasers (incorporated by reference to Exhibit 4.5 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.1

Term Loan Credit Agreement, dated May 25, 2011, by and among CDRT Merger Sub, Inc., Deutsche Bank AG New York Branch, as administrative agent and collateral agent, and several lenders from time to time party thereto (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.2

Term Loan Guarantee and Collateral Agreement, dated May 25, 2011, by and among CDRT Acquisition Corporation, Emergency Medical Services Corporation, certain Subsidiaries named therein and Deutsche Bank AG New York Branch, as collateral agent (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.3

ABL Credit Agreement, dated May 25, 2011, by and among CDRT Merger Sub, Inc., Deutsche Bank AG New York Branch, as administrative agent and collateral agent, and several lenders from time to time party thereto (incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.4

ABL Guarantee and Collateral Agreement, dated May 25, 2011, by and among CDRT Acquisition Corporation, Emergency Medical Services Corporation, certain Subsidiaries named therein and Deutsche Bank AG New York Branch, as collateral agent (incorporated by reference to Exhibit 10.4 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.5

Intercreditor Agreement, dated May 25, 2011, by and between Deutsche Bank AG New York Branch, as ABL agent, and Deutsche Bank AG New York Branch, as Term Loan agent (incorporated by reference to Exhibit 10.5 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.6

Consulting Agreement, dated May 25, 2011, by and among CDRT Holding Corporation, Emergency Medical Services Corporation and Clayton, Dubilier & Rice, LLC (incorporated by reference to Exhibit 10.6 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.7

Indemnification Agreement, dated May 25, 2011, by and among CDRT Holding Corporation, Emergency Medical Services Corporation, Clayton, Dubilier & Rice Fund VIII, L.P., CD&R EMS Co-Investor, L.P., CD&R Advisor Fund VIII Co-Investor, L.P., CD&R Friends and Family Fund VIII, L.P. and Clayton, Dubilier & Rice, LLC (incorporated by reference to Exhibit 10.7 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.8

Indemnification Agreement, dated May 25, 2011, by and among CDRT Holding Corporation, Emergency Medical

 

46



Table of Contents

 

 

Services Corporation and Richard J. Schnall (incorporated by reference to Exhibit 10.8 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.9

Indemnification Agreement, dated May 25, 2011, by and among CDRT Holding Corporation, Emergency Medical Services Corporation and Ronald A. Williams (incorporated by reference to Exhibit 10.9 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.10

Indemnification Agreement, dated May 25, 2011, by and among CDRT Holding Corporation, Emergency Medical Services Corporation and William A. Sanger (incorporated by reference to Exhibit 10.10 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.11

Indemnification Agreement, dated May 25, 2011, by and among CDRT Holding Corporation, Emergency Medical Services Corporation and Kenneth A. Giuriceo (incorporated by reference to Exhibit 10.11 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.12

Letter agreement, dated May 25, 2011, between William A. Sanger and CDRT Holding Corporation.*

 

 

10.13

Letter agreement, dated May 25, 2011, between Randel G. Owen and CDRT Holding Corporation.*

 

 

10.14

Letter agreement, dated May 25, 2011, between Mark E. Bruning and CDRT Holding Corporation.*

 

 

10.15

Employment Agreement, dated August 24, 2005, between Steve W. Ratton, Jr. and Emergency Medical Services Corporation.*

 

 

10.16

CDRT Holding Corporation Stock Incentive Plan.*

 

 

10.17

Form of Option Agreement (Rollover Options).*

 

 

10.18

Form of Option Agreement (Matching and Position Options).*

 

 

10.19

Form of Rollover Agreement.*

 

 

31.1

Certification of the Chief Executive Officer of Emergency Medical Services Corporation pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

 

 

31.2

Certification of the Chief Financial Officer of Emergency Medical Services Corporation pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

 

 

32.1

Certification of the Chief Executive Officer and the Chief Financial Officer of Emergency Medical Services Corporation pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

 


*    Filed with this Report

 

47



Table of Contents

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned, thereunto duly authorized.

 

 

 

 

 

EMERGENCY MEDICAL SERVICES CORPORATION

 

 

 

 

 

 

 

(registrant)

 

 

 

 

 

 

August 15, 2011

 

By:

/s/ William A. Sanger

 

Date

 

 

William A. Sanger

 

 

 

 

Chairman and Chief Executive Officer

 

 

 

 

 

 

 

 

By:

/s/ Randel G. Owen

 

 

 

 

Randel G. Owen

 

 

 

 

Chief Financial Officer and Executive Vice President

 

48



Table of Contents

 

EXHIBIT INDEX

 

3.1

Second Amended and Restated Certificate of Incorporation of Emergency Medical Services Corporation (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

3.2

Second Amended and Restated By-Laws of Emergency Medical Services Corporation (incorporated by reference to Exhibit 3.2 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

4.1

Indenture, dated May 25, 2011, by and between CDRT Merger Sub, Inc. and Wilmington Trust FSB (incorporated by reference to Exhibit 4.1 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

4.2

First Supplemental Indenture, dated May 25, 2011, by and between CDRT Merger Sub, Inc. and Wilmington Trust FSB (incorporated by reference to Exhibit 4.2 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

4.3

Second Supplemental Indenture, dated May 25, 2011, by and among Emergency Medical Services Corporation, the Subsidiary Guarantors named therein and Wilmington Trust FSB (incorporated by reference to Exhibit 4.3 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

4.4

Exchange and Registration Rights Agreement, dated May 25, 2011, by and between CDRT Merger Sub, Inc. and Barclays Capital Inc., as representative of the Initial Purchasers named therein (incorporated by reference to Exhibit 4.4 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

4.5

Joinder Agreement to the Exchange and Registration Rights Agreement, dated May 25, 2011, by and among Emergency Medical Services Corporation, the Guarantors named therein and Barclays Capital Inc., as representative of the Initial Purchasers (incorporated by reference to Exhibit 4.5 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.1

Term Loan Credit Agreement, dated May 25, 2011, by and among CDRT Merger Sub, Inc., Deutsche Bank AG New York Branch, as administrative agent and collateral agent, and several lenders from time to time party thereto (incorporated by reference to Exhibit 10.1 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.2

Term Loan Guarantee and Collateral Agreement, dated May 25, 2011, by and among CDRT Acquisition Corporation, Emergency Medical Services Corporation, certain Subsidiaries named therein and Deutsche Bank AG New York Branch, as collateral agent (incorporated by reference to Exhibit 10.2 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.3

ABL Credit Agreement, dated May 25, 2011, by and among CDRT Merger Sub, Inc., Deutsche Bank AG New York Branch, as administrative agent and collateral agent, and several lenders from time to time party thereto (incorporated by reference to Exhibit 10.3 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.4

ABL Guarantee and Collateral Agreement, dated May 25, 2011, by and among CDRT Acquisition Corporation, Emergency Medical Services Corporation, certain Subsidiaries named therein and Deutsche Bank AG New York Branch, as collateral agent (incorporated by reference to Exhibit 10.4 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.5

Intercreditor Agreement, dated May 25, 2011, by and between Deutsche Bank AG New York Branch, as ABL agent, and Deutsche Bank AG New York Branch, as Term Loan agent (incorporated by reference to Exhibit 10.5 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.6

Consulting Agreement, dated May 25, 2011, by and among CDRT Holding Corporation, Emergency Medical Services Corporation and Clayton, Dubilier & Rice, LLC (incorporated by reference to Exhibit 10.6 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.7

Indemnification Agreement, dated May 25, 2011, by and among CDRT Holding Corporation, Emergency Medical Services Corporation, Clayton, Dubilier & Rice Fund VIII, L.P., CD&R EMS Co-Investor, L.P., CD&R Advisor Fund VIII Co-Investor, L.P., CD&R Friends and Family Fund VIII, L.P. and Clayton, Dubilier & Rice, LLC (incorporated by reference to Exhibit 10.7 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.8

Indemnification Agreement, dated May 25, 2011, by and among CDRT Holding Corporation, Emergency Medical

 

49



Table of Contents

 

 

Services Corporation and Richard J. Schnall (incorporated by reference to Exhibit 10.8 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.9

Indemnification Agreement, dated May 25, 2011, by and among CDRT Holding Corporation, Emergency Medical Services Corporation and Ronald A. Williams (incorporated by reference to Exhibit 10.9 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.10

Indemnification Agreement, dated May 25, 2011, by and among CDRT Holding Corporation, Emergency Medical Services Corporation and William A. Sanger (incorporated by reference to Exhibit 10.10 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.11

Indemnification Agreement, dated May 25, 2011, by and among CDRT Holding Corporation, Emergency Medical Services Corporation and Kenneth A. Giuriceo (incorporated by reference to Exhibit 10.11 of the Current Report on Form 8-K filed on June 1, 2011).

 

 

10.12

Letter agreement, dated May 25, 2011, between William A. Sanger and CDRT Holding Corporation.*

 

 

10.13

Letter agreement, dated May 25, 2011, between Randel G. Owen and CDRT Holding Corporation.*

 

 

10.14

Letter agreement, dated May 25, 2011, between Mark E. Bruning and CDRT Holding Corporation.*

 

 

10.15

Employment Agreement, dated August 24, 2005, between Steve W. Ratton, Jr. and Emergency Medical Services Corporation.*

 

 

10.16

CDRT Holding Corporation Stock Incentive Plan.*

 

 

10.17

Form of Option Agreement (Rollover Options).*

 

 

10.18

Form of Option Agreement (Matching and Position Options).*

 

 

10.19

Form of Rollover Agreement.*

 

 

31.1

Certification of the Chief Executive Officer of Emergency Medical Services Corporation pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

 

 

31.2

Certification of the Chief Financial Officer of Emergency Medical Services Corporation pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

 

 

32.1

Certification of the Chief Executive Officer and the Chief Financial Officer of Emergency Medical Services Corporation pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.*

 


*    Filed with this Report

 

50


 

Exhibit 10.12

 

CDRT Holding Corporation
c/o Clayton, Dubilier & Rice, LLC
375 Park Avenue
18
th  Floor
New York, NY 10152

 

May 25, 2011

 

CONFIDENTIAL

 

William A. Sanger
7 Eagle Point Lane
Castle Rock, CO 80108

 

Dear Bill:

 

This letter evidences our agreement that, from and after the closing date of the Merger (as defined in the Rollover Agreement, dated as of May 25, 2011, to which you and CDRT Holding Corporation are parties), you may use corporate aircraft of Emergency Medical Services Corporation (“EMSC”) for personal travel subject to the following restrictions:

 

1.                                        EMSC will bear the full cost for up to 25 hours of personal use of the EMSC aircraft per calendar year (including the cost of landing fees, but excluding any taxes imputed to you).  Unused hours in a calendar year will be carried over to future calendar years.

 

2.                                        If your personal use of the EMSC aircraft in any calendar year exceeds 25 hours (plus any rolled over hours), you will reimburse EMSC for such personal use (other than the cost of landing fees, which will be borne by EMSC).  As with your personal use of the EMSC aircraft generally, you will bear any imputed taxes associated with the cost of landing fees borne by EMSC.

 

3.                                        Trips on the EMSC aircraft between a personal residence of yours (even if outside of Denver) and a business destination (including EMSC’s principal offices in Denver) will not be included in the 25 hour maximum.  As noted, trips between a personal residence of yours (if outside of Denver) and Denver will not be included in calculating the 25 hour maximum, but will be excludable from the 25 hour maximum only up to a maximum of four round trips per month between such personal residence and Denver.

 



 

4.                                        Of course, business use of the EMSC aircraft will take precedence over your personal use.

 

To the extent that, following an initial public offering, the board of directors of the public company no longer permits your use of corporate aircraft in a manner consistent with this letter, EMSC will increase your annualized base salary by $30,000 to maintain the economic equivalent of this letter.  All other terms and conditions of your employment agreement dated December 6, 2004, as amended on June 18, 2007, January 1, 2009 and March 12, 2009, will remain the same

 

[signature page follows]

 

2



 

 

Sincerely,

 

 

 

CDRT Holding Corporation

 

 

 

By:

/s/ Randel G. Owen

 

Name: Randel G. Owen

 

Title: Chief Financial Officer

 

Accepted and agreed:

 

/s/ William A. Sanger

 

William A. Sanger

 

 

3


Exhibit 10.13

 

CDRT Holding Corporation
c/o Clayton, Dubilier & Rice, LLC
375 Park Avenue
18
th  Floor
New York, NY 10152

 

May 25, 2011

 

CONFIDENTIAL

 

Randel G. Owen
1103 Northwood Lane
Castle Rock, CO 80108

 

Dear Randy:

 

Effective with respect to the period beginning on the closing of the Merger (as defined in the Rollover Agreement, dated as of May 25, 2011, to which you and CDRT Holding Corporation are parties), your base salary will increase to $505,000 per year.  All other terms and conditions of your employment agreement dated February 10, 2005, as amended on January 1, 2009, March 12, 2009, and May 18, 2010 will remain the same.

 

 

Sincerely,

 

 

 

/s/William Sanger

 

William A. Sanger

 

Chief Executive Officer

 

Accepted and agreed:

 

/s/Randel G. Owen

 

Randel G. Owen

 

 


Exhibit 10.14

 

CDRT Holding Corporation
c/o Clayton, Dubilier & Rice, LLC
375 Park Avenue
18
th  Floor
New York, NY 10152

 

May 25, 2011

 

CONFIDENTIAL

 

Mark Bruning
725 Forest View Way
Monument, CO 80132

 

Dear Mark:

 

Effective with respect to the period beginning on the closing date of the Merger (as defined in the Rollover Agreement, dated as of May 25, 2011, to which you and CDRT Holding Corporation are parties), your base salary will increase to $515,000 per year and your automobile allowance will increase to $1,200 per month.  All other terms and conditions of your employment agreement dated May 4, 2009, as amended on March 16, 2010, will remain the same.

 

 

Sincerely,

 

 

 

/s/William Sanger

 

William A. Sanger

 

Chief Executive Officer

 

Accepted and agreed:

 

/s/Mark Bruning

 

Mark Bruning

 

 


Exhibit 10.15

 

EMPLOYMENT AGREEMENT

 

This Agreement is made as of August 24, 2005 by and between Emergency Medical Services Corporation, a Delaware Corporation (the “Company”), and Steve W. Ratton, Jr. (the “Executive”), effective as of the date set forth below.

 

RECITALS

 

WHEREAS , Emergency Medical Services Corporation (the general partner of the Company) has entered Into that certain (i) Stock Purchase Agreement, dated as of December 6, 2004 by and among Laidlaw International, Inc., Laidlaw Medical Holdings, Inc. and Emergency Medical Services Corporation (the “AMR Purchase Agreement”) and (ii) Stock Purchase Agreement, dated as of December 6, 2004 by and among Laidlaw International, Inc., Laidlaw Medical Holdings, Inc. and Emergency Medical Services Corporation (the “EmCare Purchase Agreement” and together with the AMR Purchase Agreement, the “Stock Purchase Agreements”);

 

WHEREAS , Executive is employed by EmCare (as defined below), a subsidiary of the Company, and will continue to be employed by the Company, in a confidential relationship during which Executive has and will become familiar with and aware of information as to the specific manner of doing business, strategic plans for future business, and the identity of customers of the Company and its subsidiaries, affiliates and managed entities, all of which will be established and maintained at great expense to the Company, all of which information is a trade secret and constitutes the valuable goodwill of the Company;

 

WHEREAS , Executive recognizes that the Company and its subsidiaries are engaged in the business of medical transportation services and physician practice management services as related to hospital emergency department and hospitalist outsourcing;

 

WHEREAS , Executive recognizes that the Company and its subsidiaries and managed entities depend upon a number of trade secrets (including secret techniques, methods and data) in the course of providing services to their clients and that the protection of these trade secrets is of critical importance to the Company and its subsidiaries; and

 

WHEREAS , the Company and its subsidiaries will sustain great loss and damage if Executive should violate the provisions of this Agreement, particularly with respect to confidential information and restrictions on competition and that monetary damages for such losses would be extremely difficult to measure.

 



 

NOW THEREFORE , in consideration of the mutual promises, terms, covenants and conditions set forth herein and the performance of each, effective as of the time of the Effective Date, it is hereby agreed as follows:

 

1.                                        Definitions :

 

Whenever used in this Agreement, the following terms shall have the meanings set forth below, and when the meaning is intended, the initial letter of the word is capitalized:

 

A.                                    “Agreement” means this employment agreement, as amended from time to time.

 

B.                                      “AMR” means American Medical Response, Inc., a Delaware corporation and a wholly owned subsidiary of the Company.

 

C.                                      “Base Salary” means the salary of record paid to the Executive as annual salary, as further indicated in paragraph (A) of Article 4.

 

D.                                     “Board” means the board of directors of the Company’s general partner unless the Company (or its successor) is then a corporation, in which event it means the Company’s board of directors.

 

E.                                       “Change in Control” means, during the Term, the sale of all or substantially all of the assets of the Company.

 

F.                                       “Company” means Emergency Medical Services Corporation formed under the laws of Delaware, and except where the context requires otherwise, including all affiliates and Subsidiaries of the Company, and any successor thereto.

 

G.                                      “Effective, Date” means April 1, 2005.

 

H.                                     “EmCare” means EmCare Holdings Inc., a Delaware corporation and a wholly owned subsidiary of the Company.

 

I.                                          “Executive” means Steve W. Rattan, Jr..

 

J.                                         “15% Internal Rate of Return” means an Investor Return, in cash or cash equivalent, at least equal to an amount determined by increasing the amount of the initial investment, and all subsequent direct or indirect investments by Onex, by the total compounded annual rate of return of 15%, taking into account for these purposes the exercise of all options to purchase Partnership Units outstanding under the Plan or otherwise (including, without limitation, options, other equity awards or interests held by affiliates of Onex and their respective employees), which are then exercisable or become exercisable as a result of the realization of the 15% Internal Rate of Return.  Whether the

 

2



 

15% Internal Rate of Return has been realized shall be determined by the Board whose decision shall be final and binding on the Executive.  For the avoidance of doubt, a 15% Internal Rate of Return shall be, deemed realized only if the Investor Return includes both the amount of the investments and the required return on the investments.

 

K.                                     “Investor Return” means the sum of all cash amounts actually received by Onex, on a cumulative basis through the date of determination, in the form of cash dividends, other distributions or sale proceeds in connection with (a) a disposition of all or any part of its Partnership Units calculated based on the actual net proceeds received from the disposition of such Partnership Units (b) a disposition of all or substantially all of the assets of the Company or a Subsidiary or (c) a recapitalization of the Company or any Subsidiary.  Such calculation shall take into account any transaction costs and fees and shall exclude any management, consulting or other similar fees received by Onex or its affiliates.

 

L.                                       “IPO/Recap” means an initial public offering of the equity of the Company or Emergency Medical Services L.P. (an “IPO”) or a recapitalization of the Company or Emergency Medical Services L.P.

 

M.                                  “Liquidity Event” means (i) the sale of all, or substantially all, of the Company’s consolidated assets, including, without limitation, a sale of all or substantially all of the assets of the Company or any of its Subsidiaries whose assets constitute all or substantially all of the Company’s consolidated assets in any single transaction or series of related transactions or (ii) any merger or consolidation of the Company with or into another entity unless, after giving effect to such merger or consolidation, the holders of the Partnership Units (on a fully-diluted basis) immediately prior to the merger or consolidation, own voting securities (on a fully-diluted basis) of the surviving or resulting entity representing a majority of the outstanding voting power to elect directors of the surviving or resulting corporation (or the general partner of a surviving partnership) in the same proportions that they held their Partnership Units prior to such merger.

 

N.                                     “Onex” means Onex Partners LP.

 

O.                                     “Partnership Units” means units representing limited partnership interests in Emergency Medical Services L.P.

 

P.                                       “Subsidiary” means any corporation that is a subsidiary of the Company including, but not limited to EmCare and AMR.

 

2.                                        Employment .

 

A.                                    From the Effective Date, the Company shall employ the Executive as Senior Vice President, Finance and Treasury of the Company, AMR and EmCare, and

 

3



 

the Executive shall serve in such capacity, performing such duties as are consistent with the position, along with such other duties and responsibilities assigned to the Executive by the Chief Financial Officer (“CFO”) of the Company.  The Executive shall devote his best efforts to the performance of his duties under this Agreement and shall perform them faithfully, diligently, competently and in a manner consistent with the policies of the Company as determined from time to time by the CFO.

 

B.                                      The Executive shall report to the CFO, and shall provide support to the President of AMR or the President of EmCare, as applicable on all matters pertaining to his duties hereunder.

 

C.                                      The Executive shall not engage in other business activities outside the scope of this Agreement, without the express approval of the CFO.

 

D.                                     The Executive shall not serve as an officer or director (or the equivalent position) of any entity other than the Company or its affiliates or managed entities, and shall hot receive fees or other remuneration for work performed outside the scope of his employment without prior written consent of the CFO.

 

3.                                        Term of Employment .  The Executive’s employment under this Agreement shall commence on the Effective Date, shall continue for a period of two years, and shall be renewed for additional one year periods thereafter unless either party informs the other in writing within 90 days of this Agreement’s expiration that it does not wish to renew the Agreement, or unless sooner terminated as provided in this Agreement.

 

4.                                        Compensation .

 

A.                                    As full compensation for all services rendered by the Executive pursuant to this Agreement, the Company shall pay, or shall cause a Subsidiary to pay, to the Executive a salary of $240,000 per year (“Base Salary”), less applicable withholdings.  The Base Salary shall be payable twice monthly on the 15th business day and last business day of each month.  Executive’s compensation shall be reviewed by the CFO annually during the Company’s normal review period, beginning in the year following the first anniversary of the Effective Date.

 

B.                                      The Executive will be eligible to participate in a short term incentive plan.  For fiscal years commencing September 1, 2004 and thereafter, the Executive’s target bonus under such plan will be 35% of Base Salary (pro-rated for a partial fiscal year, including the first fiscal year in the term).  The Executive’s right to receive any bonus under such plan shall be determined based upon performance targets for each year fixed by the CFO; provided , that in the case of the partial fiscal year beginning on February 1, 2005, the Executive’s right to receive any bonus under such plan shall be based on the achievement of the budget/business plan of EmCare and AMR

 

4



 

for the fiscal year beginning August 31, 2004 approved by the board of directors of Laidlaw International, Inc.

 

C.                                      Pursuant to an equity option plan (the “Plan”) adopted by the Company, the Company will grant to the Executive options to purchase Twenty Five Thousand (25,000) of the Partnership Units outstanding on the Effective Date (the “Ratton Options”).  The Ratton Options will contain the following terms and will otherwise be subject to the terms and provisions of the Plan:

 

1.                                        Exercise Price .  The exercise price will be the per unit purchase price paid by the initial equity investors in Emergency Medical Services L.P.

 

2.                                        Vesting and Exercisability .

 

a.                                        50% of the Ratton Options will become vested and exercisable 25% on each of the first four anniversaries of February 10, 2005 (the “Grant Date”) without further condition.

 

b.                                       50% of the Ratton Options will become vested and exercisable 25% on each of the first four anniversaries of the Grant Date; provided , that exercisability is subject to the further condition that Onex has realized a 15% Internal Rate of Return.

 

c.                                        Notwithstanding the provisions of clause (b), upon the occurrence of a Liquidity Event in which Onex realizes a 15% Internal Rate of Return, all of the Ratton Options shall become fully vested and exercisable on the occurrence of the Liquidity Event, and the Rattan Options shall terminate and be of no further force or effect if they are not exercised in connection with the Liquidity Event.  For the purposes of this clause (c) only, the 15% Internal Rate of Return shall be determined based on (i) cash received by Onex at any time and/or (ii) the fair market value of assets received by Onex at any time (as such fair market value is determined by the Board).  Any assets received by the Executive in the Liquidity Event shall be subject to the same restrictions (such as lock-up provisions) to which the assets received by Onex are subject.

 

d.                                       On the fourth anniversary of the Grant Date, if the Ratton Options referred to in clause (b) have not terminated pursuant to clause (c) and have vested but are not exercisable because Onex has not realized a 15% Internal Rate of Return, then such Ratton Options shall also become exercisable if:

 

(i)                                     the Company has met the Cumulative Cash Flow Test, as such term will be defined in the Plan, or

 

5



 

(ii)                                   if (x) the Company’s common stock is publicly traded and listed on a national securities exchange and (y) Onex would have realized a 15% Internal Rate of Return if it had sold its remaining common stock interest in the Company at a per share price equal to the weighted average sale price of the Company common stock (as quoted by such national securities exchange) for any 30 consecutive trading days.

 

3.                                        Term .  For the avoidance of doubt, options that have vested according to paragraph 4.C.2.b (by acceleration or otherwise) upon the occurrence of a Liquidity Event but are not exercisable because Onex has not realized a 15% Internal Rate of Return shall terminate on the occurrence of the Liquidity Event, and be of no further force or effect.  The occurrence of an IPO/Recap shall not affect the vesting of the Ratton Options.

 

5.                                        Fringe Benefits; Expenses .

 

A                                       The Executive shall be entitled to welfare benefit coverages (such as medical insurance, dental insurance, short and long-term disability insurance and group term life insurance) in accordance with employee benefit plans and policies maintained by the Company or a Subsidiary or affiliate for the benefit of the employees of the Company, and as amended from time to time.

 

B.                                      The Company shall reimburse, or shall cause a Subsidiary to reimburse, the Executive for all reasonable and necessary expenses incurred by him in connection with the performance of services hereunder, in accordance with the Company’s policies and procedures applicable to similarly situated executives of the Company.

 

C.                                      The Executive shall be entitled to such vacation time per calendar year as is applicable to similarly situated executives of the Company, which shall be greater than or equal to three (3) weeks per calendar year, the use of which vacation time shall be subject to prior approval by the CFO.

 

D.                                     The Company shall obtain and maintain directors and officers liability insurance policies covering Executive’s actions hereunder on the same terms as similarly situated executives of the Company.

 

E.                                       In the event Executive moves his place of primary residence from Dallas, Texas to Denver, Colorado, Company shall pay expenses associated with Executive’s relocation in accordance with the AMR Tier II Plan on file with the Company or a Subsidiary.

 

6



 

6.                                        Disability or Death .

 

A.                                    If, as the result of any physical or mental disability, the Executive shall have failed or is unable to perform his duties for a period of 180 consecutive days, the Company may, by notice to the Executive subsequent thereto, terminate this Agreement as of the date of the notice, subject to paragraph 6.C below.

 

B.                                      The term of the Executive’s employment under this Agreement shall terminate upon his death without any further payment or the furnishing of any benefit by the Company under this Agreement (other than accrued and unpaid Base Salary and expenses and benefits which have accrued pursuant to any plan or by law).

 

C.                                      Executive shall be entitled to receive, for a period of up to six (6) months, his base salary and a pro rata portion of his annual performance bonus payable pursuant to paragraph 4.B during such time as he is unable to perform his duties under this Agreement due to illness or physical or mental disability or other incapacity.  Such amounts shall be offset by any amounts paid to Executive under disability insurance policies maintained by the Company.

 

7.                                        Termination .

 

A.                                    The Company shall have the right to terminate this Agreement immediately for cause in the event of the occurrence of any of the following:

 

1.                                        Fraud, theft, gross misconduct or gross negligence on the part of the Executive, including, without limitation, conduct of a felonious or criminal nature, conduct involving moral turpitude, embezzlement, misappropriation of assets or substantial neglect of duties;

 

2.                                        Alcohol or drug abuse that impairs the Executive’s ability to properly perform his duties;

 

3.                                        Violation of the Company’s Corporate Compliance Policy; or

 

4.                                        A material breach of the Agreement by the Executive which has not been cured within 30 days of receipt by Executive of written notice of the breach.

 

B.                                      Either party may terminate this Agreement without cause by providing the other party with 90 days prior written notice of termination.  If termination is by Executive, the Company may waive notice, in whole or in part, upon immediate payment to the Executive of the Executive’s Base Salary for such portion of the 90-day notice period as is waived by the Company.  Upon such termination, the Company may

 

7



 

elect, in its sole and absolute discretion, to pay the Executive his Base Salary in effect at the time of such termination for a period of 12 months following such termination as consideration for Executive’s agreement set forth in paragraph 9.A.

 

C.                                      Executive may terminate this Agreement in the event of a material breach of the Agreement by the Company which has not been cured within 30 days of receipt by the Company of written notice of the breach.

 

D.                                     The Executive may terminate employment with the Company and any Subsidiary with the right to severance compensation as provided in paragraph 8.B.  upon the occurrence of a Change in Control followed by one or more of the following events:

 

1.                                        Failure to elect or reelect or otherwise to maintain the Executive in the office or position, or a substantially equivalent office or position, of or with the Company which the Executive held immediately prior to the Change in Control;

 

2.                                        (a) A significant adverse change in the nature or scope of the authorities, powers, functions, responsibilities or duties attached to the position with the Company which the Executive held immediately prior to the Change in Control, (b) a reduction in the aggregate of the Executive’s Base Salary received from the Company or the value of the Executive’s incentive pay opportunity from the Company or its Subsidiaries, or (c) the termination of the Executive’s rights to employee benefits or a reduction in the scope or value thereof to a level that is substantially lower in the aggregate from the level in effect at the time of the Change in Control, any of which is not remedied by the Company with 10 calendar days after receipt by the Company of written notice from the Executive of such change, reduction, or termination, as the case may be; or

 

3.                                        The liquidation, dissolution, merger, consolidation or reorganization of the Company or transfer of all or substantially all of its business and/or assets, unless the successor or successors (by liquidation, merger, consolidation, reorganization, transfer or otherwise) to which all or substantially all of its business and/or assets have been transferred (by operation of law or otherwise) assumed all duties and obligations of the Company.

 

8.                                        Salary/Benefit Continuation .

 

A.                                    Upon termination of this Agreement by the Company for cause or in the event of the Executive’s termination of this Agreement without cause, Executive shall be entitled to receive all salary earned under this Agreement up to the date of termination.

 

8



 

B.                                      Upon termination of this Agreement by the Company without cause or in the event of the Executive’s termination of this Agreement in accordance with paragraph 7.C, the Executive shall be entitled to receive the following:

 

1.                                        All salary earned under this Agreement up to the date of termination; and

 

2.                                        Base compensation at the rate payable on the date immediately prior to termination for an additional period of 12 months; and

 

3.                                        For a period of 12 months following the date of termination, the Company shall continue to pay for the cost of Executive’s participation in the Company’s group medical and dental insurance plans and group life insurance at the same rate as applicable to Executive immediately prior to termination, provided that Executive is entitled to continue such participation under applicable state and federal law and under the terms of the Company’s employment benefit plans in effect at the time (including provisions in the Company’s medical and dental plans related to coordination with other insurance, as applicable); and

 

4.                                        If the performance targets for the year are met, a prorata portion (equal to a fraction, of which the numerator is the number of full months of Executive’s employment in the year and the denominator is 12), of the bonus payable to Executive pursuant to paragraph 4.B., payable at such time as the Company pays annual incentive bonuses for the year to executives of the Company.

 

C.                                      Upon termination of this Agreement by Executive in accordance with paragraph 7.D, the Executive shall be entitled to receive the compensation set forth in paragraphs 8.B.1, 8.B.2 and 8.B.3.

 

D.                                     As a condition to receipt of the items set forth in paragraph 8.B.2, 8.B.3 and 8.B.4, as applicable, Executive shall execute promptly upon termination a Settlement and Release Agreement, pursuant to which Executive shall release the Company from any and all claims and demands which Executive may possess against the Company.

 

9,                                        Restrictive Covenants .

 

A.                                    Executive agrees that during the term of this Agreement, and for 24 months thereafter, Executive will not in any manner, without the prior written consent of the Company, directly or indirectly:  (1) disclose or divulge to any person, entity, firm, company or employer, or use for Executive’s own benefit or the benefit of any other person, entity, firm, company or employer directly or indirectly in competition with the

 

9



 

Company, any knowledge, information, business methods, techniques or data of the Company; (2) solicit, divert, take away or interfere with any of the customers, accounts, trade, business patronage, employees or contractual arrangements of the Company; (3) compete with the Company or enter into any contractual arrangements for the provision of medical transportation services, and physician practice management services as related to hospital emergency department and hospitalist outsourcing with any governmental authority, provider or hospital with which Executive has come into contact while an employee of the Company; or (4) either individually or in partnership; or jointly in conjunction with any other person, entity or organization, as principal, agent, consultant, lender, contractor, employer, employee, investor, shareholder, or in any other manner, directly or indirectly, advise, manage, carry on, establish, control, engage in, invest in, offer financial assistance or services to, or permit his name to be used by any business that Competes with the then-existing business of the Company, provided that the Executive shall be entitled, for investment purposes, to purchase and trade shares of a public company which are listed and posted for trading on a recognized stock exchange and the business of which public company may be in competition with the business of the Company, provided that the Executive shall not directly or indirectly own more than five percent (5%) of the issued share capital of the public company, or participate in its management or operation, or in any advisory capacity within the time limits set out herein.  Solely for the purposes of this paragraph 9, the term “Company” shall mean the Company, its subsidiaries, its affiliates, their subsidiaries and companies for whom such entities provide services.

 

B.                                      Executive further agrees that for a period of 24 months following termination of employment, however caused, he will not solicit for hire or rehire, or take away, or cause to be hired, or taken away, employee(s) of the Company.

 

C.                                      It is the intention of the parties to restrict the activities of Executive in a manner which reasonably protects the legitimate business interests of the Company.  In the event this paragraph 9 is deemed overly broad or unenforceable by a court of competent jurisdiction, it is the intent of the parties that this paragraph be enforced to the fullest extent allowed under applicable law, and be reformulated by such court to the- extent necessary to so enforce it.

 

D.                                     Executive agrees that the damages and remedies at law for any breach under this paragraph would be inadequate and that, in addition, in the event of a breach under this paragraph, the Company may apply to a court of competent jurisdiction and be entitled to an injunction by such court to prevent a breach or further breach thereof on the part of the Executive.  Such injunction shall be in addition to damages or other relief afforded under this Agreement.

 

E.                                       The Executive acknowledges that the agreements provided in this Section 9 were an inducement to the Company to enter into this Agreement and that the remedy at law for breach of his covenants under this Section 9 will be inadequate. 

 

10



 

Accordingly, in the event of any breach or threatened breach by the Executive of any provision of this Section 9, the Company shall be entitled, in addition to all other remedies, to an injunction restraining any breach by Executive.

 

10.                                  Miscellaneous .

 

A.                                    This Agreement shall become operative automatically on the Effective Date and, as of the Effective Date, shall constitute the entire agreement between the parties with respect to the employment and appointment of the Executive and any and all previous agreements, written or oral, express or implied, between the parties or on their behalf, relating to the employment and appointment of the Executive by the Company or any Subsidiary, are terminated and cancelled effective on the Effective Date and each of the parties releases and forever discharges the other of and from all manner of actions, causes of action, claims and demands whatsoever, under or in respect of any previous agreement, including without limitation, the Agreement, dated as of September 1, 2003, between EmCare and the Executive which is hereby terminated and cancelled effective on the Effective Date.

 

B.                                      This Agreement shall be governed by and construed: in accordance with the laws of the State of Delaware applicable to agreements made and performed in Delaware, and shall be construed- without regard to any presumption or other rule requiring construction against the party causing the Agreement to be drafted.

 

C.                                      This Agreement cannot be modified, amended, or terminated orally. Amendments may be made to this Agreement at any time if mutually agreed upon in writing.

 

D.                                     Any amendment, notice, or other communication under this Agreement shall be in writing and shall be considered given when received and shall be delivered personally or mailed by certified mail, return receipt requested, to the parties at their respective addresses set forth below (or at such other address as a party may specify by notice to the other):

 

If to Company:

Emergency Medical Services Corporation

 

6200 S. Syracuse Way, Suite 200

 

Greenwood Village, CO 80111

 

 

If to Executive:

Last known address on file with the Company

 

E.                                       The failure of a party to insist upon strict adherence to any term of this Agreement on any occasion shall not be considered a waiver or deprive that party of

 

11



 

the right thereafter to insist upon strict adherence to that term or any other term of this Agreement.  Any waiver must be in writing.

 

F.                                       Each of the parties irrevocably submits to the exclusive jurisdiction of any court of the State of Delaware and consents that any action, suit, or proceeding relating to or arising out of this Agreement and the transactions contemplated hereby may be brought in such court.

 

G.                                      The invalidity or unenforceability of any term or provision of this Agreement shall not affect the validity or enforceability of the remaining terms or provisions of this Agreement which shall remain in full force and effect and any such invalid or unenforceable term or provision shall be given full effect as far as possible.  If any term or provision of this Agreement is invalid or unenforceable in one jurisdiction, it shall not affect the validity or enforceability of that term or provision in any other jurisdiction.

 

H.                                     This Agreement is not assignable by either party except that it shall inure to the benefit of and be binding upon any successor to the Company by merger or consolidation or the acquisition of all or substantially all of the Company’s assets, provided such successor assumes all of the obligations of the Company, and shall inure to the benefit of the heirs and legal representatives of the Executive.

 

I.                                          The parties acknowledge that none of the benefits granted to either party here under are conditioned on any requirement that either party make referrals to, be in a position to make or influence referrals to, or otherwise generate business for the other.

 

J.                                         If the Executive is made a party to any action, suit, proceeding or any other claim whatsoever, by reason of the fact that the Executive is or was a director, officer, employee or agent of the Company and one or more Subsidiaries, or is or was serving at the request of Company and one or more Subsidiaries, as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, whether or not the basis of such claim is the Executive’s alleged action in an official capacity while in service as a director, officer, employee or agent of the Company and one or more Subsidiaries the Executive shall be Indemnified and held harmless by the Company and one or more Subsidiaries to the fullest extent legally permitted or authorized by the Company’s and such Subsidiaries’ certificate of incorporation or bylaws or resolutions of the Board against all expenses, liability and loss, including, without limitation, legal fees, fines or penalties and amounts paid or to be paid in settlement, all as reasonably incurred by the Executive in connection therewith, and such indemnification shall continue as to the Executive even after the Executive has ceased to be a director, officer, employee or agent of the Company or such Subsidiaries, and shall inure to the benefit of the Executive’s heirs, executors and administrators.

 

12



 

IN WITNESS WHEREOF, the Company and Executive have executed this Agreement, in multiple counterparts, each of which shall be deemed an original, effective the day and year first above written.

 

 

 

Emergency Medical Services Corporation

 

 

 

 

 

By:

/s/ Randel Owen

 

 

Name:  Randel Owen

 

 

Title:  EVP and CFO

 

 

 

 

 

Date of Execution:

8/24/05

 

 

 

 

 

/s/ Steve W. Ratton, Jr.

 

Steve W. Ratton, Jr.

 

 

 

 

 

Date of Execution:

8/24/2005

 

13


Exhibit 10.16

 

CDRT HOLDING CORPORATION
STOCK INCENTIVE PLAN

 

Article I
Purpose

 

CDRT Holding Corporation has established this stock incentive plan to foster and promote its long-term financial success.  Capitalized terms have the meaning given in Article XI.

 

Article II
Powers of the Board

 

Section 2.1           Power to Grant Awards .  The Board shall select officers and key Employees and Directors to participate in the Plan.  The Board shall determine the terms of each Award, consistent with the Plan.

 

Section 2.2           Administration .  The Board shall be responsible for the administration of the Plan.  The Board may prescribe, amend and rescind rules and regulations relating to the administration of the Plan, provide for conditions and assurances it deems necessary or advisable to protect the interests of the Company and make all other determinations necessary or advisable for the administration and interpretation of the Plan.  Any authority exercised by the Board under the Plan shall be exercised by the Board in its sole discretion.  Determinations, interpretations or other actions made or taken by the Board under the Plan shall be final, binding and conclusive for all purposes and upon all persons.

 

Section 2.3           Delegation by the Board .  All of the powers, duties and responsibilities of the Board specified in this Plan may be exercised and performed by any duly constituted committee thereof to the extent authorized by the Board to exercise and perform such powers, duties and responsibilities, and any determination, interpretation or other action taken by such committee shall have the same effect hereunder as if made or taken by the Board.

 

Article III
Shares Subject to Plan

 

Section 3.1           Number .  The maximum number of shares of Common Stock that may be issued under the Plan or be subject to Awards may not exceed [INSERT] shares.  The shares of Common Stock to be delivered under the Plan may consist, in whole or in part, of authorized but unissued shares of Common Stock that are not reserved for any other purpose.

 



 

Section 3.2           Canceled, Terminated or Forfeited Awards; Share Counting .

 

(a)            Upon the sale of Common Stock pursuant to Article IV, the maximum number of shares of Common Stock set forth in Section 3.1 shall be reduced by the number of shares sold.  In the event that, subsequent to any such sale, the Company reacquires any of such shares of Common Stock, such reacquired shares of Common Stock shall again be available for grant under the Plan.

 

(b)            Upon the grant of an Option, share of Restricted Stock or Restricted Stock Unit, the maximum number of shares of Common Stock set forth in Section 3.1 shall be reduced by the number of shares subject to such Award.  Upon the exercise, settlement or conversion of any Award or portion thereof, there shall again be available for grant under the Plan the number of shares subject to such Award or portion thereof minus the actual number of shares of Common Stock issued in connection with such exercise, settlement or conversion.  If any such Award or portion thereof is for any reason forfeited, canceled, expired or otherwise terminated without the issuance of shares of Common Stock, the Common Stock subject to such forfeited, canceled, expired or otherwise terminated Award or portion thereof shall again be available for grant under the Plan.  If shares of Common Stock are withheld from issuance with respect to an Award by the Company in satisfaction of any tax withholding or similar obligations, such withheld shares shall again be available for grant under the Plan.  Awards which the Board reasonably determines will be settled in cash or will be forfeited shall not reduce the Plan maximum set forth in Section 3.1.

 

Section 3.3           Adjustment in Capitalization .  If and to the extent necessary or appropriate to reflect any stock dividend, extraordinary dividend, stock split or share combination or any recapitalization, merger, consolidation, exchange of shares, spin-off, liquidation or dissolution of the Company or other similar transaction affecting the Common Stock, the Board shall adjust the number of shares of Common Stock available for issuance under the Plan and the number, class and exercise price of any outstanding Award, or make such substitution, revision or other provisions with respect to any outstanding Award or the holder or holders thereof, in each case as it determines to be equitable.  Without limiting the generality of the foregoing, in the event of any such transaction, the Board shall have the power to make such changes as it deems appropriate in the number and type of shares covered by outstanding Awards, the prices specified therein (if applicable), and the securities, cash or other property to be received upon the exercise, settlement or conversion thereof.  After any adjustment made pursuant to this Section, the number of shares subject to each outstanding Award shall be rounded down to the nearest whole number.  Any action taken pursuant to this Section 3.3 shall be effected in a manner that is exempt from or otherwise complies with Section 409A of the Code.

 

2



 

Article IV
Stock Purchase

 

Section 4.1           Awards and Administration .  The Board may offer and sell Common Stock to Participants at such time or times as it shall determine, the terms of which shall be set forth in a Subscription Agreement.

 

Section 4.2           Minimum Purchase Price .  Unless otherwise determined by the Board, the purchase price for any Common Stock to be offered and sold pursuant to this Article IV shall not be less than the Fair Market Value on the Grant Date.

 

Section 4.3           Payment .  Unless otherwise determined by the Board, the purchase price with respect to any Common Stock offered and sold pursuant to this Article IV shall be paid in cash or other readily available funds simultaneously with the closing of the purchase of such Common Stock.

 

Article V
Terms of Options

 

Section 5.1           Grant of Options .  The Board may grant Options to Participants at such time or times as it shall determine.  Options granted pursuant to the Plan will not be “incentive stock options” as defined in the Code unless otherwise determined by the Board.  Each Option granted to a Participant shall be evidenced by an Option Agreement that shall specify the number of shares of Common Stock that may be purchased pursuant to such Option, the exercise price at which shares of Common Stock may be purchased pursuant to such Option, the duration of such Option (not to exceed the tenth anniversary of the Grant Date), and such other terms as the Board shall determine.

 

Section 5.2           Exercise Price .  The exercise price per share of Common Stock to be purchased upon exercise of an Option other than a Rollover Option shall not be less than the Fair Market Value on the Grant Date.  Rollover Options shall have the per share exercise price specified in the applicable Rollover Agreement, which per share exercise price may be less than the Fair Market Value.

 

Section 5.3           Vesting and Exercise of Options .  Options other than Rollover Options shall become vested or exercisable in accordance with the vesting schedule or upon the attainment of such performance criteria as shall be specified by the Board on or before the Grant Date.  Rollover Options shall be fully vested and exercisable at all times while they are outstanding.  The Board may accelerate the vesting or exercisability of any Option, all Options or any class of Options at any time and from time to time.

 

Section 5.4           Payment .  The Board shall establish procedures governing the exercise of Options, which procedures shall, unless the Board determines otherwise and/or as otherwise specified in an Award Agreement, generally require

 

3



 

that prior written notice of exercise be given and that the exercise price (together with any required withholding taxes or other similar taxes, charges or fees) be paid in full in cash, cash equivalents or other readily-available funds at the time of exercise.  Notwithstanding the foregoing, on such terms as the Board may establish from time to time following a Public Offering ( i ) the Board may permit a Participant to tender to the Company any Common Stock such Participant has owned for minimum period of time necessary to avoid any adverse accounting charges for all or a portion of the applicable exercise price or minimum required withholding taxes and ( ii ) the Board may authorize the Company to establish a broker-assisted exercise program.  In connection with any Option exercise, the Company may require the Participant to furnish or execute such other documents as it shall reasonably deem necessary to ( a ) evidence such exercise, ( b ) determine whether registration is then required under the U.S. federal securities laws or similar non-U.S. laws or ( c ) comply with or satisfy the requirements of the U.S. federal securities laws, applicable state or non-U.S. securities laws or any other law.  Unless the Board determines otherwise, as a condition to the exercise of any Option before a Public Offering, a Participant shall enter into a Subscription Agreement annexed to the Award Agreement for the Option or, if a Subscription Agreement is not so annexed, as otherwise provided to the Participant.

 

Article VI
Restricted Stock and Restricted Stock Units

 

Section 6.1           Grants of Restricted Stock and Restricted Stock Units .  The Board may grant Restricted Stock or Restricted Stock Units to Participants at such time or times and on such terms and conditions as it shall determine.  Restricted Stock and Restricted Stock Units granted to a Participant shall be evidenced by an Award Agreement that shall specify the number of shares of Restricted Stock or the number of Restricted Stock Units that are being granted to the Participant, the vesting conditions applicable to such Restricted Stock or Restricted Stock Units, the rights and obligations of the Participant with respect to such Restricted Stock or Restricted Stock Units, and such other terms and conditions as the Board shall determine (including, if determined by the Board, payment of a portion of the Fair Market Value thereof).

 

Section 6.2           Conditions to Grant .  Unless otherwise determined by the Board, it shall be a condition to the issuance of Restricted Stock and the settlement of Restricted Stock Units that the Participant who receives such Award enter into a Subscription Agreement annexed to the related Award Agreement or, if a Subscription Agreement is not so annexed, as otherwise provided to the Participant.  Unless otherwise determined by the Board, the certificates evidencing shares of Restricted Stock shall be held by the Secretary of the Company or another custodian selected by the Company.

 

Section 6.3           Vesting Conditions .  Awards of Restricted Stock and

 

4



 

Restricted Stock Units shall vest in accordance with the vesting conditions specified in the applicable Award Agreement.  These vesting conditions may include, without limitation and alone or in any combination, the continued provision of services to the Company or any of its Affiliates or the achievement of individual, corporate, business unit or other performance goals.  Awards of Restricted Stock (prior to the vesting thereof) and Restricted Stock Units (prior to the settlement thereof) may not be sold, transferred, pledged, assigned or otherwise alienated or hypothecated other than as permitted by the Board.

 

Section 6.4           Stockholder Rights; Dividend Equivalents .  Awards of Restricted Stock shall have such voting and dividend rights as the Board shall, in its discretion, determine.  With respect to Awards of Restricted Stock Units, the Board may, in its discretion, determine that the payment of dividends, or a specified portion thereof, declared or paid on shares of Common Stock by the Company shall be ( i ) not paid to Participants holding Awards of Restricted Stock Units in respect of any period prior to the issuance of shares of Common Stock therefor, ( ii ) paid without restriction or deferral or ( iii ) credited but deferred until the lapsing of the vesting restrictions imposed upon such Restricted Stock Units.  In the event that dividend equivalent payments are to be deferred, the Board shall determine whether such dividend equivalent payments are to be deemed reinvested in shares of Common Stock (which shall be held as additional Restricted Stock Units) or held in cash or other notional instruments.  Payment of deferred dividend equivalent payments in respect of Restricted Stock Units (whether held in cash or as additional Restricted Stock Units or other notional instruments), shall be made upon the vesting of the Restricted Stock Units to which such deferred dividend equivalent payments relate, and any dividend equivalent payments so deferred in respect of any Restricted Stock Units shall be forfeited upon the forfeiture of the related Restricted Stock Units.

 

Section 6.5           Board Discretion .  Notwithstanding anything else contained in this Plan to the contrary, the Board may accelerate the vesting of any Restricted Stock or Restricted Stock Units or any class or series of Restricted Stock or Restricted Stock Units for any reason on such terms and subject to such conditions, as the Board shall determine, at any time and from time to time.

 

Article VII
Termination of Employment

 

Section 7.1           Expiration of Options Following Termination of Employment .  Unless otherwise determined by the Board on or before the Grant Date, or thereafter in a manner more favorable to the Participant, if a Participant’s employment with the Company terminates, such Participant’s Options shall be treated as follows:

 

(a)            any unvested Options shall terminate effective as of such termination of employment (determined without regard to any statutory or

 

5



 

deemed or express contractual notice period); provided that if the Participant’s employment with the Company is terminated in a Special Termination (i.e., by reason of the Participant’s death or Disability), any unvested Options held by the Participant shall immediately vest as of the effective date of such Special Termination;

 

(b)            except in the case of a termination for Cause, vested Options shall remain exercisable through the earliest of ( i ) the normal expiration date, ( ii ) 90 days after the Participant’s termination of employment (determined without regard to any statutory or deemed or express contractual notice period) or 180 days in the case of a Special Termination or Retirement, and ( iii ) any cancellation pursuant to Section 8.1; and

 

(c)            in the case of a termination for Cause, any and all Options held by such Participant (whether or not then vested or exercisable) other than Rollover Options shall terminate immediately upon such termination of employment.

 

The effect of a termination for Cause on Rollover Options shall be as set forth in the Option Agreement evidencing such Rollover Options.

 

Section 7.2           Effect of Termination of Employment on Restricted Stock and Restricted Stock Units . Unless otherwise determined by the Board, upon the termination of a Participant’s employment or service with the Company or any Subsidiary, any unvested Restricted Stock and any unvested Restricted Stock Units held by the Participant shall be automatically forfeited and canceled.

 

Section 7.3             Call Rights upon Termination of Employment Prior to a Public Offering .  Each Subscription Agreement shall provide that the Company and one or more of the Investors shall have successive rights prior to a Public Offering to purchase all or any portion of a Participant’s Common Stock upon any termination of employment (determined without regard to any statutory or deemed or express contractual notice period), at such time and at a purchase price per share equal to the Fair Market Value as of the date specified in the Subscription Agreement (or, if the Participant’s employment termination qualifies as a termination for Cause, for a purchase price per share equal to the lesser of ( i ) the Fair Market Value as of the date specified in the Subscription Agreement and ( ii ) such Participant’s per share purchase price; provided , that the effect of a termination for Cause on shares of Common Stock acquired upon exercise of a Rollover Option shall be as set forth in the Subscription Agreement applicable to such shares of Common Stock).

 

Article VIII
Change in Control

 

Section 8.1             Accelerated Vesting and Payment .  Except as otherwise

 

6



 

provided in this Article VIII or in the Award Agreement, upon a Change in Control:  ( i ) ( x ) each Option, whether vested or unvested, shall automatically vest such that all then-outstanding Options shall, immediately prior to the effective date of the Change in Control, be fully vested and exercisable and ( y ) except as otherwise provided in Section 8.2, upon the Change in Control, each then-outstanding Option shall be canceled in exchange for a payment in an amount or with a value equal to the excess, if any, of the Change in Control Price over the exercise price for such Option; and ( ii ) the Restriction Period applicable to all shares of Restricted Stock shall expire and all such shares shall vest and become non-forfeitable.  The effect (if any) of a Change in Control upon Restricted Stock Units shall be as provided in the written Award Agreement governing such Restricted Stock Unit consistent with Section 409A of the Code.

 

Section 8.2           Alternative Award .  Except as otherwise provided in an Award Agreement, no cancellation in exchange for a payment described in Section 8.1 shall occur with respect to any Option if the Board reasonably determines in good faith, prior to the occurrence of a Change in Control, that such Option shall be honored or assumed, or new rights substituted therefor following the Change in Control (such honored, assumed or substituted award, an “ Alternative Award ”), provided that any Alternative Award must give the Participant who held such Option rights and entitlements substantially equivalent to or better than the rights and terms applicable under such Option, including, but not limited to, identical or better timing and methods of payment and, if the Alternative Award or the securities underlying it are not publicly-traded, identical or better rights following a termination of employment to require the Company or the acquiror in such Change in Control to repurchase the Alternative Award or securities underlying such Alternative Award.

 

Article IX
Authority to Vary Terms or Establish Local Jurisdiction Plans

 

The Board may vary the terms of Awards under the Plan, or establish sub-plans under this Plan to authorize the grant of awards that have additional or different terms or features from those otherwise provided for in the Plan, if and to the extent the Board determines necessary or appropriate to permit the grant of awards that are best suited to further the purposes of the Plan and to comply with applicable securities laws in a particular jurisdiction or provide terms appropriately suited for Participants in such jurisdiction in light of the tax laws of such jurisdiction while being as consistent as otherwise possible with the terms of Awards under the Plan; provided that this Article IX shall not be deemed to authorize any increase in the number of shares of Common Stock available for issuance under the Plan set forth in Section 3.1.

 

7



 

Article X
Amendment, Modification, and Termination of the Plan

 

The Board may terminate or suspend the Plan at any time, and may amend or modify the Plan from time to time.  No amendment, modification, termination or suspension of the Plan shall have a substantial adverse effect on the economic terms of any Award theretofore granted under the Plan without the consent of the Participant holding such Award or the consent of a majority of Participants holding similar Awards (such majority to be determined based on the number of shares covered by such Awards).  Shareholder approval of any such amendment, modification, termination or suspension shall be obtained to the extent mandated by applicable law, or if otherwise deemed appropriate by the Board.

 

Article XI
Definitions

 

Section 11.1           Definitions .  Whenever used herein, the following terms shall have the respective meanings set forth below:

 

Affiliate ” shall mean, with respect to any Person, any other Person directly or indirectly controlling, controlled by or under common control with such first Person; provided that a director, member of management or other Employee of the Company shall not be deemed to be an Affiliate of the Investors.  For these purposes, “control” (including the terms “controlled by” and “under common control with”) means the possession, directly or indirectly, of the power to direct or cause the direction of the management policies of a Person by reason of ownership of voting securities, by contract or otherwise.

 

Alternative Award ” has the meaning given in Section 8.2.

 

Award ” shall mean an Option, an offer and sale of Common Stock pursuant to Article IV, or any Restricted Stock or Restricted Stock Unit, in each case granted pursuant to the terms of the Plan.

 

Award Agreement ” means a Subscription Agreement, an Option Agreement or any other agreement evidencing an Award.

 

Board ” means the Board of Directors of the Company or, to the extent that a delegation to a committee has occurred as provided in Section 2.3, such committee (to the extent of such delegation).

 

Cause ” shall, as to any Participant, have the meaning set forth in the employment agreement to which the Participant is a party with the Company or an Affiliate, or, in the absence of such an employment agreement, shall mean any of the following:  ( i ) the Participant’s commission of a crime involving fraud, theft, false statements or other similar acts or commission of any crime that is a felony (or a comparable classification in a jurisdiction that does not use these terms); ( ii ) the

 

8



 

Participant’s willful refusal, after explicit written notice, to obey any lawful resolution of or direction by his direct supervisor or the Board; ( iii ) the Participant’s material breach of any Award Agreement, employment agreement, or noncompetition, nondisclosure or nonsolicitation agreement to which the Participant is a party or by which the Participant is bound or ( iv ) the Participant’s engaging in any conduct that is materially injurious or materially detrimental to the Company or any of its Subsidiaries.  No act or failure to act by a Participant shall be considered willful unless it is done, or omitted to be done, by a Participant in bad faith and without reasonable belief that he or she was acting in the best interests of the Company.  The determination as to whether “Cause” has occurred shall be made by the Board, which shall have the authority to waive the consequences under the Plan of the existence or occurrence of any of the events, acts or omissions constituting “Cause.”   A termination for Cause shall be deemed to include a determination following a Participant’s termination of employment for any reason that the circumstances existing prior to such termination for the Company or one of its Subsidiaries to have terminated such Participants employment for Cause.

 

Change in Control ” means the first to occur of the following events after the Effective Date:

 

(i)  the acquisition by any person, entity or “group” (as defined in Section 13(d) of the Securities Exchange Act of 1934, as amended) of more than 50% of the combined voting power of the Company’s then outstanding voting securities, other than any such acquisition by the Company, any of its Subsidiaries, any employee benefit plan of the Company or any of its Subsidiaries, or by the Investors, or any Affiliates of any of the foregoing;

 

(ii)  the merger, consolidation or other similar transaction involving the Company, as a result of which both ( x ) persons who were stockholders of the Company immediately prior to such merger, consolidation, or other similar transaction do not, immediately thereafter, own, directly or indirectly, more than 50% of the combined voting power entitled to vote generally in the election of directors of the merged or consolidated company, and ( y ) any or all of the Investors (individually or collectively) do not, immediately thereafter, own, directly or indirectly, more than 50% of the combined voting power entitled to vote generally in the election of directors of the merged or consolidated company;

 

(iii)  within any 12-month period, the persons who were directors of the Company at the beginning of such period (the “ Incumbent Directors ”) shall cease to constitute at least a majority of the Board, provided that any director elected or nominated for

 

9



 

election to the Board by a majority of the Incumbent Directors then still in office shall be deemed to be an Incumbent Director for purposes of this clause (iii); or

 

(iv)  the sale, transfer or other disposition of all or substantially all of the assets of the Company to one or more persons or entities that are not, immediately prior to such sale, transfer or other disposition, Affiliates of the Company.

 

Notwithstanding the foregoing, a Public Offering shall not constitute a Change in Control.

 

Change in Control Price ” means the price per share of Common Stock offered in conjunction with any transaction resulting in a Change in Control.  If any part of the offered price is payable other than in cash, the Change in Control price shall be determined in good faith by the Board as constituted immediately prior to the Change in Control.

 

Code ” means the United States Internal Revenue Code of 1986, as amended, and any successor thereto.

 

Common Stock ” means the Common Stock, par value U.S. $0.01 per share, of the Company and, if applicable, any securities which may be issued after the Effective Date in respect of, or in exchange for, the shares of Common Stock.

 

Company ” means CDRT Holding Corporation, a Delaware corporation, and any successor thereto; provided that for purposes of determining the status of a Participant’s employment with the “Company,” such term shall include the Company and its Subsidiaries.

 

Director ” means a non-employee member of the Board.

 

Disability ” means, unless otherwise provided in an Award Agreement, a Participant’s long-term disability within the meaning of the long-term disability insurance plan or program of the Company or any Subsidiary then covering the Participant, or in the absence of such a plan or program, as determined by the Board.  The Board’s reasoned and good faith judgment of Disability shall be final and shall be based on such competent medical evidence as shall be presented to it by the Participant or by any physician or group of physicians or other competent medical expert employed by the Participant or the Company to advise the Board.

 

Effective Date ” has the meaning given in Section 12.10.

 

Employee ” means any executive, officer or other employee of the Company or any Subsidiary (including an executive member of the Board).

 

10



 

Fair Market Value ” means, as of any date of determination prior to a Public Offering, the per share fair market value on such date of a share of Common Stock as determined in good faith by the Board, in compliance with section 409A of the Code.  In making a determination of Fair Market Value, the Board shall give due consideration to such factors as it deems appropriate, including, but not limited to, the earnings and other financial and operating information of the Company in recent periods, any purchase of Common Stock of the Company by a bona fide third party investor made within the three-month period preceding the date for which the Fair Market Value determination is being made, the potential value of the Company as a whole, the future prospects of the Company and the industries in which it competes, the history and management of the Company, the general condition of the securities markets, the fair market value of securities of companies engaged in businesses similar to those of the Company, and any recent valuation of the Common Stock that shall have been performed by an independent valuation firm reasonably acceptable to the Chief Executive Officer of the Company (although nothing herein shall obligate the Board to obtain any such independent valuation).  The determination of Fair Market Value shall not take into account the fact that such shares would represent a minority interest in the Company.  Following a Public Offering, “Fair Market Value” shall mean, as of any date of determination, the mid-point between the high and the low trading prices for such date per share of Common Stock as reported on the principal stock exchange on which the shares of Common Stock are then listed.

 

Financing Agreements ” means any guaranty, financing or security agreement or document entered into by the Company or any Subsidiary from time to time.

 

Good Reason ” shall, as to any Participant, mean any of the following:

 

(a)            a material diminution of the Participant’s annual base salary from the annual base salary as in effect at the Effective Date;

 

(b)            a material diminution in the Participant’s title, authority, duties or responsibilities from those as in effect immediately following the Effective Date (and after giving effect to the fact that Emergency Medical Services Corporation is no longer a public company), except that the following shall not constitute Good Reason:  ( i ) the appointment of a Chairman or Executive Chairman of the Board; and ( ii ) changes in lines of reporting into the Participant’s position adopted in good faith as part of a bona fide restructuring of the businesses of the Company and its Subsidiaries;

 

11



 

(c)            the relocation of the Participant’s principal place of business to a location more than seventy-five miles from the location as in effect at the Effective Date; or

 

(d)            a material breach by the Company or any of its Affiliates of any written agreement between the Participant, on the one hand, and the Company or any of its Affiliates, on the other hand.

 

Prior to any termination for Good Reason hereunder, the Participant must provide written notice to the Company within the 60 days following the occurrence of an alleged Good Reason event setting forth in reasonable detail the conduct alleged to be a basis for a termination for Good Reason.  The Participant shall not have the right to terminate his or her employment hereunder for Good Reason (i) if, within the 15-day period following receipt of the Participant’s written notice, the Company shall have substantially cured the conduct alleged to be a basis for termination with Good Reason and (ii) absent such cure, unless the Participant actually terminates employment within 30 days following the end of the Company’s cure period.

 

Grant Date ” means, with respect to any Award, the date as of which such Award is granted pursuant to the Plan.

 

Investor ” means any of Clayton, Dubilier & Rice Fund VIII, L.P.; CD&R Friends & Family Fund VIII, L.P.; CD&R Advisor Fund VIII Co-Investor, L.P.; and CD&R EMS Co-Investor, L.P.

 

Option ” means the right granted pursuant to the Plan to purchase one share of Common Stock.

 

Option Agreement ” means an agreement between the Company and a Participant embodying the terms of any Options granted pursuant to the Plan and in the form approved by the Board from time to time for such purpose.

 

Participant ” means any Employee who is granted an Award.

 

Person ” means any natural person, firm, partnership, limited liability company, association, corporation, company, trust, business trust, governmental authority or other entity.

 

Plan ” means this CDRT Holding Corporation Stock Incentive Plan.

 

Public Offering ” means the first day as of which ( i ) there has occurred an initial public offering of Common Stock pursuant to an effective registration statement under the Securities Act with aggregate gross cash proceeds (without regard to any underwriting discount or

 

12



 

commission) of at least $150,000,000 (whether to the Company, its stockholders, or both), or ( ii ) the Board has determined that shares of the Common Stock otherwise have become publicly-traded for this purpose.

 

Restricted Stock ” means shares of Common Stock subject to a Restriction Period granted to a Participant under the Plan.

 

Restricted Stock Unit ” means a contractual right of a Participant to receive a stated number of shares of Common Stock, or, at the discretion of the Board, cash based on the Fair Market Value of such shares of Common Stock, under the Plan at the end of a specified period of time, that is forfeitable by the Participant until the completion of a specified period of future service or in accordance with the terms of the Plan or applicable Award Agreement or that is otherwise subject to a Restriction Period.

 

Restriction Period ” means the period during which any Restricted Stock or Restricted Stock Units are subject to forfeiture and/or restrictions on transfer pursuant to the terms of the Plan.

 

Retirement ” means termination of a Participant at or after age 62.

 

Rollover Agreement ” means, with respect any Participant, the Rollover Agreement to which the Company and such Participant are parties.

 

Rollover Option ” has the same meaning, with respect any Participant, as set forth in the applicable Rollover Agreement.

 

Securities Act ” means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.

 

Special Termination ” means a termination by reason of the Participant’s death or Disability.

 

Subscription Agreement ” means a stock subscription agreement between the Company and a Participant embodying the terms of any stock purchase made pursuant to the Plan and in the form approved by the Board from time to time for such purpose.

 

Subsidiary ” means any corporation, limited liability company or other entity, a majority of whose outstanding voting securities is owned, directly or indirectly, by the Company.

 

Section 11.2         Rules of Construction .

 

(a)            Gender and Number .  Except when otherwise indicated by the context, words in the masculine gender used in the Plan shall include the

 

13



 

feminine gender, the singular shall include the plural, and the plural shall include the singular.

 

(b)            Use of the term “Employ” .  The words “employment”, “employ” and corollary terms used herein and in an Award Agreement with respect to a Director shall be construed to refer to the Director’s service as a non-employee member of the Board.  The phrase “employment with the Company” and corollary terms used herein and in an Award Agreement with respect to an Employee shall be construed to refer to the employment with the Company and/or the Affiliates of the Company that actually employ the Employee.

 

Article XII
Miscellaneous Provisions

 

Section 12.1         Nontransferability of Awards .  Except as otherwise provided herein, in a Subscription Agreement or as the Board may permit on such terms as it shall determine, no Awards granted under the Plan may be sold, transferred, pledged, assigned, hedged, encumbered or otherwise alienated or hypothecated, other than by will or by the laws of descent and distribution.  All rights with respect to Awards granted to a Participant under the Plan shall be exercisable during the Participant’s lifetime by such Participant only (or, in the event of the Participant’s Disability, such Participant’s legal representative).  Following a Participant’s death, all rights with respect to Awards that were outstanding at the time of such Participant’s death and have not terminated shall be exercised by his designated beneficiary or by his estate in the absence of a designated beneficiary.

 

Section 12.2         Tax Withholding .  The Company or the Subsidiary employing a Participant shall have the power to withhold up to the minimum statutory requirement, or to require such Participant to remit to the Company or such Subsidiary, an amount sufficient to satisfy all U.S. federal, state, local and any non-U.S. withholding tax or other governmental tax, charge or fee requirements in respect of any Award granted under the Plan.

 

Section 12.3         Beneficiary Designation .  Pursuant to such rules and procedures as the Board may from time to time establish, a Participant may name a beneficiary or beneficiaries (who may be named contingently or successively) by whom any right under the Plan is to be exercised in case of such Participant’s death.  Each designation will revoke all prior designations by the same Participant, shall be in a form reasonably prescribed by the Board, and will be effective only when filed by the Participant in writing with the Board during his lifetime.

 

Section 12.4         No Guarantee of Employment or Participation .  Nothing in the Plan or in any agreement granted hereunder shall interfere with or limit in any way the right of the Company or any Subsidiary to terminate any Participant’s employment or retention at any time, or confer upon any Participant any right to

 

14



 

continue in the employ or retention of the Company or any Subsidiary.  No individual shall have a right to be selected as a Participant or, having been so selected, to receive any other or future Awards.

 

Section 12.5         No Limitation on Compensation; No Impact on Benefits .  Nothing in the Plan shall be construed to limit the right of the Company or any Subsidiary to establish other plans or to pay compensation to its Employees, in cash or property, in a manner that is not expressly authorized under the Plan.  Except as may otherwise be specifically and unequivocally stated under any employee benefit plan, policy or program, no amount payable in respect of any Award shall be treated as compensation for purposes of calculating a Participant’s rights under any such plan, policy or program.  The selection of an Employee as a Participant shall neither entitle such Employee to, nor disqualify such Employee from, participation in any other award or incentive plan.

 

Section 12.6         No Voting Rights .  Except as otherwise required by law, no Participant holding any Awards granted under the Plan shall have any right in respect of such Awards to vote on any matter submitted to the Company’s stockholders until such time as the shares of Common Stock underlying such Awards have been issued, and then, subject to the voting restrictions contained in the Subscription Agreement.

 

Section 12.7         Requirements of Law .  The granting of Awards and the issuance of shares of Common Stock pursuant to the Plan shall be subject to all applicable laws, rules and regulations, and to such approvals by any governmental agencies or national securities exchanges as may be required.  No Awards shall be granted under the Plan, and no Common Stock shall be issued under the Plan, if such grant or issuance would result in a violation of applicable law, including U.S. federal securities laws and any applicable state or non-U.S. securities laws.

 

Section 12.8         Freedom of Action .  Nothing in the Plan or any Award Agreement evidencing an Award shall be construed as limiting or preventing the Company or any Subsidiary from taking any corporate action (such as acquisitions, dispositions, entry into new lines of business and the incurrence of indebtedness) that it deems appropriate or in its best interest (as determined in its sole and absolute discretion) and no Participant (or person claiming by or through a Participant) shall have any right relating to the diminishment in the value of any Award as a result of any such action, so long as such action is not directly governed by or is not directly related to the administration of the Plan or any Award Agreement.  This Section 12.8 shall not be construed to enlarge the rights of the Company or the Board hereunder with respect to the interpretation or administration of the Plan or any Award Agreements.

 

Section 12.9         Unfunded Plan; Plan Not Subject to ERISA .  The plan is an unfunded plan and Participants shall have the status of unsecured creditors of the Company.  The Plan is not intended to be subject to the Employee Retirement

 

15



 

Income and Security Act of 1974, as amended.

 

Section 12.10       Term of Plan .  The Plan shall be effective as of May 25, 2011 (the “ Effective Date ”) and shall continue in effect, unless sooner terminated pursuant to Article X, until the tenth anniversary of such date.  The provisions of the Plan shall continue thereafter to govern all outstanding Awards.

 

Section 12.11       Governing Law .  The Plan, and all agreements hereunder, shall be governed by and construed in accordance with the law of the State of Delaware regardless of the application of rules of conflict of law that would apply the laws of any other jurisdiction.

 

Section 12.12       Section 409A of the Code .  This Plan and the Award Agreements entered into pursuant to this Plan are intended to be exempt from or comply with the requirements of Section 409A of the Code and shall be construed and interpreted in accordance with such intent.

 

16


Exhibit 10.17

 

Employee Stock Option Agreement
(Rollover Options)

 

This Employee Stock Option Agreement, dated as of May 25, 2011, between CDRT Holding Corporation, a Delaware corporation, and the Employee whose name appears on the signature page hereof, is being entered into pursuant to the CDRT Holding Corporation Stock Incentive Plan.  The meaning of capitalized terms may be found in Section 7.

 

The Company and the Employee hereby agree as follows:

 

Section 1.               Grant of Options

 

(a)                  Confirmation of Grant .  The Company hereby evidences and confirms, effective as of the date hereof, its grant to the Employee of Options to purchase the number of shares of Common Stock specified on the signature page hereof.  The Options are not intended to be incentive stock options under the Code.  This Agreement is entered into pursuant to, and the terms of the Options are subject to, the terms of the Plan and the Rollover Agreement to which the Employee and the Company are parties.  If there is any inconsistency between this Agreement and the terms of the Plan and the Rollover Agreement, the terms of the Plan and the Rollover Agreement shall govern.  As a condition to the grant of the Options, the Employee agrees that, as of the Effective Time, the definition of “Good Reason” contained in the Plan shall supersede and replace the same definition or other provision having similar effect relating to the constructive discharge of the Employee in all agreements containing such definition or provision entered into between the Employee, on the one hand, and the Company or any of its Affiliates, on the other hand, including but not limited to any employment agreement containing such definition or provision.

 

(b)                 Option Price .  Each share covered by an Option shall have the Option Price specified on the signature page hereof.

 

Section 2.               Vesting and Exercisability

 

(a)                  Vesting .  The Options are fully vested and exercisable as of the Grant Date.

 

(b)                 Exercise . The Options may be exercised at any time and from time to time prior to the date such Options terminate pursuant to Section 3.  Options may only be exercised with respect to whole shares of Common Stock and must be exercised in accordance with Section 4.

 



 

Section 3.               Termination of Options

 

(a)                  Normal Termination Date .  Unless earlier terminated pursuant to Section 3(b) or Section 6, the Options shall terminate on the termination dates set forth on the signature page of this Agreement (the “ Normal Termination Date ”), if not exercised prior to such date.

 

(b)                 Early Termination .  All Options held by the Employee following the effective date of a termination of employment, other than a termination of employment for Cause, shall remain exercisable until the first to occur of ( i ) the 90 th  day following the effective date of the Employee’s termination of employment (or the 180th day in the case of a Special Termination or a Retirement), ( ii ) the Normal Termination Date or ( iii ) the cancellation of the Options pursuant to Section 6, and if not exercised within such period the Options shall automatically terminate upon the expiration of such period.

 

(c)                  Special Rules Applicable to Certain Terminations of Employment .

 

(i)          Termination for Cause .  In the event of the Employee’s termination by the Company for Cause, all Options held by the Employee shall automatically be cancelled, and, in consideration of such cancellation, the Employee shall be paid the Notional Cause Repurchase Value (less any required withholding taxes).(1)

 


(1)                Example :  Assume that, prior to the closing of the merger, employee E elected to roll over an option to purchase 10,000 shares of Emergency Medical Services Corporation common stock with an exercise price of $29.65 per share.  This option was converted at the closing of the merger into an option to purchase the same number of shares (i.e., 10,000) of CDRT Holding Corporation common stock with the same exercise price (i.e., $29.65).  Assume that E is fired for “Cause” in 2012 at a time when the fair market value of the CDRT Holding common stock is $100 per share.  Instead of the option being cancelled for no value, E would receive a payment of $343,500 (less withholding taxes).  This payment is intended to replicate the payment that E would have received if ( 1 ) E’s 10,000 options had been cashed out at the closing of the merger, ( 2 ) E had reinvested the cash from the cashout in shares of CDRT Holding common stock at the then-fair market value of $64 per share and ( 3 ) those shares of CDRT Holding common stock had been repurchased at the time of E’s departure at the lower of cost and fair market value (i.e. $64, as $64 is less than $100).  This formula is the “Notional Cause Repurchase Value” contained in the definitions to this Agreement.  If the fair market value at the time of E’s departure was $50, the deemed repurchase price in step 3 would be $50 and the payment to E would be $268,359 (less withholding taxes).

 

2



 

(ii)         Termination without Cause, or with Good Reason; Death; Disability .  In the event that ( i ) the Employee’s employment is terminated ( x ) by the Company without Cause, ( y ) by the Employee with Good Reason or ( z ) by reason of the Employee’s death or Disability, and ( ii ) one or more of the Options terminates without being exercised because the Fair Market Value of a Share equals or exceeds the applicable Option Price (such Options, the “ Out-of-the-Money Options ”), then the Employee shall be paid cash in an amount that is not less than the Notional Cause Repurchase Value determined as if ( I ) the Employee’s employment had been terminated by the Company for Cause and ( II ) the Out-of-the-Money Options were the only Options subject to this Agreement.  Such payment shall be made within 30 days following the date that the Options so terminate.

 

Section 4.               Manner of Exercise

 

(a)                  General .  Subject to such reasonable administrative regulations as the Board may adopt from time to time, the Employee may exercise vested Options by giving at least 15 business days prior written notice to the Secretary of the Company specifying the proposed date on which the Employee desires to exercise a vested Option (the “ Exercise Date ”), the number of whole shares with respect to which the Options are being exercised (the “ Exercise Shares ”) and the aggregate Option Price for such Exercise Shares (the “ Exercise Price ”); provided that following a Public Offering notice may be given within such lesser period as the Board may permit.  The Exercise Shares shall be subject to the Subscription Agreement to which the Employee is then a party, or, if the Employee is not then a party to a Subscription Agreement, the Company and the Employee shall enter into the Subscription Agreement attached to this Agreement as Exhibit A.  Except as provided in Section 4(c) or as otherwise determined by the Board, and subject to such other terms, representations and warranties as may be provided for in the Subscription Agreement, ( i ) on or before the Exercise Date the Employee shall deliver to the Company full payment for the Exercise Shares in United States dollars in cash, or cash equivalents satisfactory to the Company, in an amount equal to the Exercise Price plus any required withholding taxes or other similar taxes, charges or fees and ( ii ) the Company shall register the issuance of the Exercise Shares on its records (or direct such issuance to be registered by the Company’s transfer agent).  The Company may require the Employee to furnish or execute such other documents as the Company shall reasonably deem necessary ( i ) to evidence such exercise, ( ii ) to determine whether registration is then required under the Securities Act or other applicable law or ( iii ) to comply with or satisfy the requirements of the Securities Act, applicable state or non-U.S. securities laws or any other law.

 

3



 

(b)                 Restrictions on Exercise .  Notwithstanding any other provision of this Agreement, the Options may not be exercised in whole or in part, and no certificates representing Exercise Shares shall be delivered, unless ( A ) all requisite approvals and consents of any governmental authority of any kind shall have been secured, ( B ) the purchase of the Exercise Shares shall be exempt from registration under applicable U.S. federal and state securities laws, and applicable non-U.S. securities laws, or the Exercise Shares shall have been registered under such laws, and ( C ) all applicable U.S. federal, state and local and non-U.S. tax withholding requirements shall have been satisfied.  The Company shall use its commercially reasonable efforts to obtain any consents or approvals referred to in clause (A) of the preceding sentence, but shall otherwise have no obligations to take any steps to prevent or remove any impediment to exercise described in such sentence.

 

(c)                  Exercise by Net Issuance .  Except to the extent limited by any of the Financing Agreements, at the election of the Employee made upon exercise of the Options, and in lieu of the Employee being required to pay the Exercise Price plus any required withholding taxes or other similar taxes, charges or fees in United States dollars in cash or cash equivalents satisfactory to the Company, the Company shall deliver to the Employee a lesser number of shares of Common Stock having a Fair Market Value on the date of exercise equal to the amount by which the Fair Market Value of the Exercise Shares exceeds the Exercise Price plus any required withholding taxes or other similar taxes, charges or fees; provided , that the Company may elect not to permit exercise of the Options in the manner set forth in this Section 4(c) following a Public Offering if the Company makes available to the Employee a broker-assisted cashless exercise feature with respect to such exercise.  In no event shall this Section 4(c) be construed to permit net issuance in excess of the applicable portion of the exercise price and minimum required withholding taxes.

 

(d)                 Automatic Exercise .  Notwithstanding Section 4(a), vested Options that have not been exercised prior to the applicable termination date contained in Section 3(a) or 3(b) and that are not Out-of-the-Money Options shall be exercised automatically pursuant to the procedure set forth in Section 4(c) (except to the extent limited by any of the Financing Agreements) on such termination date; provided , that ( i ) the Employee shall enter into the Subscription Agreement not later than five business days following the date of a request by the Company to do so and ( ii ) if the Employee fails to enter into the Subscription Agreement as aforesaid, the exercise of the vested Options shall be rescinded and the Employee shall be paid the Notional Cause Repurchase Value (less any required withholding taxes).

 

4



 

Section 5.               Employee’s Representations; Investment Intention .  The Employee represents and warrants that the Options have been, and any Exercise Shares will be, acquired by the Employee solely for the Employee’s own account for investment and not with a view to or for sale in connection with any distribution thereof.  The Employee represents and warrants that the Employee understands that none of the Exercise Shares may be transferred, sold, pledged, hypothecated or otherwise disposed of unless the provisions of the Subscription Agreement shall have been complied with or have expired.

 

Section 6.               Cancellation upon a Change in Control .  In the event of a Change in Control, all then-outstanding Options shall be canceled in exchange for a payment having a value equal to the excess, if any, of ( i ) the product of the Change in Control Price multiplied by the aggregate number of shares covered by all such Options immediately prior to the Change in Control over ( ii ) the aggregate Option Price for all such shares, to be paid as soon as reasonably practicable, but in no event later than 30 days following the Change in Control.  The foregoing notwithstanding, if mutually agreed to by the Board and the Employee, in lieu of such cancellation the Employee shall receive an Alternative Award meeting the requirements of the Plan.

 

Section 7.               Certain Definitions .  As used in this Agreement, capitalized terms that are not defined herein have the respective meaning given in the Plan, and the following additional terms shall have the following meanings:

 

Agreement ” means this Employee Stock Option Agreement, as amended from time to time in accordance with the terms hereof.

 

Code ” means the United States Internal Revenue Code of 1986, as amended, and any successor thereto.

 

Company ” means CDRT Holding Corporation, provided that for purposes of determining the status of Employee’s employment with the “Company,” such term shall include the Company and/or any of its Subsidiaries that employ the Employee.

 

Effective Time ” has the meaning set forth in the Rollover Agreement to which the Company and the Employee are parties.

 

Employee ” means the grantee of the Options, whose name is set forth on the signature page of this Agreement; provided that for purposes of Section 4 and Section 8, following such person’s death “Employee” shall be deemed to include such person’s beneficiary or estate and following such Person’s Disability, “Employee” shall be deemed to include such person’s legal representative.

 

Exercise Date ” has the meaning given in Section 4(a).

 

Exercise Price ” has the meaning given in Section 4(a).

 

5



 

Exercise Shares ” has the meaning given in Section 4(a).

 

Grant Date ” means the date hereof, which is the date on which the Options are granted to the Employee.

 

Normal Termination Date ” has the meaning given in Section 3(a).

 

Notional Cause Repurchase Value ” means the result produced from the formula ((X/Y)*Z), where:

 

X equals the amount of cash that the Employee would have been paid (determined without regard to taxes that would have been payable on such amount of cash) with respect to the number of Converting Company Options corresponding to the number of Options outstanding immediately prior to the date of termination if such number of Converting Company Options had been cancelled for cash pursuant to Section 3.04(a) of the Merger Agreement;

 

Y equals $64; and

 

Z equals the lesser of $64 and the Fair Market Value of a share of Common Stock on the date of termination.

 

For purposes of this definition, the terms “Converting Company Options” and “Merger Agreement” have the meanings set forth in the Rollover Agreement.

 

Option ” means the right granted to the Employee hereunder to purchase one share of Common Stock for a purchase price equal to the Option Price subject to the terms of this Agreement and the Plan.

 

Option Price ” means, with respect to each share of Common Stock covered by an Option, the purchase price specified in Section 1(b) for which the Employee may purchase such share of Common Stock upon exercise of an Option.

 

Plan ” means the CDRT Holding Corporation Stock Incentive Plan.

 

Section 8.               Miscellaneous .

 

(a)                  Withholding .  Subject to the terms and conditions of Section 4(c), the Company or one of its Subsidiaries may require the Employee to remit to the Company an amount in cash sufficient to satisfy any applicable U.S. federal, state and local and non-U.S. tax withholding or other similar charges or fees that may arise in connection with the grant, vesting, exercise or purchase of the Options.

 

(b)                 No Rights as Stockholder; No Voting Rights .  The

 

6



 

Employee shall have no rights as a stockholder of the Company with respect to any shares covered by the Options until the exercise of the Options and delivery of the shares.  Except as provided in Section 3.3 of the Plan, no adjustment shall be made for dividends or other rights for which the record date is prior to the delivery of the shares.  Any shares delivered in respect of the Options shall be subject to the Subscription Agreement and the Employee shall have no voting rights with respect to such shares until such time as specified in the Subscription Agreement.

 

(c)                  No Right to Continued Employment .  Nothing in this Agreement shall be deemed to confer on the Employee any right to continue in the employ of the Company or any Subsidiary, or to interfere with or limit in any way the right of the Company or any Subsidiary to terminate such employment at any time.

 

(d)                 Non-Transferability of Options .  The Options may be exercised only by the Employee, or, following the Employee’s death, by his designated beneficiary or by his estate in the absence of a designated beneficiary.  The Options are not assignable or transferable, in whole or in part, and they may not, directly or indirectly, be offered, transferred, sold, pledged, assigned, alienated, hypothecated or otherwise disposed of or encumbered (including, but not limited to, by gift, operation of law or otherwise) other than by will or by the laws of descent and distribution to the estate of the Employee upon the Employee’s death or with the Company’s consent.

 

(e)                  Notices .  All notices and other communications required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been given if delivered personally or sent by certified or express mail, return receipt requested, postage prepaid, or by any recognized international equivalent of such delivery, to the Company or the Employee, as the case may be, at the following addresses or to such other address as the Company or the Employee, as the case may be, shall specify by notice to the other:

 

(i)           if to the Company, to it at:

 

CDRT Holding Corporation
c/o Clayton, Dubilier & Rice, LLC
375 Park Avenue
18th Floor
New York, New York  10152
Attn:  Theresa Gore
Facsimile:  (212) 407-5252

 

7



 

(ii)         if to the Employee, to the Employee at his or her most recent address as shown on the books and records of the Company or Subsidiary employing the Employee; and

 

with copies (each of which shall not by itself constitute notice hereunder) to:

 

Debevoise & Plimpton LLP

919 Third Avenue

New York, New York 10022

 

Attention:

Paul S. Bird, Esq.

 

Jonathan E. Levitsky, Esq.

 

Fax: (212) 909-6836

 

All such notices and communications shall be deemed to have been received on the date of delivery if delivered personally or on the third business day after the mailing thereof.

 

(f)                  Binding Effect; Benefits .  This Agreement shall be binding upon and inure to the benefit of the parties to this Agreement and their respective successors and assigns.  Nothing in this Agreement, express or implied, is intended or shall be construed to give any person other than the parties to this Agreement or their respective successors or assigns any legal or equitable right, remedy or claim under or in respect of any agreement or any provision contained herein.

 

(g)                 Waiver; Amendment .

 

(i)          Waiver .  Any party hereto or beneficiary hereof may by written notice to the other parties ( A ) extend the time for the performance of any of the obligations or other actions of the other parties under this Agreement, ( B ) waive compliance with any of the conditions or covenants of the other parties contained in this Agreement and ( C ) waive or modify performance of any of the obligations of the other parties under this Agreement.  Except as provided in the preceding sentence, no action taken pursuant to this Agreement, including, without limitation, any investigation by or on behalf of any party or beneficiary, shall be deemed to constitute a waiver by the party or beneficiary taking such action of compliance with any representations, warranties, covenants or agreements contained herein.  The waiver by any party hereto or beneficiary hereof of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any preceding or succeeding breach and no failure by a party or beneficiary to exercise any right or privilege hereunder shall be deemed a waiver of such party’s or beneficiary’s rights or privileges hereunder or shall be deemed a waiver of such party’s or beneficiary’s rights to exercise the same at

 

8



 

any subsequent time or times hereunder.

 

(ii)         Amendment .  This Agreement may not be amended, modified or supplemented orally, but only by a written instrument executed by the Employee and the Company.

 

(h)                 Assignability .  Neither this Agreement nor any right, remedy, obligation or liability arising hereunder or by reason hereof shall be assignable by the Company or the Employee without the prior written consent of the other party.

 

(i)                   Applicable Law .  This Agreement shall be governed by and construed in accordance with the law of the State of Delaware regardless of the application of rules of conflict of law that would apply the laws of any other jurisdiction.

 

(j)                   Waiver of Jury Trial .  Each party hereby waives, to the fullest extent permitted by applicable law, any right it may have to a trial by jury in respect of any suit, action or proceeding arising out of this Agreement or any transaction contemplated hereby.  Each party ( i ) certifies that no representative, agent or attorney of any other party has represented, expressly or otherwise, that such other party would not, in the event of litigation, seek to enforce the foregoing waiver and ( ii ) acknowledges that it and the other parties have been induced to enter into the Agreement by, among other things, the mutual waivers and certifications in this Section 8(j).

 

(k)                  Section and Other Headings, etc .  The section and other headings contained in this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement.

 

(l)                   Counterparts .  This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same instrument.

 

(m)                 Entire Agreement .  This Agreement sets forth the entire understanding of the parties hereto with respect to the subject matter hereof and supersedes all prior agreements, written or oral, between them as to such subject matter.  Without limiting the generality of the immediately preceding sentence, effective as of the Effective Time, this Agreement shall supersede the agreements and plans evidencing the Converting Company Options (as defined in the Rollover Agreement).

 

[Signature Page Follows]

 

9



 

IN WITNESS WHEREOF, the Company and the Employee have executed this Agreement as of the date first above written.

 

 

 

CDRT HOLDING CORPORATION

 

 

 

 

 

By:

 

 

 

Name:

 

 

Title:

 

 

 

 

 

THE EMPLOYEE:

 

 

 

«Name»

 

 

 

 

 

By:

 

 

 

as Attorney-in-Fact

 

 

Name:

 

 

 

 

 

Address of the Employee:

 

 

 

«Address»

 

 

 

 

2005 Grant

 

2007 Grant

 

2008 Grant

 

2009 Grant

 

2010 Grant

 

Number of Shares for the Purchase of Which Options have been Granted

 

«M_2005_Options»

 

«M_2007_Options»

 

«M_2008_Options»

 

«M_2009_Options»

 

«M_2010_Options»

 

Option Price

 

«M_2005_Strike_Price»

 

«M_2007_Strike_Price»

 

«M_2008_Strike_Price»

 

«M_2009_Strike_Price»

 

«M_2010_Strike_Price»

 

Normal Termination Date

 

«M_2005_Exp_Date»

 

«M_2007_Exp_Date»

 

«M_2008_Exp_Date»

 

«M_2009_Exp_Date»

 

«M_2010_Exp_Date»

 

 

10



 

Exhibit A

 

Form of Subscription Agreement

 

11


Exhibit 10.18

 

Employee Stock Option Agreement
(Matching Options and Position Options)

 

This Employee Stock Option Agreement, dated as of May 25, 2011, between CDRT Holding Corporation, a Delaware corporation, and the Employee whose name appears on the signature page hereof, is being entered into pursuant to the CDRT Holding Corporation Stock Incentive Plan.  The meaning of capitalized terms may be found in Section 7.

 

The Company and the Employee hereby agree as follows:

 

Section 1.               Grant of Options

 

(a)                  Confirmation of Grant .  The Company hereby evidences and confirms, effective as of the date hereof, its grant to the Employee of Options to purchase the number of shares of Common Stock specified on the signature page hereof.  The Options are not intended to be incentive stock options under the Code.  This Agreement is entered into pursuant to, and the terms of the Options are subject to, the terms of the Plan.  If there is any inconsistency between this Agreement and the terms of the Plan, the terms of the Plan shall govern.

 

(b)                 Option Price .  Each share covered by an Option shall have the Option Price specified on the signature page hereof.

 

Section 2.               Vesting and Exercisability

 

(a)                  Vesting .  Except as otherwise provided in Section 6(a) or Section 2(b) of this Agreement, the Options shall become vested in five equal annual installments, with the first installment becoming vested on December 31, 2011, and the subsequent installments becoming vested on December 31 of each of the four subsequent calendar years; provided that if the Employee’s employment with the Company is terminated in a Special Termination (i.e., by reason of the Employee’s death or Disability), any Options held by the Employee shall immediately vest as of the effective date of such Special Termination.

 

(b)                 Discretionary Acceleration .  The Board, in its sole discretion, may accelerate the vesting or exercisability of all or a portion of the Options, at any time and from time to time.

 

(c)                  Exercise .  Once vested in accordance with the provisions of this Agreement, the Options may be exercised at any time and from time to time prior to the date such Options terminate

 



 

pursuant to Section 3.  Options may only be exercised with respect to whole shares of Common Stock and must be exercised in accordance with Section 4.

 

(d)                 No Other Accelerated Vesting .  The vesting and exercisability provisions set forth in this Section 2 or in Section 6, or expressly set forth in the Plan, shall be the exclusive vesting and exercisability provisions applicable to the Options and shall supersede any other provisions relating to vesting and exercisability, unless such other such provision expressly refers to the Plan by name and this Agreement by name and date.

 

Section 3.               Termination of Options

 

(a)                  Normal Termination Date .  Unless earlier terminated pursuant to Section 3(b) or Section 6, the Options shall terminate on the tenth anniversary of the Grant Date (the “ Normal Termination Date ”), if not exercised prior to such date.

 

(b)                 Early Termination .  If the Employee’s employment with the Company terminates for any reason, any Options held by the Employee that have not vested before the effective date of such termination of employment or that do not become vested on such date in accordance with Section 2 shall terminate immediately upon such termination of employment and, if the Employee’s employment is terminated for Cause, all Options (whether or not then vested or exercisable) shall automatically terminate immediately upon such termination.  All vested Options held by the Employee following the effective date of a termination of employment shall remain exercisable until the first to occur of ( i ) the 90 th  day following the effective date of the Employee’s termination of employment (or the 180th day in the case of a Special Termination or a Retirement), ( ii ) the Normal Termination Date or ( iii ) the cancellation of the Options pursuant to Section 6(a), and if not exercised within such period the Options shall automatically terminate upon the expiration of such period.

 

Section 4.               Manner of Exercise

 

(a)                  General .  Subject to such reasonable administrative regulations as the Board may adopt from time to time, the Employee may exercise vested Options by giving at least 15 business days prior written notice to the Secretary of the Company specifying the proposed date on which the Employee desires to exercise a vested Option (the “ Exercise Date ”), the number of whole shares with respect to which the Options are being exercised (the “ Exercise Shares ”) and the aggregate Option Price for such Exercise Shares (the “ Exercise Price ”); provided that following a Public Offering

 

2



 

notice may be given within such lesser period as the Board may permit.  The Exercise Shares shall be subject to the Subscription Agreement to which the Employee is then a party, or, if the Employee is not then a party to a Subscription Agreement, the Company and the Employee shall enter into the Subscription Agreement attached to this Agreement as Exhibit A.  Except as provided in Section 4(c) or as otherwise determined by the Board, and subject to such other terms, representations and warranties as may be provided for in the Subscription Agreement, ( i ) on or before the Exercise Date the Employee shall deliver to the Company full payment for the Exercise Shares in United States dollars in cash, or cash equivalents satisfactory to the Company, in an amount equal to the Exercise Price plus any required withholding taxes or other similar taxes, charges or fees and ( ii ) the Company shall register the issuance of the Exercise Shares on its records (or direct such issuance to be registered by the Company’s transfer agent).  The Company may require the Employee to furnish or execute such other documents as the Company shall reasonably deem necessary ( i ) to evidence such exercise, ( ii ) to determine whether registration is then required under the Securities Act or other applicable law or ( iii ) to comply with or satisfy the requirements of the Securities Act, applicable state or non-U.S. securities laws or any other law.

 

(b)                 Restrictions on Exercise .  Notwithstanding any other provision of this Agreement, the Options may not be exercised in whole or in part, and no certificates representing Exercise Shares shall be delivered, unless ( A ) all requisite approvals and consents of any governmental authority of any kind shall have been secured, ( B ) the purchase of the Exercise Shares shall be exempt from registration under applicable U.S. federal and state securities laws, and applicable non-U.S. securities laws, or the Exercise Shares shall have been registered under such laws, and ( C ) all applicable U.S. federal, state and local and non-U.S. tax withholding requirements shall have been satisfied.  The Company shall use its commercially reasonable efforts to obtain any consents or approvals referred to in clause (A) of the preceding sentence, but shall otherwise have no obligations to take any steps to prevent or remove any impediment to exercise described in such sentence.

 

(c)                  Exercise by Net Issuance .  Except to the extent limited by any of the Financing Agreements, at the election of the Employee made upon exercise of the Options following a termination of the Employee’s employment prior to a Public Offering in a Special Termination, by the Company without Cause or by the Employee with Good Reason, and in lieu of the Employee being required to pay the Exercise Price plus any required withholding taxes or other similar taxes, charges or fees in United States dollars in cash or cash

 

3



 

equivalents satisfactory to the Company, the Company shall deliver to the Employee a lesser number of shares of Common Stock having a Fair Market Value on the date of exercise equal to the amount by which the Fair Market Value of the Exercise Shares exceeds the Exercise Price plus any required withholding taxes or other similar taxes, charges or fees.  In no event shall this Section 4(c) be construed to permit net issuance in excess of the applicable portion of the exercise price and minimum required withholding taxes.

 

Section 5.               Employee’s Representations; Investment Intention .  The Employee represents and warrants that the Options have been, and any Exercise Shares will be, acquired by the Employee solely for the Employee’s own account for investment and not with a view to or for sale in connection with any distribution thereof.  The Employee represents and warrants that the Employee understands that none of the Exercise Shares may be transferred, sold, pledged, hypothecated or otherwise disposed of unless the provisions of the Subscription Agreement shall have been complied with or have expired.

 

Section 6.               Change in Control

 

(a)                  Vesting and Cancellation .  In the event of a Change in Control, all then-outstanding unvested Options shall automatically vest in full such that all Options outstanding hereunder shall, immediately prior to the effective date of the Change in Control, be fully vested and exercisable.  Subject to Section 6(b), upon the Change in Control, all Options then outstanding shall be canceled in exchange for a payment having a value equal to the excess, if any, of ( i ) the product of the Change in Control Price multiplied by the aggregate number of shares covered by all such Options immediately prior to the Change in Control over ( ii ) the aggregate Option Price for all such shares, to be paid as soon as reasonably practicable, but in no event later than 30 days following the Change in Control.

 

(b)                 Alternative Award .  Notwithstanding Section 6(a), no cancellation, termination, or settlement or other payment shall occur with respect to any Option pursuant to Section 6(a) if the Board reasonably determines prior to the Change in Control that the Employee shall receive an Alternative Award meeting the requirements of the Plan.

 

Section 7.               Certain Definitions .  As used in this Agreement, capitalized terms that are not defined herein have the respective meaning given in the Plan, and the following additional terms shall have the following meanings:

 

Agreement ” means this Employee Stock Option Agreement, as amended from time to time in accordance with the terms hereof.

 

Code ” means the United States Internal Revenue Code of 1986, as

 

4



 

amended, and any successor thereto.

 

Company ” means CDRT Holding Corporation, provided that for purposes of determining the status of Employee’s employment with the “Company,” such term shall include the Company and/or any of its Subsidiaries that employ the Employee.

 

Employee ” means the grantee of the Options, whose name is set forth on the signature page of this Agreement; provided that for purposes of Section 4 and Section 8, following such person’s death “Employee” shall be deemed to include such person’s beneficiary or estate and following such Person’s Disability, “Employee” shall be deemed to include such person’s legal representative.

 

Exercise Date ” has the meaning given in Section 4(a).

 

Exercise Price ” has the meaning given in Section 4(a).

 

Exercise Shares ” has the meaning given in Section 4(a).

 

Grant Date ” means the date hereof, which is the date on which the Options are granted to the Employee.

 

Normal Termination Date ” has the meaning given in Section 3(a).

 

Option ” means the right granted to the Employee hereunder to purchase one share of Common Stock for a purchase price equal to the Option Price subject to the terms of this Agreement and the Plan.

 

Option Price ” means, with respect to each share of Common Stock covered by an Option, the purchase price specified in Section 1(b) for which the Employee may purchase such share of Common Stock upon exercise of an Option.

 

Plan ” means the CDRT Holding Corporation Stock Incentive Plan.

 

Section 8.               Miscellaneous .

 

(a)                  Withholding .  Subject to the terms of Section 4(c), the Company or one of its Subsidiaries may require the Employee to remit to the Company an amount in cash sufficient to satisfy any applicable U.S. federal, state and local and non-U.S. tax withholding or other similar charges or fees that may arise in connection with the grant, vesting, exercise or purchase of the Options.

 

(b)                 No Rights as Stockholder; No Voting Rights .  The Employee shall have no rights as a stockholder of the Company with respect to any shares covered by the Options until the exercise of the Options and delivery of the shares.  Except as provided in Section 3.3

 

5



 

of the Plan, no adjustment shall be made for dividends or other rights for which the record date is prior to the delivery of the shares.  Any shares delivered in respect of the Options shall be subject to the Subscription Agreement and the Employee shall have no voting rights with respect to such shares until such time as specified in the Subscription Agreement.

 

(c)                  No Right to Continued Employment .  Nothing in this Agreement shall be deemed to confer on the Employee any right to continue in the employ of the Company or any Subsidiary, or to interfere with or limit in any way the right of the Company or any Subsidiary to terminate such employment at any time.

 

(d)                 Non-Transferability of Options .  The Options may be exercised only by the Employee, or, following the Employee’s death, by his designated beneficiary or by his estate in the absence of a designated beneficiary.  The Options are not assignable or transferable, in whole or in part, and they may not, directly or indirectly, be offered, transferred, sold, pledged, assigned, alienated, hypothecated or otherwise disposed of or encumbered (including, but not limited to, by gift, operation of law or otherwise) other than by will or by the laws of descent and distribution to the estate of the Employee upon the Employee’s death or with the Company’s consent.

 

(e)                  Notices .  All notices and other communications required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been given if delivered personally or sent by certified or express mail, return receipt requested, postage prepaid, or by any recognized international equivalent of such delivery, to the Company or the Employee, as the case may be, at the following addresses or to such other address as the Company or the Employee, as the case may be, shall specify by notice to the other:

 

(i)          if to the Company, to it at:

 

CDRT Holding Corporation
c/o Clayton, Dubilier & Rice, LLC
375 Park Avenue
18th Floor
New York, New York  10152
Attention:  Theresa Gore
Fax:  (212) 407-5252

 

(ii)         if to the Employee, to the Employee at his or her most recent address as shown on the books and records of the Company or Subsidiary employing the Employee; and

 

6



 

with copies (which shall not by itself constitute notice hereunder) to:

 

Debevoise & Plimpton LLP

919 Third Avenue

New York, New York 10022

 

Attention:

Paul S. Bird, Esq.

 

Jonathan E. Levitsky, Esq.

 

Fax: (212) 909-6836

 

All such notices and communications shall be deemed to have been received on the date of delivery if delivered personally or on the third business day after the mailing thereof.

 

(f)                  Binding Effect; Benefits .  This Agreement shall be binding upon and inure to the benefit of the parties to this Agreement and their respective successors and assigns.  Nothing in this Agreement, express or implied, is intended or shall be construed to give any person other than the parties to this Agreement or their respective successors or assigns any legal or equitable right, remedy or claim under or in respect of any agreement or any provision contained herein.

 

(g)                 Waiver; Amendment .

 

(i)        Waiver .  Any party hereto or beneficiary hereof may by written notice to the other parties ( A ) extend the time for the performance of any of the obligations or other actions of the other parties under this Agreement, ( B ) waive compliance with any of the conditions or covenants of the other parties contained in this Agreement and ( C ) waive or modify performance of any of the obligations of the other parties under this Agreement.  Except as provided in the preceding sentence, no action taken pursuant to this Agreement, including, without limitation, any investigation by or on behalf of any party or beneficiary, shall be deemed to constitute a waiver by the party or beneficiary taking such action of compliance with any representations, warranties, covenants or agreements contained herein.  The waiver by any party hereto or beneficiary hereof of a breach of any provision of this Agreement shall not operate or be construed as a waiver of any preceding or succeeding breach and no failure by a party or beneficiary to exercise any right or privilege hereunder shall be deemed a waiver of such party’s or beneficiary’s rights or privileges hereunder or shall be deemed a waiver of such party’s or beneficiary’s rights to exercise the same at any subsequent time or times hereunder.

 

(ii)       Amendment .  This Agreement may not be amended, modified or supplemented orally, but only by a written instrument

 

7



 

executed by the Employee and the Company.

 

(h)                 Assignability .  Neither this Agreement nor any right, remedy, obligation or liability arising hereunder or by reason hereof shall be assignable by the Company or the Employee without the prior written consent of the other party.

 

(i)                   Applicable Law .  This Agreement shall be governed by and construed in accordance with the law of the State of Delaware regardless of the application of rules of conflict of law that would apply the laws of any other jurisdiction.

 

(j)                   Waiver of Jury Trial .  Each party hereby waives, to the fullest extent permitted by applicable law, any right it may have to a trial by jury in respect of any suit, action or proceeding arising out of this Agreement or any transaction contemplated hereby.  Each party ( i ) certifies that no representative, agent or attorney of any other party has represented, expressly or otherwise, that such other party would not, in the event of litigation, seek to enforce the foregoing waiver and ( ii ) acknowledges that it and the other parties have been induced to enter into the Agreement by, among other things, the mutual waivers and certifications in this Section 8(j).

 

(k)                  Section and Other Headings, etc .  The section and other headings contained in this Agreement are for reference purposes only and shall not affect the meaning or interpretation of this Agreement.

 

(l)                   Counterparts .  This Agreement may be executed in any number of counterparts, each of which shall be deemed to be an original and all of which together shall constitute one and the same instrument.

 

[Signature Page Follows]

 

8



 

IN WITNESS WHEREOF, the Company and the Employee have executed this Agreement as of the date first above written.

 

 

 

CDRT HOLDING CORPORATION

 

 

 

 

 

By:

 

 

 

Name:

 

 

Title:

 

 

 

 

 

THE EMPLOYEE

 

 

 

«Name»

 

 

 

 

 

By:

 

 

 

as Attorney-in-Fact

 

 

Name:

 

 

 

 

 

Address of the Employee:

 

 

 

«Address»

 

Total Number of
Shares
for the Purchase
of Which
Options have been
Granted

 

Option Price

 

«Total_Options» Shares

 

$

64

 

 

9



 

Exhibit A

 

Form of Subscription Agreement

 

10


Exhibit 10.19

 

ROLLOVER AGREEMENT

 

This ROLLOVER AGREEMENT (this “ Agreement ”), dated as of May     , 2011, is entered into by and among the undersigned individual (the “ Executive ”), CDRT Holding Corporation, a Delaware corporation (“ Parent ”), and CDRT Acquisition Corporation (“ Intermediate Parent ”), a Delaware corporation and a wholly owned subsidiary of Parent.  Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to such terms in the Merger Agreement (as defined below).

 

RECITALS

 

WHEREAS, under the Emergency Medical Services L.P Equity Option Plan and the Emergency Medical Services Corporation Amended and Restated 2007 Long-Term Incentive Plan (the “ Plans ”), the Executive was previously granted options to purchase shares of common stock, par value $0.01 per share, of Emergency Medical Services Corporation, a Delaware corporation (the “ Company ”, and such options, the “ Company Options ”);

 

WHEREAS, the number of Company Options and related exercise prices of the Company Options held by the Executive as the date of this Agreement are set forth under the heading “Total Company Options” on Schedule A hereto;

 

WHEREAS, as of February 13, 2011, the Company, Intermediate Parent, and CDRT Merger Sub, Inc., a Delaware Corporation and a wholly owned subsidiary of Parent and Intermediate Parent (“ Merger Sub ”), entered into that certain Agreement and Plan of Merger (as the same may be amended, amended and restated or otherwise modified from time to time, the “ Merger Agreement ”), pursuant to which, at the Effective Time, Merger Sub will merge with and into the Company (such merger, the “ Merger ”);

 

WHEREAS, the Merger Agreement provides that, at the Effective Time, each unvested Company Option will vest and become fully exercisable pursuant to the terms of the applicable Plan and related option agreement, and either ( x ) each Company Option will be cancelled for an amount in cash, without interest, equal to the amount produced by the formula set forth in the first sentence of Section 3.04(a) of the Merger Agreement or ( y ) if Parent and the holder of the Company Option mutually agree, such Company Option shall be converted at the Effective Time, pursuant to the formula contained in the third sentence of Section 3.04(a) of the Merger Agreement, into a fully vested and exercisable option to purchase common stock of Intermediate Parent, on the same terms and conditions as were applicable under such Company  Option and such other terms as may be mutually agreed by Intermediate Parent and the holder thereof;

 

WHEREAS, Parent and the Executive intend hereby to evidence and set forth their mutual agreement as to the terms and conditions of the conversion, at the Effective Time, of the number of Company Options set forth on Schedule A hereto under the heading “Converting Company Options” (the “ Converting Company Options ”) into the number of options to purchase common stock of Parent, par value $0.01 per share (the “ Parent Common Stock ”), as set forth on Schedule A hereto under the heading “Rollover Options” (such options to purchase Parent Common Stock, the “ Rollover Options ”, and such conversion, the “ Rollover ”); and

 



 

WHEREAS, Parent, Intermediate Parent and the Executive also intend hereby to evidence and set forth their mutual agreement that Intermediate Parent is assigning to Parent its rights and obligations under Section 3.04(a) of the Merger Agreement with respect to the Converting Company Options and the Rollover Options, and Parent’s acceptance of such assignment.

 

NOW, THEREFORE, in order to implement the foregoing and in consideration of the mutual representations, warranties, covenants and agreements contained herein and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the parties hereto agree as follows:

 

AGREEMENT

 

Section 1.                The Rollover .

 

1.1.         Rollover and Grant of Matching Options .

 

(a)            On the terms and conditions set forth herein and subject to Section 1.3, at the Effective Time, the Converting Company Options shall automatically, and without further action, be converted into that number of Rollover Options as set forth on Schedule A hereto, with a per share exercise price as set forth opposite such number of Rollover Options.  The Rollover Options shall be subject to the same terms and conditions as in effect immediately prior to the Rollover, but giving effect to the Rollover.

 

(b)            Effective immediately following the Rollover, Parent and the Executive agree that the Rollover Options shall be evidenced by the Parent Stock Incentive Plan in the form attached as Exhibit B hereto and the form of Employee Stock Option Agreement attached as Exhibit C-1 hereto (the “ Rollover Stock Option Agreement ”).

 

(c)            The Executive acknowledges and agrees that from and after the Rollover, the Executive shall have no right, title or interest in or to the Converting Company Options, including without limitation, any right to receive the cash payment contemplated by the first sentence of Section 3.04(a) of the Merger Agreement with respect thereto.

 

(d)            In consideration of the agreement of the Executive to the Rollover, Parent shall, as of the Effective Time, grant the Executive additional options to purchase Parent Common Stock in the number set forth on Schedule A hereto under the heading “Matching Options” (the “ Matching Options ”).  The Matching Options shall be evidenced by the Parent Stock Incentive Plan in the form attached as Exhibit B hereto and the form of Employee Stock Option Agreement attached as Exhibit C-2 hereto (the “ Matching Stock Option Agreement ”).

 

(e)            The Company and the Executive intend that this Agreement satisfy the requirements of Treasury Regulation §1.409A-1(b)(5)(v)(D) (including, without limitation, the requirements of Treasury Regulation §1.424-1 referenced therein) and, as such, immediately following the Rollover, the Rollover Options shall not provide the Executive with any additional benefits that he or she did not have under the Converting Company Options and shall contain all terms of the Converting Company Options, except to the extent such terms are rendered inoperative by reason of the corporate transaction giving rise to the grant of the Rollover Options.  The foregoing notwithstanding, the post-employment exercise terms of the Rollover Options shall, effective as of the date of this Agreement but following the Rollover, be modified

 

2



 

(as permitted by Treasury Regulation §1.409A-1(b)(5)(v)(B)) to reflect the terms as set forth in Section 3 of the Rollover Option Agreement; provided, however, that in no event will such modification extend the term of the Rollover Options beyond the Normal Termination Date (as such term is defined in the Rollover Option Agreement).

 

1.2.         Rollover Closing .  The closing of the Rollover (the “ Rollover Closing ”) shall occur at the Effective Time on the Closing Date.  The Rollover Closing shall take place at the offices of Debevoise & Plimpton LLP, 919 Third Avenue, New York, New York, or such other place as the parties hereto may mutually agree upon in writing.

 

1.3.         Failure to Consummate the Merger .  In the event that the Merger fails to be consummated for any reason whatsoever and the Merger Agreement is terminated, the parties hereto agree that concurrently with the termination of the Merger Agreement, automatically and without any action of the parties hereto, the rights and obligations of the parties under this Agreement shall cease to be of any force or effect (and, for avoidance of doubt, the Rollover shall not occur).  In such event, each party hereto shall provide all such cooperation as the other party may reasonably request in order to ensure that the foregoing has been made effective.

 

1.4.         Conditions to Closing .  The Rollover Closing shall be subject to the satisfaction of the following conditions unless waived in writing by Parent and the Executive (in the case of clause (a)) or by Parent (in the case of clause (b)) or by the Executive (in the case of clause (c)):

 

(a)            Merger Agreement Conditions .  The conditions set forth in Article VII of the Merger Agreement shall have been satisfied or waived, and none of the parties to the Merger Agreement shall have given notice to the other parties that it does not intend to consummate the Merger at the Effective Time.

 

(b)            Representations, Warranties and Covenants of the Executive .  The representations and warranties contained in Section 3 of this Agreement shall be true and correct in all material respects as of the Closing Date (or, if given as of a specific date, at and as of such date), and the Executive shall have performed and complied with and observed in all material respects all covenants and agreements required by this Agreement to be performed or complied with by the Executive on or prior to the Closing Date.

 

(c)            Representations, Warranties and Covenants of Parent .  The representations and warranties contained in Section 2 of this Agreement shall be true and correct in all material respects as of the Closing Date (or, if given as of a specific date, at and as of such date), and Parent shall have performed and complied with and observed in all material respects all covenants and agreements required by this Agreement to be performed or complied with by Parent on or prior to the Closing Date.

 

1.5.         Parent Deliveries .  On the Closing Date and prior to the Rollover Closing, Parent shall deliver to the Executive the Rollover Stock Option Agreement and the Matching Stock Option Agreement, each duly executed by Parent.

 

1.6.         Executive Deliveries .  On the Closing Date and prior to the Rollover Closing, the Executive shall deliver to Parent the Rollover Stock Option Agreement and the Matching Stock Option Agreement, each duly executed by the Executive.

 

3



 

Section 2.                Representations and Warranties of Parent .  Parent hereby represents and warrants to the Executive that ( i ) Parent is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware, ( ii ) Parent has all requisite corporate power and authority to enter into this Agreement and to perform all of its obligations hereunder, to carry out the transactions contemplated hereby and to issue the Rollover Options and the Matching Options; ( iii ) the execution and delivery of this Agreement, the performance of Parent’s obligations hereunder and the consummation by Parent of the transactions contemplated hereby have been duly and validly authorized by all requisite corporate action on the part of Parent, ( iv ) this Agreement has been duly executed by Parent and, assuming due authorization, execution and delivery of this Agreement by the Executive, constitutes a legal, valid and binding obligation of Parent enforceable against Parent in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization or other similar laws affecting creditors’ rights generally and by general equitable principles (regardless of whether enforceability is considered in a proceeding in equity or at law); ( v ) the issuance of the Rollover Options and the Matching Options has been duly and validly authorized by all requisite corporate action on the part of Parent; and ( vi ) Parent is an “accredited investor” as such term is defined by Rule 501(a).

 

Section 3.                Representations and Warranties of the Executive .  The Executive hereby represents and warrants to Parent as follows:

 

3.1.         Ownership of the Company Options .  The Executive is the valid holder of the Company Options set forth under the heading “Total Company Options” on Schedule A hereto, and as of the Closing Date all such Company Options listed in Schedule A hereto are unexercised.

 

3.2.         No Agreements.   Except for this Agreement, the Executive has not entered into or agreed to be bound by any other arrangements or agreements of any kind with any other Person with respect to the Company Options, including, but not limited to, arrangements or agreements with respect to the acquisition or disposition thereof.

 

3.3.         Place of Residence  The principal residence of the Executive is as shown on the signature page hereof.

 

3.4.         Authority .  The Executive has all requisite power and authority to execute and deliver this Agreement, to perform his or her obligations hereunder and to consummate the transactions contemplated hereby.  This Agreement has been, assuming the due authorization, execution and delivery by Parent, duly and validly executed and delivered by the Executive and constitutes a legal, valid and binding obligation of the Executive, enforceable against the Executive in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization or other similar laws affecting creditors’ rights generally and by general equitable principles (regardless of whether enforceability is considered in a proceeding in equity or at law).

 

3.5.         No Conflicts; No Consents .  The execution and delivery by the Executive of this Agreement, the consummation by the Executive of the transactions contemplated hereby and the performance of the Executive’s obligations hereunder do not and will not (a) materially conflict with or result in a material violation or breach of applicable Law or (b) assuming the due authorization, execution and delivery of this Agreement by Parent, violate in any material respect, conflict with in any material respect or result in any material breach of, or constitute

 

4



 

(with or without notice or lapse of time or both) a material default under, or require the Executive to obtain any consent, approval or action of, make any filing with or give any notice to any Person as a result or under the terms of, any contract, agreement, instrument, commitment, arrangement or understanding to which the Executive is a party or to which any of the Company Options are subject.

 

3.6.         Investment Intention; Restriction on Dispositions .  The Executive is acquiring the Rollover Options and the Matching Options solely for the Executive’s own account for investment and not on behalf of any other person or with a view to, or for sale in connection with, any distribution thereof.  The Executive acknowledges that the Rollover Options and the Matching Options are not transferable except as provided in the Rollover Stock Option Agreement or the Matching Stock Option Agreement.  The Executive further agrees that the Executive will not, directly or indirectly, offer, transfer, sell, pledge, hypothecate or otherwise dispose of any of the shares of Parent Common Stock subject to the Rollover Options or the Matching Options (or solicit any offers to buy, purchase or otherwise acquire or take a pledge of any such shares of Parent Common Stock), except in compliance with ( i ) the Securities Act of 1933, as amended (the “ Securities Act ”), and the rules and regulations of the Securities and Exchange Commission thereunder, ( ii ) applicable state and non-U.S. securities or “blue sky” laws and ( iii ) the provisions of this Agreement, the Rollover Option Agreement, the Matching Option Agreement and any applicable subscription agreement to which the Executive is a party (a “ Subscription Agreement ”).  The Executive further understands, acknowledges and agrees that none of the shares of Parent Common Stock acquired upon exercise of the Rollover Options and the Matching Options or any interest therein or any rights relating thereto may be transferred, sold, pledged, hypothecated or otherwise disposed of unless ( i ) the provisions of the applicable Subscription Agreement shall have been complied with and ( ii ) such disposition is exempt from the provisions of Section 5 of the Securities Act or is pursuant to an effective registration statement under the Securities Act and is exempt from (or in compliance with) applicable state securities or “blue sky” laws.  Any attempt by the Executive, directly or indirectly, to offer, transfer, sell, pledge, hypothecate or otherwise dispose of any such shares of Parent Common Stock, or any interest therein, or any rights relating thereto, without complying with the provisions of this Agreement and the applicable Subscription Agreement, shall be void and of no effect.

 

3.7.         Securities Laws Matters .  The Executive acknowledges receipt of advice from the Company that ( i ) neither the Rollover Options, nor the Matching Options, nor the shares of Parent Common Stock received on exercise thereof have been registered under the Securities Act or qualified under any state securities or “blue sky” laws or non-U.S. securities laws, ( ii ) it is not anticipated that there will be any public market for the Rollover Options, the Matching Options or the shares of Parent Common Stock acquired on the exercise thereof, ( iii ) the Executive must continue to bear the economic risk associated with the Rollover Options, the Matching Options and the shares of Parent Common Stock acquired on the exercise thereof unless such shares are subsequently registered under the Securities Act and such state or non-U.S. securities laws or an exemption from such registration is available, ( iv ) a restrictive legend shall be placed on any certificates representing shares of Parent Common Stock that makes clear that the shares of Parent Common Stock are subject to the restrictions on transferability set forth in this Agreement and the applicable Subscription Agreement, and ( v ) a notation shall be made in the appropriate records of Parent or any transfer agent indicating that the shares of Parent Common Stock are subject to such restrictions.

 

5



 

3.8.         Ability to Bear Risk .  The Executive understands that ( i ) the transfer restrictions that apply to the shares of Parent Common Stock may effectively preclude the transfer of any of the shares of Parent Common Stock prior to a Public Offering; ( ii ) the financial situation of the Executive is such that he or she can afford to bear the economic risk of holding the Rollover Options, the Matching Options and the shares of Parent Common Stock acquired on the exercise thereof for an indefinite period; ( iii ) Parent’s financing agreements may restrict the ability of Parent to repurchase any shares of Parent Common Stock pursuant to the applicable Subscription Agreement and that Parent and its Subsidiaries may enter into or amend, refinance or enter into new financing agreements without regard to the impact on Parent’s ability to repurchase shares of Parent Common Stock.  The Executive can afford to suffer the complete loss of his or her investment in the Rollover Options, the Matching Options and the shares of Parent Common Stock acquired on the exercise thereof.

 

3.9.         Access to Information; Sophistication; Lack of Reliance .  The Executive is familiar with the business and financial condition, properties, operations and prospects of Parent and the Executive has been granted the opportunity to ask questions of, and receive answers from, representatives of Parent concerning Parent and the terms and conditions of the Rollover Options and to obtain any additional information that the Executive deems necessary to verify the accuracy of the information so provided.  The Executive’s knowledge and experience in financial and business matters is such that the Executive is capable of evaluating the merits and risk of the Executive’s investment in the Rollover Options, the Matching Options and the shares of Parent Common Stock acquired on the exercise thereof.  The Executive has carefully reviewed the terms and provisions of this Agreement and the Schedule and Exhibits hereto and has evaluated the restrictions and obligations contained therein.  In furtherance of the foregoing, the Executive represents and warrants that, as of the Effective Time, ( i ) no representation or warranty, express or implied, whether written or oral, as to the financial condition, results of operations, prospects, properties or business of Parent or as to the desirability or value of an investment in Parent has been made to the Executive by or on behalf of Parent, except for those representations and warranties expressly set forth in Section 2 of this Agreement, ( ii ) the Executive has relied upon the Executive’s own independent appraisal and investigation and the advice of the Executive’s own counsel, tax advisors and other advisors regarding the risks of an investment in Parent and ( iii ) the Executive will continue to bear sole responsibility for making his or her own independent evaluation and monitoring of the risks of his or her investment in Parent.

 

3.10.       Accredited Investor .  The Executive is an “accredited investor” as such term is defined by Rule 501(a) promulgated under the Securities Act.

 

Section 4.                Binding Effect; Benefits .  This Agreement shall be binding upon the successors, heirs, executors and administrators of the parties hereto.  Nothing in this Agreement, express or implied, is intended or shall be construed to give any person other than the parties to this Agreement and their respective successors or permitted assigns any legal or equitable right, remedy or claim under or in respect of any agreement or any provision contained herein.

 

Section 5.                Waiver .  Any term or provision of this Agreement may be waived at any time by the party which is entitled to the benefits thereof, but only in writing signed by such party.  Except as provided in the preceding sentence, no action taken pursuant to this Agreement, including, without limitation, any investigation by or on behalf of any party, shall be deemed to constitute a waiver by the party taking such action of compliance with any representations, warranties, covenants or agreements contained herein.  The waiver by any party hereto of a

 

6



 

breach of any provision of this Agreement shall not operate or be construed as a waiver of any preceding or succeeding breach, and no failure by any party to exercise any right or privilege hereunder shall be deemed a waiver of such party’s rights or privileges hereunder or shall be deemed a waiver of such party’s rights to exercise the same at any subsequent time or times hereunder.

 

Section 6.                Tax Treatment .  The parties agree to treat the Rollover as a transaction that does not result in taxable income to the Executive and that has been effected in compliance with Treasury Regulation § 1.409A-1(b)(5)(v)(D).

 

Section 7.                Amendments .  This Agreement may not be modified, amended, altered or supplemented except upon the execution and delivery of a written agreement executed by Parent and the Executive.

 

Section 8.                Assignability .  Effective as of immediately prior to the Effective Time, Intermediate Parent hereby assigns to Parent all of its rights and obligations under Section 3.04(a) of the Merger Agreement with respect to the Converting Company Options and the Rollover Options, and Parent accepts such assignment and agrees to perform Intermediate Parent’s obligations thereunder with respect to the Rollover Options.  The Executive acknowledges and consents to such assignment.  Except as set forth in the preceding sentence, neither this Agreement nor any right, remedy, obligation or liability arising hereunder or by reason hereof shall be assignable by the Executive without the prior written consent of Parent.

 

Section 9.                Governing Law .  This Agreement shall be governed in all respects, including as to validity, interpretation and effect, by the laws of the State of Delaware, without giving effect to its principles or rules of conflict of laws to the extent such principles or rules are not mandatorily applicable by statute and would require or permit the application of the laws of another jurisdiction.

 

Section 10.              Jurisdiction .  Except as otherwise expressly provided in this Agreement, the parties hereto agree that any suit, action or proceeding seeking to enforce any provision of, or based on any matter arising out of or in connection with, this Agreement or the transactions contemplated hereby shall be brought in the any state court (or, in the case of any claim as to which the federal courts have exclusive subject matter jurisdiction, the federal court of the United States of America) sitting in the State of New York, and each of the parties hereby consents to the exclusive jurisdiction of those courts (and of the appropriate appellate courts therefrom) in any suit, action or proceeding and irrevocably waives, to the fullest extent permitted by law, any objection which it may now or hereafter have to the laying of the venue of any suit, action or proceeding in any of those courts or that any suit, action or proceeding which is brought in any of those courts has been brought in an inconvenient forum.  Process in any suit, action or proceeding may be served on any party anywhere in the world, whether within or without the jurisdiction of any of the named courts.  Without limiting the foregoing, each party agrees that service of process on it by notice as provided in Section 12 shall be deemed effective service of process.

 

Section 11.              Enforcement .  Each party agrees that, subject to Section 1.3, the parties shall be entitled to specific performance of the terms hereof.  Notwithstanding any other term or condition of this Agreement, the Executive’s liability under this Agreement shall be limited to a willful and material breach of this Agreement and under no circumstances shall his or her maximum liability for any reason, including the Executive’s willful and material breach of any

 

7



 

of his or her commitments set forth herein, extend beyond the Executive’s obligation to effect the Rollover, nor shall the Executive be liable for any special, indirect, or consequential damages.

 

Section 12.              Notices .  All notices, requests, demands, letters, waivers and other communications required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been duly given if ( i ) delivered personally, ( ii )  sent by next-day or overnight mail or delivery or ( iii ) sent by facsimile, as follows:

 

(A)           If to Parent or Intermediate Parent:

 

CDRT Holding Corporation

c/o Clayton, Dubilier & Rice, LLC

375 Park Avenue, 18th Floor

New York, New York 10152

Attention: Theresa Gore

Facsimile No.: (212) 407-5252

 

With copies to (which shall not constitute notice):

 

Debevoise & Plimpton LLP

919 Third Avenue

New York, New York 10022

 

Attention:

Paul S. Bird, Esq.

 

Jonathan E. Levitsky, Esq.

 

Facsimile No.: (212) 909-6836

 

(B)            If to the Executive, to the address set forth on the signature page hereof.

 

All such notices, requests, demands, letters, waivers and other communications shall be deemed to have been received ( x ) if by personal delivery, on the day delivered, ( y ) if by next-day or overnight mail or delivery, on the day delivered, or ( z ) if by facsimile, on the day delivered; provided that in the case of (z) such delivery is confirmed by one of the other methods of delivery provided in clause (x) or (y) above.

 

Section 13.              Headings .  The headings contained herein are for convenience and shall not control or affect the meaning or interpretation of any provision hereof.

 

Section 14.              Counterparts .  This Agreement may be executed by facsimile and in two or more counterparts, each of which shall be deemed to be an original, but all of which together shall constitute one and the same instrument.

 

Section 15.              Severability .  In case any provision of this Agreement shall be invalid or unenforceable in any jurisdiction, the validity and enforceability of the remaining provisions shall not in any way be affected thereby.

 

Section 16.              Entire Agreement .  This Agreement, together with the Schedule and Exhibits hereto, shall constitute the entire agreement of the parties hereto with respect to the subject matter hereof and shall supersede all prior agreements, arrangements, understandings, documents, instruments and communications, whether written or oral, with respect to such subject matter.

 

8



 

Section 17.              Termination of Agreement .  This Agreement may be terminated by the mutual written consent of Parent and the Executive.  This Agreement shall terminate automatically without any action of the parties hereto upon termination of the Merger Agreement.  Upon such termination, this Agreement shall not have any further force and effect; provided that termination of this Agreement shall not relieve any party from liability for ( i ) any willful breach of this Agreement occurring prior to such termination or ( ii ) such party’s obligations under Section 1.3 of this Agreement.

 

Section 18.              Further Assurances .  Subject to the terms and conditions provided herein, each party hereto covenants and agrees to use commercially reasonable efforts to take, or cause to be taken, all action, and to do, or cause to be done, all things necessary, proper or advisable, whether under applicable Law or otherwise, in order to consummate and make effective the transactions contemplated by this Agreement.

 

[signature page follows]

 

9



 

IN WITNESS WHEREOF, the parties have hereby executed this Agreement as of the date first above written.

 

 

 

PARENT

 

 

 

 

 

By:

 

 

 

Name:

 

 

Title:

 

 

 

 

 

INTERMEDIATE PARENT

 

 

 

 

 

By:

 

 

 

Name:

 

 

Title:

 

 

 

 

 

EXECUTIVE

 

 

 

 

 

By:

 

 

 

Name:

 

 

 

Address:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Facsimile:

 

 

10



 

SCHEDULE A*

 

Name of Executive:  [                    ]

 

Total Company Options

 

Converting Company
Options

 

Rollover Options

 

Number of
Options

 

Exercise
Price

 

Number of
Options

 

Exercise
Price

 

Number of
Options

 

Exercise
Price

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Matching Options and
Position Options

 

Number of
Options

 

Exercise
Price

 

 

 

 

 

 


* To be completed on the Executive’s behalf and in accordance with the Executive’s instructions pursuant to the Power of Attorney granted by the Executive in connection with the Rollover.

 

11



 

EXHIBIT B

 

PARENT STOCK INCENTIVE PLAN

 

(See attached.)

 



 

EXHIBIT C-1

 

FORM OF EMPLOYEE STOCK OPTION AGREEMENT
(Rollover Options)

 

(See attached.)

 



 

EXHIBIT C-2

 

FORM OF EMPLOYEE STOCK OPTION AGREEMENT
(Matching Options and Position Options)

 

(See attached.)

 


Exhibit 31.1

 

CERTIFICATION

 

I, William A. Sanger, certify that:

 

1.        I have reviewed this Form 10-Q of Emergency Medical Services Corporation;

 

2.        Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.        Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.        The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.        The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 15, 2011

 

 

 

/s/ William A. Sanger

 

Name: William A. Sanger

 

Title: Chief Executive Officer

 

 


 

Exhibit 31.2

 

CERTIFICATION

 

I, Randel G. Owen, certify that:

 

1.        I have reviewed this Form 10-Q of Emergency Medical Services Corporation;

 

2.        Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.        Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.        The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.        The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: August 15, 2011

 

 

 

/s/ Randel G. Owen

 

Name: Randel G. Owen

 

Title: Chief Financial Officer

 

 


Exhibit 32.1

 

Written Statement of the Chief Executive Officer and Chief Financial Officer

 

Pursuant to Section 906

 

of the Sarbanes-Oxley Act of 2002 (18 U.S.C. Section 1350)

 

The undersigned, the Chief Executive Officer and the Chief Financial Officer of Emergency Medical Services Corporation, a Delaware corporation (the “Company”), each hereby certifies that, to his knowledge on the date hereof:

 

(a)       the Form 10-Q of the Company for the fiscal quarter ended June 30, 2011, filed on the date hereof with the Securities and Exchange Commission (the “Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(b)       the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

/s/ William A. Sanger

 

William A. Sanger

 

Chief Executive Officer

 

August 15, 2011

 

 

 

/s/ Randel G. Owen

 

Randel G. Owen

 

Chief Financial Officer

 

August 15, 2011